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 We are living within the age of information. The ever increasing flow of data and 
publications poses a monumental bottleneck to scientific progress as despite the 
amazing abilities of the human mind, it is woefully inadequate in processing such 
a vast quantity of multidimensional information. The small bits of flotsam and 
jetsam that we leverage belies the amount of useful information beneath the 
surface. It is imperative that automated tools exist to better search, retrieve, and 
summarize this content. Combinations of document indexing and search engines 
can quickly find you a document whose content best matches your query - if the 
information is all contained within a single document. But it doesn’t draw 
connections, make hypotheses, or find knowledge hidden across multiple 
documents. Literature-based discovery is an approach that can uncover hidden 
interrelationships between topics by extracting information from existing 
published scientific literature. The proposed study utilizes a semantic-based 
approach that builds a graph of related concepts between two user specified sets 
of topics using semantic predications. In addition, the study includes properties of 
bibliographically related documents and statistical properties of concepts to 
further enhance the quality of the proposed intermediate terms. Our results show 
an improvement in precision-recall when incorporating citations. 
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Chapter 1 
 
Introduction 
 
1.1 Relevance and Significance 
We are living within the age of information. Since the 1970’s we have progressed 
from traditional industrialization into an age categorized by the creation, distribution, and 
manipulation of information as a significant factor to society. This Information Age 
continues to redefine not only our technology but the level of integration the technology 
impacts each of us on a daily basis. Already there are more mobile connected devices 
than there are people across the planet, and within a few years there will be 50 billion 
smart connected devices collecting, storing, and sharing information. 
No matter where you go you’ll find people on their cell phones, tablets, laptops, 
and computers creating data. Every second there are 6,000 tweets over Twitter and 
40,000 Google searches. Every minute there are 125,000 photos uploaded to Facebook 
along with half a million comments posted. Every day there are 200 billion emails sent. 
Numerous other cameras, scanners, and sensors actively record anything that might be 
useful from the weather, to traffic patterns measured by the GPS movements of cellular 
phones, to heart rate information collected by fitness devices that is used within medical 
studies. We are drowning in a vast sea of information of which less than a single percent 
is used. 
Over 100 million scientific papers have been published to date and approximately 
two million a year join their ranks. In some fields there may be tens of thousands of 
articles published every year. Despite the amazing abilities of the human mind, it is 
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woefully inadequate in processing such a vast quantity of multidimensional information. 
The small bits of flotsam and jetsam that we leverage belies the amount of useful 
information beneath the surface. As such, our tools to organize and examine this ever-
expanding flow of information becomes a bottleneck to scientific progress. Traditional 
techniques such as document indexing and search engines can quickly find you a 
document whose content best matches your query - if the information is all contained 
within a single document. But it doesn’t draw connections, make hypotheses, or find 
knowledge hidden across multiple documents. The volume of scientific literature being 
published may be overwhelming for an individual researcher, and it is nigh impossible to 
keep track of the developments in other research areas, which can cause logical 
connections between separate areas of knowledge to be overlooked (Weeber, Vos, Klein, 
Aronson, and Molema 2003).  
 
1.2 Literature Based Discovery 
Literature-based discovery (LBD) was first proposed by Don R. Swanson in 1986 
through the Raynaud Syndrome–Dietary Fish Oils hypothesis (Swanson 1986). By 
reading portions of more than four thousand MEDLINE articles, Swanson discovered that 
dietary fish oils lowers blood viscosity, reduces platelet aggregation, and inhibit 
vasoconstriction. He also observed that a reduction in both blood viscosity and platelet 
aggregation, as well as the inhibition of vasoconstriction, appeared to prevent Raynaud 
disease (Cameron et al. 2015). 
Swanson therefore theorized that dietary fish oil might prevent Raynaud’s 
syndrome - this hypothesis was later confirmed clinically in 1989 (DiGiacomo, Kremer, 
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and Shah 1989). The significance of the observation was that at the time none of the 
literature had a direct association between fish oils and Raynaud disease but it was 
possible to derive an implicit indirect association via existing intermediate topics.  
Although Swanson has been largely credited with the concept of LBD, the general 
concept predates him. Several decades earlier, American biologist James Peters stated 
that:  
 
When an author takes a series of apparently unrelated facts and ideas from two 
areas of investigation, combines them so that they make new sense, and develops 
a new hypothesis from the combination, he not only aids in the advance of both 
fields but also is quite likely to open up a new one... In Sutton’s paper (Sutton 
1902) you will see this development of relationships between the fields of 
cytology and heredity, which, at the time Sutton wrote, were considered to be 
fairly divergent from one another, in that no research techniques were shared... 
Sutton’s paper can be considered the beginning of cytogenetics... This paper is a 
good model to follow in the preparation of a study involving synthesis and 
correlation (Peters 1959, p. 27).  
 
This notion has been studied, such as reports from the US National Research 
Council of the National Academies. They indicate that many scientific discoveries 
involve drawing new connections between scientific domains (Feller and Stern 2007). 
Furthermore, many scientific breakthroughs can be characterized by linking disjoint 
collections of research papers (Chen 2009). Similarly, in a study on US Patent records in 
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between 1790 and 2010 they discovered that many previously reported inventions 
featured new combinations between already existing technologies and techniques (Youn, 
Strumsky, Bettencourt, and Lobo 2015). 
 To date there have been many connections and discoveries made due to the use of 
literature based discovery: Fish oils and Raynaud’s syndrome (Swanson 1986), migraines 
and magnesium (Swanson 1988), estrogen and Alzheimer’s disease (Smalheiser and 
Swanson 1996), Parkinson’s Disease and Crohn’s disease (Kostoff 2014), new 
treatments for cataracts (Kostoff 2008) and breast cancer (Li, Zhu, and Chen 2010), and 
others. Given that the number of new scientific papers added to the human body of 
knowledge each year is only going to continue to grow, it is essential that we improve our 
existing tools to better search, process, and visualize this expanding volume. 
As a research field, LBD aims at exploring approaches to discover these hidden 
connections between pieces of already existing knowledge, either in automatic or 
semiautomatic fashion (Smalheiser 2012). Its main goal is to produce both interesting and 
novel knowledge that has yet to be published in scientific literatures (Swanson 2008). 
 
1.3 Semantic-Based Literature Based Discovery 
 Most LBD systems produce a list of intermediate terms as their results. This 
serves to illuminate a potential relationship, but does nothing to illustrate the underlying 
mechanisms of those interactions. Semantic-based approaches are designed to provide 
this contextual relevance in addition to the association. Existing research in this area have 
made use of natural language processing (NLP) tools such as SemRep (Rindflesch and 
Fiszman 2003) and BioMedLEE (Lussier, Borlawsky, Rappaport, Liu, and Friedman 
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2006) to extract semantic propositions from free-text documents. These relationships can 
help to illuminate the mechanisms of interaction and the causality between concepts.  
Here, not only is the correlation between the two concepts captured, but the 
contextual relevance of that relationship as well. For example, a predicate such as 
[Serotonin - CAUSES - Contraction] indicates that the concepts of Serotonin and 
Contraction show up together, and that Serotonin causes Contraction. As the predicates 
relate one concept to another it is straightforward to utilize these to construct graphs for 
visualization where nodes represent concepts and connecting edges as predicates. 
Recent work by Cameron et al. has done just this, extracting semantic predicates 
via SemRep to form a directed predication graph (Cameron et al. 2015).  As an example, 
Magnesium has been known to exert an inhibitory effect on platelet prostacyclin 
(Epoprostenol) interaction, and prostacyclin is known to affect migraines (Briel, Lippert, 
and Zahradnik 1985; Peatfield, Gawel, and Rose 1981).  These relationships are 
illustrated as directed edges in Figure 1 where the concepts of Magnesium, Epoprostenol, 
and Migraine Disorders comprise the graph vertices. 
 
Figure 1. Example relationship between Magnesium and Migraine Disorders 
 
 
 
6 
 
 
 
1.4 Goals 
 A challenge of LBD is the reliance on having a collection of text documents with 
which to study, as frequently only the title and abstracts of a reference are available in 
large quantities. In the study by Cameron et al. they extracted predicates by using the 
full-text of documents as input to the SemRep tool to achieve their results (Cameron et al. 
2015). In addition, Cameron noted in his dissertation that the “results collectively suggest 
that titles and abstracts alone, might NOT be sufficient for LBD” (Cameron 2014). 
The goal of this dissertation is to measure the effectiveness of incorporating 
bibliographic citations into semantic-based LBD. When an author chooses to cite another 
document, they do so because there is some important piece of information that is 
foundational or related to their own work.  
LBD approaches typically start with a literature search of all documents that 
contain those concepts specified by the user. By also utilizing references that are 
bibliographically related to our search terms, we are leveraging additional documents that 
are semantically related to our primary terms of interest that don’t already include those 
terms.  
 
Figure 2. Content of References 
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Illustrated in Figure 2, the initial search returns a set of documents (S) that contain those 
concepts. We then expand this set, naming it S’, to also include the cited documents of S. 
Any documents within S’ that are not within S do not contain the search concepts but are 
related. Therefore this approach provides the benefit of potentially adding new 
intermediate terms and possible pathways from these documents with a low risk of 
cluttering up the results with totally unrelated knowledge. 
This study proposes to accomplish this goal by modifying the approach by 
Cameron et al. (2015) to take into account cited documents. This will then be followed by 
performing a retrospective analysis against past LBD discoveries to investigate if the 
inclusion of citation information can retrieve better results such as revealing new 
relationships. The studies in chapter four show a comparison of the results of the 
expanded document set S’ and the baseline set S. 
 
1.5 Research Questions 
This proposed dissertation research concerning the blend of bibliographic 
citations with semantic-based predicate graphs suggests the following research questions: 
Quantitative Study: Many LBD approaches begin with an initial set of references 
which include one or more concepts of interest to the user. This is generally done to 
reduce the scope of the problem down from the full corpus to a smaller more manageable 
subset that is more likely to have points of interest. Cameron’s approach constructs 
predication subgraphs using only those predicates that exist in that collection of 
documents. By expanding the initial set of documents via citations, how does this affect 
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the precision and recall of the returned answers? Many LBD studies use retrospective 
studies as a means of evaluation, comparing the results to those of the original discovery. 
We have performed several retrospective studies to investigate this question with positive 
results, discussed in Chapter 4. 
Qualitative Study: Many concepts will appear related to other terms, but what are 
good ways to ignore concepts that provide little information? This can be accomplished 
statistically such as using IDF, which is a measure of how much information a word 
provides, or employing the use of existing knowledge like ontological hierarchies. We 
have used a combination of the IDF values for individual concepts calculated over the 
entire corpus and the concept’s position within the MeSH ontology. 
Quantitative Study: Our results are essentially a ranked order of intermediate 
concepts/paths, thus the quantitative results of the retrospective studies are shown as 
precision-recall curves. The use of citations expands the potential number of paths within 
the results, how does this affect the precision-recall curves? Our citationally enhanced 
studies have a better precision-recall curve. This is attributed to two cases. The first, and 
most important, case is due to new paths being generated from the addition of citations. 
The second case is caused by an increase in the IDF concept threshold.  
 
1.6 Barriers and Issues 
The potential of Swanson’s research has been widely acknowledged, but so has 
the depth and complexity of the field when considering the expansive quantity of source 
documents and the potential numbers of interconnections (Hearst 1999; Weeber et al. 
2001). There have been three large research challenges within LBD. The first is the 
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scalability of algorithms in dealing with very large volumes of information. The second is 
the heavy reliance on subject matter experts or domain-specific knowledge sources. 
Typically their help, whether automatic or manual, better refines a search for the 
researcher or helps filter the results. For example, every concept within the 
Metathesaurus has been assigned one or more semantic types (“Cell function”, 
“molecular function”, etc.). Thus a researcher could make use of this by only wanting to 
look at connecting concepts that match these additional criteria (Weeber et al. 2001). The 
utilization of domain-specific sources helps natural language processing (NLP) to tackle 
the variation and intricacies of natural language. Finally, the third difficulty is the lack of 
a standard means of comparing the successfulness of LBD approaches. By its very 
definition LBD attempts to uncover previously unknown details. This lack of a true gold 
standard has caused many to simply qualitatively compare results to a select few original 
studies (Yetisgen-Yildiz and Pratt 2008). 
 
1.7 Summary 
This expanding sphere of human knowledge has precipitated the need for 
researchers to narrow their focus as it is infeasible for an individual to keep abreast of the 
swelling volume of information. LBD is an attempt to help solve these challenges - 
dedicated to building tools to discover, visualize, and traverse the hidden connections of 
knowledge across many disciplines.  
Semantic-based LBD techniques attempt to expand this by not only uncovering 
connections, but illustrating the meaning of those connections. Stating that Fish Oils are 
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related to Raynaud’s disease is useful, but not as useful as the statement: Fish Oils are 
related to Raynaud’s disease due to their effect on blood viscosity.  
Research into summarization techniques, discussed in chapter 2, has shown that 
there are semantic correlations between a document and another references that cite it. 
This dissertation explores the usefulness of incorporating bibliographic citations into 
implementations of semantic LBD.  
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Chapter 2 
 
Review of the Literature 
 
2.1 Introduction 
Hypothesis generation is a key step in the process of making scientific discoveries 
as much time and effort can be wasted just to disprove an initial hypothesis only to repeat 
the cycle again. Traditionally, this step relies on prior knowledge, experience, and even 
intuition (Srinivasan 2004). Much of what was involved with Swanson’s work was 
reading and assimilating the literature and then using good judgment to explore related 
topics until finally happening upon a plausible discovery. Automating this knowledge 
discovery needs to focus on extracting useful patterns or relationships within large data 
sets. 
 Literature-Based Discovery, is, in essence, a field focused on a blend of text 
mining, information retrieval, and summarization in an attempt to answer questions 
regarding the relationship between two concepts. Much of the work in these areas is 
relevant and is covered within this chapter first, followed by a review of current research 
within the field of LBD. 
2.2 Text Mining 
 The process of discovering patterns in large data sets is termed data mining. Data 
mining typically focuses on structured data stored within a database - looking for trends, 
identifying clusters, frequently occurring sets, and so forth. A subtopic, text mining, 
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makes use of many data mining techniques but instead looks for patterns among the 
unstructured raw text of document collections.  
In the simplest form a document collection, or corpus, can be any grouping of 
text-based documents from a few to millions. An example of a well-used document 
collection suitable for text mining is PubMed – the National Library of Medicine’s online 
repository of biomedical research papers. To date PubMed contains over 28 million 
document abstracts and is widely used by computer scientists in employing text mining 
(Feldman and Sanger 2007). 
 As a research area, text mining incorporates techniques from other areas such as 
information retrieval (IR) systems, natural language processing (NLP), and machine 
learning combined into three different tasks: Information Retrieval, Question Answering, 
and Text Summarization. 
 
2.3 Information Retrieval 
 Information Retrieval can be defined as “finding material (usually documents) of 
an unstructured nature (usually text) that satisfies an information need from within large 
collections (usually stored on computers)” (Manning, Raghavan, and Schütze 2008). The 
task itself is to find a subset of a larger collection which contains the desired information. 
Most IR systems commonly extract meaningful words, concepts, or text fragments and 
index the entire corpus in advance to avoid having to linearly scan all text in response to 
a query.  
 The IR system also provides a search system containing a user interface or query 
language. A user can express their needs by means of search primitives that can be 
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understood by the system. The user query is then translated into a query that can be 
executed by the underlying system. For example, a user may request information about 
Fish Oils via the provided interface. If the IR system makes use of a Relational Database 
Management System (RDBMS) this might be converted into a SQL query that 
specifically looks for the given text within both the titles and abstract fields: SELECT 
DocumentIds From SomeTable WHERE (Title LIKE ‘%Fish Oils%’ OR Abstract 
LIKE ‘%Fish Oils%’). A second example that is frequently utilized for text processing 
is Apache Solr coupled with Apache Lucene. A similar query using a solr-based system 
might look like: Title:“Fish Oils” OR Abstract:”Fish Oils”.  
 Once the system queries are executed against the indexed corpus, matching results 
are returned to the user ordered by relevancy. Despite the power of such systems one 
drawback is that users must look through potentially large volumes of results to find 
relevant information. The combination of document indexing and search engines can 
quickly find you documents whose content best matches your query - if the information is 
all contained within a single document. This can be problematic when the information 
desired is spread across multiple documents. A user must therefore already know exactly 
what they are looking for and sift through the multitudes of results or continually 
reformulate their queries in an ad hoc fashion to search for all the pieces to the puzzle. An 
area of research known as Question Answering has techniques to help address these 
limitations. 
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2.4 Question Answering 
 Unlike the traditional Information Retrieval approaches, Question Answering 
(QA) attempts to provide users with precise answers to their questions instead of 
providing a large number of documents that are potentially relevant. To do so, QA 
systems consist of three distinct phases: question processing, document processing, and 
answer processing. These phases use a combination of Information Extraction and 
Natural Language Processing techniques (Athenikos and Han 2010).  
 The question processing phase works much like Information Retrieval systems in 
that they interpret the user’s input and translate it into an internal query. However, there 
may be additional linguistic processing of the user query to determine the type of 
question being asked and the expected answer type. Additional steps may also include 
Named Entity Recognition (NER) to identify keywords or concepts.  
 In the second phase, Document Processing, the internal query is used to fetch a set 
of resulting documents. The system attempts to select specific sections from the resulting 
documents (termed candidate answer passages) that are most relevant to the query. To 
accomplish this many QA systems make use of semantic knowledge in a combination of 
named entity recognition and word/query disambiguation. 
Named entities can be identified via the use of domain specific ontologies such as 
Medical Subject Headings (MeSH) which is the National Library of Medicine’s (NLM) 
controlled vocabulary thesaurus used with PubMed, and will be described in more detail 
later. Systems like this are useful to both identify key terms for indexing articles but also 
to identify when there may be more than one name for the same thing, such as 
Epoprostenol and Prostacyclin. 
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Another type of useful semantic source is WordNet, a large lexical database of 
English. Within WordNet different parts of speech are grouped into sets of cognitive 
synonyms (Athenikos and Han 2010). Consider an information retrieval search of the 
word “iron”, here, possible results may include metals, golf clubs, and laundry services. 
Identifying how a word is being used (noun vs verb) and the words with which it keeps 
company (context) can help determine relevancy of search results.  
 Inclusion of semantic information can ensure that when a user searches for 
Epoprostenol that the results also include documents that talk about Prostacyclin, or that 
a search about Magnesium deficiency, might also include results with hypomagnesaemia. 
In addition, a search of “iron oxide” likely means a user is not interested in oxides and 
their use within laundry. 
 In the answer processing phase the candidate answers are then matched against 
the expected answer types specified and then ranked according to matching scores as 
determined by the search.  
 As a whole, Question Answering is considered an effective, but more challenging 
task than information retrieval. It necessitates additional processing during corpus 
indexing and processing of user queries. Furthermore, semantic knowledge systems tend 
to be domain specific and thus cannot necessarily be applied across diverse texts. When 
considering complex problems it can be challenging for a user to identify the best queries 
to use, these techniques attempt to do some of that work for the user.  
 
 
 
 
16 
 
 
 
2.5 Text Summarization 
 Text summarization is designed to combat the problem of large result sets by 
providing a concise overview of the information from one or multiple documents in 
either a textual or graphical summary (Mishra et al. 2014; Mani 1999). In general, 
automatic text summarization can be categorized into several different types, each 
described based on its input type (single or multi document), the output type (extraction 
or abstraction), and the approach (Statistical, Latent semantic analysis, Natural Language 
Processing, and others) (Yogan 2016).  
 Most of the initial research in this area focused on single document extractive 
summarization (Aliguliyev 2009; Ko and Seo 2008). Extractive summarization works by 
identifying the most important sections of the original text and compiling them together. 
With the alternative, abstractive summarization, the system attempts to paraphrase the 
content by means of natural language processing (Ganesan et al., 2010; Khan et al., 2015; 
Allahyari et al. 2017). There has been less work in this area due to its complexity, but 
there has been a growing interest in multi-document summarization. This is likely due to 
the volume of information available and that relevant information is often scattered 
among multiple sources (Mishra et al. 2014).  
 
2.5.1 Statistical Text Summarization 
 Statistical implementations are typically based on the early works of Luhn, Spärck 
Jones, and Edmundson. Luhn proposed that more important words will be repeated 
within a document more often than others - this measurement became known as Term 
Frequency (Luhn 1958). Karen Spärck Jones later created a second measure called 
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Inverse Document Frequency (IDF) to account for the idea that if a word shows up 
repeatedly in many documents then it loses meaning by being too general (Spärck Jones 
1972). A common approach is to use the combination of both, entitled Term Frequency 
Inverse Document Frequency (TF-IDF). Consider a single document that contains 
“Hypomagnesemia” many times. In this case, it is likely that it is a central point of that 
document. Whereas the word “patients”, which despite appearing in large numbers across 
many documents, has far less useful meaning.  
TF-IDF(w,d):= TermFrequency(w,d) x InverseDocFrequency(w) (2.1) TF-IDF(w,d):= TermFrequency(w,d) x log( |Corpus |
DocFrequency(w))  
 
Although there are multiple variations, a simple form of the TF-IDF is shown in Equation 
2.1. The first variable, TermFrequency, is a function of term w and document d. For a 
given term and document, it is the number of times that w appears within d divided by the 
total number of terms contained within d. The second variable, InverseDocFrequency, is 
the log of the total number of documents within the corpus divided by the number of 
documents that contain the term w.  
As an example, suppose our corpus consists of two documents (Table 1). The first 
document, d1, contains the text “example: this is an example” and the second, d2, “this is 
a second sample”. The term frequency of a term is calculated for a given document, and 
is equal to the number of times that particular term appears within that document divided 
by the total number of terms for the document.  
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Table 1. Example term counts for two documents 
d1 d2 
Term Term Count Term Term Count 
this 1 this 1 
is 1 is 1 
an 1 a 1 
example 2 second 1 
  sample 1 
 
The term frequency of the term “example” for each document is calculated as follows: 
 tf("example", d1) =  term count("example", d1)total terms(d1) = 25 =  0.4 tf("example", d2) =  term count("example", d2)total terms(d2) = 05 =  0 
 
The inverse document frequency is calculated once for the entire corpus and represents 
the ratio of documents that include that particular term. For the term “example”, it would 
calculated as follows: 
 idf("example") =  log( # of documents# of documents with term) =  𝑙𝑙𝑙𝑙𝑙𝑙(21) =  0.301 
 
If we examine the idf of the term “this” we find that since every document in our corpus 
contains this word, thus the idf equates to zero: 
 idf("this")  =  log( # of documents# of documents with term) =  𝑙𝑙𝑙𝑙𝑙𝑙 (22) =  0 
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This implies that the word is not very informative as it appears in all documents. The 
measure of tf-idf appears often within statistical text mining when considering individual 
terms, but doesn’t account for sentence level constructs. 
An intuitive approach to determine the importance of a sentence is to first identify 
the characteristics that highlight the relevance of the sentence. In 1969, Edmundson 
defined features which reflect the relevance of a sentence such as the sentence position 
and the presence of title or cue words (Edmundson 1969).  For title words, the idea is 
simple: as the title is the most succinct summary of the document by its authors, 
sentences that contain words that also occur within the title are likely to be more 
important. This is in contrast to cue words, which are not important by themselves but 
rather signify that something else is more likely to be important. Adjectives and adverbs 
like “significant”, “irrelevant”, “impossible”, and others are applied in text to highlight 
the neighboring word or phrase to the reader. Thus, if a list of such words is provided to a 
summarization system it can be used within the scoring process. Each sentence is then 
ranked based upon some scoring algorithm such as in Equation 2.2. 
 Score = �𝑤𝑤𝑤𝑤𝑛𝑛
𝑤𝑤 = 1  × 𝑓𝑓𝑤𝑤 (2.2) 
 
where wi is the weight of a particular feature and fi is the score of that feature. Each 
sentence will receive a score based upon all of its features, and the document summary is 
produced from the highest valued content. Note that although specific words may be 
called out (such as cue words, stop words, title words, etc.) only statistical properties, 
relative positioning, and existence are examined in those methods.  
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2.5.2 Latent Semantic Analysis 
 Latent Semantic Analysis (LSA) is a method that attempts to identify the 
underlying meaning of a document. In other words, it extracts the relationships between a 
set of documents and the terms they contain. This might be simple if a given term 
described only a single concept, and a concept could always be described by a single 
term. But natural languages have many situations where this is not the case. Thus the idea 
behind LSA is that “the aggregate of all the word contexts in which a given word does 
and does not appear provides a set of mutual constraints that largely determines the 
similarity of meaning of words and sets of words to each other” (Landauer, Foltz, and 
Laham 1998). For example, the word “bank” in English can refer either to a financial 
institution or to the land alongside a river. If a document contains the word along with 
other words such as loans and interest then it likely refers to a financial institution, but if 
the document also contains terms such as fishing and rivers then it refers to the second. 
 The algorithm first constructs an m x n matrix whose m rows represent each 
unique term and n columns represent each document. Each entry within the matrix, ai,j is 
the weight of the term i within sentence j, computed by TF-IDF. The next step applies a 
linear algebra technique to the matrix called single value decomposition (SVD) which 
factors the original matrix into several derived from its eigenvectors.  If desired, 
dimensionality reduction can also be applied during the SVD to retain only the k principal 
eigenvectors. The result of this produces three new matrices U, Σ, and VT (See Eq. 2.3).  
M = U Σ VT (2.3) 
If the original matrix, M, is m x n then U will be an m x m matrix, 𝛴𝛴 will be an m x n 
diagonal matrix, and VT is an n x n matrix. The U matrix contains the representation of 
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each term within a concept space, the VT matrix contains the representation of each 
document within the concept space, and the 𝛴𝛴 matrix represents the overall weight of 
each concept. 
 Although LSA has been mainly used in the context of Information Retrieval, 
returning answers that contain the concept of a user’s query if not the exact terms, it has 
also been used within document summarization. Initially proposed by Gong and Liu, 
instead of applying the LSA algorithm to terms within documents, it can instead be 
applied to individual sentences within a document (Gong and Liu 2001).  In their work 
the matrix D = Σ VT describes how much any given sentence represents a topic where di,j 
is the weight of concept i within sentence j.  
  
2.5.3 Natural Language Processing 
Natural Language Processing (NLP) attempts to recreate a more human-like 
understanding of language. Each NLP implementation typically focuses on one or more 
levels of language processing such as Phonology, Morphology, Lexical, Syntactic, 
Semantic, Discourse, and Pragmatic (Liddy 2001). When applied to text processing 
generally only lexical, syntactic, and semantic techniques are considered. This is mainly 
due to the fact that phonology studies audible sounds, morphology analyzes the 
compositions of individual words, discourse examines text at a multi-sentence 
granularity, and pragmatic levels require a level of world knowledge to interpret the 
context of words.  
Lexical and syntactic parsing allows for the identification of words and phrases, 
parts of speech tagging, and the ability to perform disambiguation tasks. In many cases 
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approaches frequently make use of domain-specific knowledge sources to help in this 
regard such as using controlled vocabularies to generate index terms or to produce a 
summary. For example, within the biomedical area the UMLS Metathesaurus (Lindberg 
et al. 1993) is used to link similar names for the same concept from nearly 200 different 
vocabularies allowing systems to recognize that two papers might be talking about the 
same subject (e.g. one document using the term “dyspnea” while another states 
“shortness of breath”) (Verma et al. 2007).  
Semantic NLP approaches can be more challenging as they attempt to discern the 
meaning of the text. Not only does this leverage vocabularies to identify known terms but 
also requires some understanding of the relationships between them. One tool of note, 
SemRep, extracts semantic predications (subject-predicate-object triples) from raw text 
(Rindflesch and Fiszman, 2003). SemRep was developed within the biomedical research 
domain and uses domain knowledge provided by the UMLS, where its generated 
predications contain “textual content with semantic predications consisting of UMLS 
Metathesaurus concepts as arguments and UMLS Semantic Network relations as 
predicates” (Kilicoglu et al. 2008). With the use of the tool, sentences are transformed 
into any number of assertitional predications. These predications have been subsequently 
used to build abstractive summarizations in the forms of graphs (Fiszman, Rindflesch, 
and Kilicoglu 2004). Within the graphs, each vertex represents a concept while the edges 
represent the relationships between two concepts.  
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2.6 Literature Based Discovery 
 LBD is considered a more complex aspect of text mining or information retrieval 
(Berry and Castellanos 2004; Smalheiser 2012). Not only does it involve identification 
and extraction of salient information from text but seeks to uncover novel cross-
document associations that have never been publicly published (Ganiz et al. 2005; 
Swanson 2008).  
2.6.1 Literature Based Discovery Modes 
The majority of LBD approaches are built upon a paradigm now referred to as the 
ABC discovery model (Swanson 1987; Weeber et al. 2005; Smalheiser 2012). This 
model states that new knowledge can be discovered between two concepts (A, C) from 
non-interacting literatures, if hidden associations involving some intermediate concept 
(B) can be uncovered (Swanson 1986). This is simply the transitive property of relations; 
in other words, if an object A is associated with a second object B and that object B is 
associated with a third object C, then it can be inferred that first object, A, is associated 
with object C in some manner (Figure 3). These “B” concepts are frequently called 
intermediate terms.  
 
 
 
Figure 3. ABC Model Figure 4. AnC Model 
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The ABC model was later generalized by Wilkowski et al. where they proposed 
an extension where several intermediate concepts may be required to connect the A and C 
concepts (Wilkowski et al. 2011). This extension of Swanson’s ABC model is referred to 
as the AnC model wherein n = {B1, B2, ... , Bm} (Figure 4). The work of this dissertation, 
and the work by Cameron et al. (Cameron et al. 2015), are based off Wilkowski’s AnC 
model. 
Although Swanson’s work provided an explanation for his observations it did not 
propose any framework for finding such connections. As such, subsequent LBD research 
has begun to investigate better, and more automated, techniques and tools. 
 The ABC and AnC models have been implemented within LBD research in two 
modes: open and closed discovery. Open discovery is the embodiment of hypothesis 
generation and has been implemented in various approaches (Srinivasan 2004; Pratt and 
Yetisgen-Yildiz 2003; Weeber et al. 2001; Wren et al. 2004; Frijters et al. 2010). It 
assumes that the user begins with only a single concept (A) from their research questions 
and they propagate outward via associations to an unknown target concept C by means of 
one or more intermediate objects (Figure 5). 
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Figure 5. Open Discovery Mode 
 
 Closed discovery, in comparison, is characterized by testing one’s hypothesis and 
has also been widely implemented (Smalheiser, Torvik, and Zhou 2009; Srinivasan 2004; 
Hristovski et al. 2006; Hu et al. 2005; Gordon, and Dumais 1998; Ahlers et al. 2007; 
Cameron et al. 2013; Cameron et al. 2014; Lindsay and Gordon 1999; Weeber et al. 
2001). Within a closed discovery approach, typically both the source concept A and 
target concept C are known, but not necessarily the intermediate(s). These are instead 
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discovered via an exploration from both ends to determine potential interesting 
intermediates (Figure 6).  
 
Figure 6. Closed Discovery Mode 
 
 Regardless whether an LBD implementation is designed for open or closed 
discovery the algorithms used to determine intermediate candidates have included a 
variety of approaches including statistical, knowledge-based, semantic-based, citation-
based, and others.  
 
2.6.2 Statistical Literature Based Discovery 
The earliest LBD approaches established links between disjoint knowledge by 
looking for the most frequently co-occurring intermediate terms across documents 
utilizing statistical frequencies or distributions (Gordon and Lindsay, 1996; Lindsay and 
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Gordon, 1999; Gordon, Lindsay, and Fan 2002). The conventional wisdom was that 
discoveries are likely to arise from logical connections between terms or concepts that 
frequently (co)occur within literature. The intermediate terms are then ranked based on 
some relative frequency and presented to a researcher. While many of these techniques 
have been used to successfully discover (Swanson 1986; Swanson 1988), or recover 
previously discovered ones using a different approach (Gordon et al. 2002; Gordon & 
Dumais 1998; Gordon and Lindsay 1996; Lindsay and Gordon 1999), several problems 
exist. The reliance on statistical measures from text will favor co-occurring terms and 
potentially miss associations from less frequent terms (Kostoff et al. 2009). Furthermore, 
the statistics will be flawed in regards to Biomedical and Chemical entities that can be 
expressed in a variety of forms such as chemical names (Krallinger, Rabal, Lourenço, 
Oyarzabal, and Valencia 2017). In addition, these approaches rely on the researcher’s 
domain expertise and their ability to eliminate noise (terms that are too general or 
irrelevant) and refine their parameters. 
Most existing approaches for LBD use feature extraction to determine what a 
document is “about”. For example, a common approach for this type of textual analysis 
makes use of counts and frequencies of tokens (words or phrases) as they appear. If a 
particular token appears frequently within a particular document, it likely signifies 
importance to the overall meaning of that document. Furthermore, understanding the 
frequency across a collection of documents is also key. These relative frequencies give an 
indication of a term’s statistical importance (Gordon and Lindsay 1996). A typical metric 
used is TF-IDF (Sparck Jones 1972). Secondarily, the statistical approach can establish 
links between different papers by looking for the most frequently co-occurring terms or 
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concepts in those documents. This is achieved by computing the statistical distributions 
and frequencies of the terms without consideration of their semantics (Lindsay and 
Gordon 1999). 
Understanding the contextual information of a document may also illustrate an 
implicit association of concepts. If there is a large number of sources that associate two 
topics A and B together, and also a great number of sources that associate two topics B 
and C together. Then, it is plausible there is some association between A and C as well. 
Some developed strategies and tools to generate semantic associations between terms or 
compiled manual annotations. (Srinivasan 2004; Yetisgen-Yildiz and Pratt 2006; Ahlers 
2007; Frijters et al. 2010) Other work has utilized some of those strategies and direct 
mining to formulate testable hypotheses in specific areas through a series of manual 
steps. (Weeber et al. 2003) 
 The primary limitation of approaches using term co-occurrence is that although it 
can find intermediate concepts, it does not provide the relationship of those concepts. For 
example, the concepts of Reynaud Syndrome and platelet aggregation might be found, 
but not that platelet aggregation causes Reynaud Syndrome. In addition, these approaches 
break down if there is more than one level of separation between the initial and final set 
of concepts. That is to say that there might be relevant information that exists in longer 
chains of concepts that are semantically connected. 
 
2.6.3 Knowledge Based Literature Based Discovery 
A criticism of purely statistical approaches is that domain expertise is necessary to 
help refine a search, filter datasets, or extract plausible final results. In many cases it is 
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entirely left up to the researcher to employ such knowledge when interpreting results. 
However, within domain-specific knowledge repositories some of this expertise is “baked 
in” ahead of time so to speak. 
The knowledge-based approach gains its strength from the usage of additional 
knowledge-based resources such as vocabularies, databases, and ontologies. It is also 
quite common to find the usage of natural language processing as a basis of extraction 
(Weeber, Kors, and Mons 2005). 
 Knowledge-based approaches can prioritize terms according to specific semantic 
types, removing very general ones and targeting others (Hu, Yoo, Song, Zhang, and Song 
2005). Thus a more refined set of potential intermediate terms are generated which satisfy 
a set of researcher’s provided predefined semantic types. 
 An additional benefit that arises from these techniques is that variations in 
terminology and nomenclature can be recognized - that is to say, synonyms (different 
terms to designate the same concept) and homonyms (the use of words/phrases with 
multiple meanings). “For instance, IL-12, IL12, interleukin 12, CLMF, cytotoxic 
lymphocyte maturation factor, and natural killer cell stimulatory factor all refer to the 
same concept: Interleukin-12” (Weeber et al. 2003). Purely statistical approaches won’t 
draw connections between the variations, but normalizing extracted terms by means of a 
thesaurus or ontology allow them to be treated as a single term. 
 Fundamentally, knowledge sources can be subdivided into two broad categories 
based on the type of knowledge they contain. These two categories are: 1) definitional 
knowledge and 2) assertional knowledge. 
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2.6.3.1 Definitional Knowledge 
 Definitional knowledge refers to information that can be considered facts within a 
particular domain. In many cases these sources exist in the form as vocabularies, 
ontologies, or a database of facts.  One such example within the biomedical domain is the 
UMLS Metathesaurus. 
The UMLS Metathesaurus is a large biomedical thesaurus from the National 
Institute of Health that is organized by concept and links similar names for the same 
concept from nearly 200 different vocabularies and is comprised of close to 3 million 
unique concepts. 
Figure 7 shows a small portion from this dataset. In this snippet the first segment 
is the unique UMLS Concept identifier (C#) while other portions provide the 
corresponding identifier in other vocabularies such as MeSH, represented in these 
examples as D#. For example, in the figure Raynaud Disease is identified by C0034734 
and Raynaud Phenomenon is identified by C0034735 within the MetaThesaurus but are 
both associated with the same MeSH concept D011928. 
C0034734|ENG|S|L1446659|PF|S0974677|N|A3500400||M0018534|D011928|MSH|MH|D011928|Raynaud Disease|0|N|| 
C0034735|ENG|P|L1970983|PF|S0974685|N|A3486562||M0449202|D011928|MSH|PEN|D011928|Raynaud Phenomenon|0|N|| 
Figure 7. Sample entries from the UMLS Metathesaurus 
 
A second frequently used source is Medical Subject Headings (MeSH), which is a 
controlled vocabulary of biomedical terms from over 5000 biomedical journals organized 
into 16 hierarchical structures - each belonging to a different category such as Anatomy, 
Organisms, Diseases, Chemicals, and others.  MeSH has been utilized within LBD 
research to map text to known structured knowledge and to provide implicit context 
between co-occurring concepts. It also has been widely used to index, catalog, and search 
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MEDLINE articles. To accomplish this, MeSH descriptors are manually assigned to 
scientific articles by domain experts. “The quality of these assignments is considered 
high and relatively good indicators of the semantics of the content of the article to which 
they are assigned” (Cameron 2014). 
 
2.6.3.2 Assertional (Semantic) Knowledge 
Assertional knowledge refers to statements, predicates, and assertions that have 
been mined from scientific literature. Within the biomedical domain, processes are 
“inherently composed of interactions between various types of entities” (Bakal, Talari, 
Kakani, and Kavuluru 2018). Usually these statements are captured by an NLP tool, such 
SemRep from the National Institute of Health, as binary interactions connecting a subject 
entity to an object entity by means of some relation or predicate (subject-relation-object). 
SemRep matches subject and object terms with UMLS Metathesaurus concepts and the 
predicates from a list of types within the UMLS Semantic Network. An example, shown 
in Table 2, where the tool extracts a list of predicates from the given source text. 
 
Table 2. SemRep generated predicates from example source text 
Source Text: 
 
“We used hemofiltration to treat a patient with digoxin overdose that was complicated by 
refractory hyperkalemia” 
Extracted predicates: 
 
● Hemofiltration-TREATS-Patients 
● Digoxin overdose-PROCESS_OF-Patients 
● hyperkalemia-COMPLICATES-Digoxin overdose 
● Hemofiltration-TREATS(INFER)-Digoxin overdose 
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SemMedDB is a repository by the NIH consisting of semantic predications extracted 
from the titles and abstracts of Medline documents by the SemRep tool. 
 
 
2.6.4 Semantic Based Literature Based Discovery 
Traditional knowledge-based implementations that utilize definitional knowledge 
can provide improvements over standard statistical approaches, but they do not provide 
insights into the meaning of these associations. For example, in regards to the treatment 
of diseases, “drug therapies are often used effectively, even though the exact cause of 
action may be either poorly understood or unknown” (Ahlers, Hristovski, Kilicoglu, and 
Rindflesch 2007). Although providing a new novel association is ‘better than nothing’, 
LBD systems should strive to offer insight into the meaning of relationships as well. 
Several attempts have been made to employ semantic predicates to perform 
automatic abstractive summarization (Fiszman and Rindflesch 2004; Plaza, Díaz, and 
Gervás 2011). These approaches have chosen to represent their summaries using concepts 
rather than words and presenting the result as an interconnected graph. Traditionally 
graph-based summarization methods usually represent the documents as graphs where the 
vertices correspond to text units such as words, phrases, or sentences, and the edges 
represent a form of similarity (Plaza, Díaz, and Gervás 2011).  
In 2015, Cameron et al. devised a context-driven LBD approach based upon the 
earlier graph-based semantic summarization methods. Their method was a closed-
discovery approach: given a pair of concepts as user input their system automatically 
generates a graph representing the semantic associations between the two concepts. These 
graphs are then used to find semantically related pathways from one concept to another. 
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One of the main strengths of this technique is the ability to automatically extract 
subgraphs that allow researchers to interpret the meaning of the displayed predication 
pathways. In the study by Cameron et al. subgraphs were constructed with the use of a 
hierarchical agglomerative clustering algorithm to group edges based upon their 
similarity. For example one subgraph might illustrate how Fish Oils is connected to 
Raynaud’s Disease by way of Blood Viscosity effects, while a second subgraph illustrates 
this connection via Platelet Aggregation (Cameron et al. 2015). 
 
2.6.5 Citation Based Literature Based Discovery 
Bibliometric analyses in the field of scientometrics have shown that “the most 
productive authors are the ones engaged in the most innovative and varied research [and] 
in addition, these researchers draw from a larger pool of knowledge, indicating that they 
may be moving more often from topic to topic.” (Milojevic 2012). 
 Studying the structure of how documents are interrelated is usually is focused on 
citations. Several examples of which include direct citations, bibliographic coupling, and 
co-citations.  A direct citation is the simplest case where paper A cites paper B. 
Bibliographic coupling link exists between two papers A and B when each cites a 
common paper C. Lastly a co-citation link exists between two papers A and B when a 
third paper C cites both of them. Additionally, there are other possible ways to consider 
two references to have some type of link either involving citations or by other factors 
such as having authors in common.  
Kostoff was the first to explore bibliographic coupling within the field of LBD.  
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Kostoff’s approach begins like many other LBD algorithms using a pair of terms (A,C) 
and retrieving all the documents related to each. He then augments the list of records to 
include additional bibliographically coupled documents before performing some 
statistical based LBD algorithms. Results of his research indicate that shared references 
between two disjoint literatures could harbor many useful linking terms. The primary 
drawback of the technique is the labor intensive procedure and lack of automation 
(Kostoff 2014). 
 
2.7 Citational Coupling 
 Zhang, Ding, and Milojević state that it “has become a convention for scientists 
and researchers to refer to earlier work that relates to, inspires or is used by their own 
work” (Zhang, Ding, and Milojević 2013). This is in reference to an earlier document by 
Nicolaisen wherein certain basic assumptions are made about citations. That is, the 
citation of a document (1) implies the use of that document and (2) reflects the merit of 
that document (Nicolaisen 2007). 
 Sentences that contain a citation to another document are typically referred to as 
citation sentences, or citances. These sentences typically highlight the most important 
aspects of the paper being cited. This includes the research problem it addresses, a 
methodology, or the results. (Abu-Jbara and Radev 2011). The author of an article writes 
their abstract as a summarization to convey the central ideas from their perspective. 
Research has shown that citing sentences are a “collaborative summary that indicates 
what other researchers found relevant, interesting, or novel about the article” (Elkiss et al. 
2008). In bioscience literature it is common for the text around citations to state known 
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biological facts with reference to the original papers that discovered them (Nakov, 
Schwartz, and Hearst 2004). 
 Some studies have shown that the “information contained in the abstract and in 
the citances overlap to a large extent” (Divoli 2012). To that end efforts have been put 
into creating automatic summarization by using the citation sentences to build a second 
“abstract” for a given document constructed from all the papers that have cited it. This 
overlap between the meaning of the citation sentences and the abstracts of the cited 
articles goes both directions. Many times full-text is not necessarily available, and only 
titles and abstracts can be utilized. In these situations, it stands that the abstracts of cited 
references can be used as an indicator of a document’s body. 
 
2.8 Summary 
 Regardless of their implementation (i.e. statistical, semantic, etc.), LBD 
approaches are a blend of text processing techniques including text mining, information 
retrieval, question answering, and text summarization.  Each seeking to understand and 
extract salient details about documents to present the most likely connected information. 
Studies into summarization techniques have shown that strong connections between 
documents and those they cite such that they are semantically related. This paper 
therefore theorizes that bibliographic citations can improve LBD implementations when 
incorporated. 
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Chapter 3 
 
Methodology 
 
3.1 System Design 
The foundation for the proposed work relies on replicating the research performed 
by Cameron and then incorporating citationally related documents to improve the results. 
The foundation portion was completed first going so far as to produce a single graph of 
all uncovered predicates between two concepts focusing on the Fish Oils - Raynaud 
Disease study. This work was further extended wherein cited documents were added to 
the corpus and citational information was included as an initial study to determine if the 
hypothesis had merit. Due to the positive initial results subsequent retrospective 
experiments were conducted. 
A standard three tier architecture is utilized to process the requests (Figure 8). 
Upon receiving the request from the client, the web tier constructs an appropriate internal 
query for our in house search engine. The distributed search engine executes the queries 
(Apache Solr and otherwise) across multiple instances over an HDFS cluster and returns 
the query results. 
 
Figure 8. Three tier architecture 
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Chemical Abstracts, a division of the American Chemical Society, has multiple 
software products that allow researchers to search patents, journals, and other sources for 
chemically related information, including MEDLINE. Forms were added in an existing 
product’s user interface where a researcher simply types in the concept(s) of interest.  
  
3.2 Query Specification 
 Users need some method of querying the LBD system. For closed discovery 
approaches they will need to specify at least one ‘A’ concept and at least one ‘C’ concept 
for the AnC methodology described earlier. Whereas for open discovery only a single 
concept is needed as a starting point to explore.  
 
3.2.1 Query Specification (Open) 
 For open discovery, our interface allows the user to select a single concept from 
within the corpus and the initial predicate type of interest such as affects, causes, treats, 
and others (Figure 9).  
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Figure 9.  Example open subgraph query 
 
3.2.2 Query Specification (Closed) 
 Following the AnC pattern the design of our closed discovery system requires a 
query in the form of two sets of concepts. Our user interface for the closed query 
specification can be seen in Figure 10. The first set (Source) corresponds to the “A” set, 
and the second (Destination) to the “C” set. There are also additional configuration 
options to specify the desired path length, if citational information should be used, and if 
the user wishes to only return paths that pass through a particular intermediate.  
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Figure 10. Example closed subgraph query 
 
3.3 Preprocessing 
 Cameron’s closed discovery implementation (Cameron et al. 2015) is the basis for 
our approach, where the essential idea is to search all documents within the corpus that 
contain at least one of the terms provided (MeSH or UMLS) and to use semantic 
predications from those documents to build graphs. To accomplish this we need to have 
several distinct types of data: 1) we need to process a collection of MEDLINE documents 
and identify what concepts are contained within those documents, 2) we need to process 
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document citations to expand our document results, and 3) we need to identify what 
predicates are contained within those documents. 
All MEDLINE (currently over 29 million) documents along with their basic 
information were already available at Chemical Abstracts in the form of xml files 
available via HDFS. This includes the title, abstract, authors, and indexed MeSH 
concepts as defined within PubMed.  Documents within PubMed are only abstracts and, 
in general, do not contain information on their references. According to the National 
Institute of Health 37% of records added in the last five years contain full text (stored in 
PubMed Central) that is freely available. In these cases, the cited references were also 
available within the xml records, unfortunately, for our studies we found that less than 
one in ten fit this category. As such, when citational associations were not available this 
information was added manually for each study.  Additionally, in a small number of cases 
the PubMed record was also missing an abstract - for these, the abstracts were gathered 
from Publisher websites. This is indicated appropriately for each document within the 
appendix corresponding to each research study. 
The predicate information was acquired from the National Institute of Health as 
an export of the SemRep tool. It is periodically run against the entire MEDLINE database 
which contains titles and abstracts, and the download is provided via their website. The 
export can be placed into the form of csv text files for processing. In cases where the 
abstract was missing from the MEDLINE database, the tool was run manually on the 
abstract/introduction when found and the information added. Figure 11 shows a small 
portion from this dataset, where each entry identifies a unique relationship between two 
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concepts from the UMLS Metathesaurus and which document and sentence it was 
derived from. 
 
"5306041","32399885","1","1296760","STIMULATES","C0024467","Magnesium","bacs","true","C
0033567","Epoprostenol","bacs","true" 
 
Field 1: "5306041" - Auto-generated primary key for each unique predication 
Field 2: "32399885" - Foreign Key to a table of sentence information 
Field 3: "1" - The number of times the predication is extracted from the sentence 
Field 4: "1296760" - Medline Document ID 
Field 5: "STIMULATES" - Predicate Semantics 
Field 6: "C0024467" - Subject UMLS Concept ID 
Field 7: "Magnesium" - Subject Concept Name 
Field 8: "bacs" - Subject Semantic Type 
Field 9: "true" - Subject Novelty based on distance from root in UMLS Metathesaurus 
Field 10: "C0033567" - Object UMLS Concept ID 
Field 11: "Epoprostenol" - Object Concept Name 
Field 12: "bacs" - Object Semantic Type 
Field 13: "true" - Object Novelty based on distance from root in UMLS Metathesaurus 
Figure 11. Sample entry from the SemRep DB export  
 
In our implementation, as is typical in search engines, we make use of an offline 
compilation process to pre-process our data (Figure 12). Using Hadoop/Cascading we 
extract data from the formatted text (XML or CSV), parse the information, and then treat 
individual records as tuples. To be able to execute our queries, we then need to identify 
the classifications of data and how they are associated with each other. Thus, we need to 
identify documents, MeSH concepts, UMLS concepts, predicates, and their underlying 
relationships. By constructing this information during offline compilation we can build 
necessary solr indexes for searching and pre-defined mapping relationships such as 
“Document A cites Document B” which allow the queries to project from a given result 
set to another. Later, using our internal syntax we can perform an online solr query for a 
particular concept identifier then cross reference for all documents related to the results 
of the query. 
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// Extracts Tuples from source files 
Pipe referencePipe = new ReferenceExtraction(referenceInput); //each Reference 
Pipe predicatePipe = new PredicateExtraction(predicateInput); //each Predication 
Pipe meshPipe = new MeshExtraction(meshInput);                //each MeSH Concept 
Pipe umlsPipe = new UmlsExtraction(metaThesaurusInput);       //each UMLS Concept 
 
/* Calculates the Context for each Reference. That is, the MeSH Tree #s of all MeSH 
terms for that reference.*/ 
Pipe referenceContextPipe = new ReferenceContext(referencePipe, meshPipe); 
 
/* Each UMLS Concept already has its MeSH Concept ID from the MetaThesaurus entry where 
it was extracted if it exists. However, here we merge in the corresponding MeSH 
TreeNumbers.*/ 
umlsPipe = new UmlsMeshMergeAssembly(umlsPipe, umlsPipe); 
 
//Calculate the IDF for each UMLS Concept as they appear from predications. 
umlsPipe = new CalculatePredicateIDF(umlsPipe, predicatePipe); 
 
/* Determine the context of a predicate as the summation of the reference contexts from 
all references where that predicate has been extracted.*/ 
predicatePipe = new PredicateContextAssembly(predicatePipe, referenceContextPipe); 
 
//For each predicate merge in the MeSH TreeNumbers and UMLS Concept IDF scores. 
predicatePipe  = new PredicateMeshAssembly(predicatePipe, umlsPipe); 
 
//Construct solr Searchable/Indexed objects for query-time searching later. 
Pipe predicateIndexedEntry = new ConstructPredicateEntity(predicatePipe); 
Pipe referenceIndexedEntry = new ConstructReferenceEntity(referencePipe); 
Pipe umlsIndexedEntry = new ConstructUmlsEntity(umlsPipe); 
Pipe meshIndexedEntry = new ConstructMeshEntity(meshPipe); 
 
//Construct relationships to allow projections between object types. 
Pipe umlsToMeshRelationshipPipe = new ConstructUmlsToMeshRelationship(umlsPipe); 
Pipe predToDocRelationshipPipe = new ConstructDocToPredRelationship(predicatePipe); 
Pipe predToUmlsRelationshipPipe = new ConstructUmlsToPredRelationship(predicatePipe); 
Pipe meshToDocRelationshipPipe = new ConstructMeshToDocRelationship(referencePipe); 
Pipe DocToDocRelationshipPipe = new ConstructCitationRelationship(referencePipe); 
Figure 12. Example Hadoop code to prepare searchable digest 
 
3.4 Closed Search Algorithm 
Closed search is the most common among LBD implementations (Ahlers, 
Hristovski, Kilicoglu, and Rindflesch 2007; Cameron et al. 2013; Gordon and Dumais 
1998; Hristovski, Friedman, Rindflesch, and Peterlin 2006; Lindsay and Gordon 1999; 
Smalheiser, Torvik and Zhou 2009; Srinivasan 2004), namely because it applies the most 
constraints and, as such, makes the results more narrow and meaningful. Our general 
approach follows the same basis as described by Cameron et al in their paper (2015). 
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● Step 1 - User specifies “A” and “C” sets of concepts, a maximum path length k, 
and a date Dt. 
● Step 2 - Define the set D as all pubmed IDs published before Dt which contain 
any concept from set A or set C. 
● Step 3 - Define G and R as an empty graphs and the set S as empty. 
● Step 4 - For each pubmed id d ∊ D, add all predicates from d as edges into the 
graph G. 
● Step 5 - For all pairs of concepts (a,c) ∊ A x C, determine all possible paths 
between concept a and concept c of maximum length k inside G. All these to R. 
● Step 6 - Divide the graph R into smaller subgraphs, adding each into S. 
● Step 7 - Sort the collection S of subgraphs by ranking. 
 
Next we discuss our approach to the closed query formulation, leaving a discussion 
regarding subgraph generation and scoring algorithms for later in the chapter. 
 
3.4.1 System Query Construction 
 Our query process is summarized in the steps below, diverging from a 
generalization of Cameron’s algorithm only by adding steps 3 and 4 where the list of 
documents may optionally be expanded to also include any additional references that the 
initial set has cited. For each resulting document in step 5, we want to collect all defined 
semantic predicates. 
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● Step 1 - User specifies “A” and “C” sets of concepts. 
● Step 2 - Define the set S as the set of all documents within the corpus that contain 
at least one of the terms. 
● Step 3 - (Optional) Define the set S’ as the set of all documents cited by 
documents within the set S. 
● Step 4 - Define the resulting set of documents S’’ = S ∪ S’ 
● Step 5 - Define the set of predicates P as the set of all predicates defined for each 
document in S’’ 
● Step 6 - Create resulting graphs from the predicates within P. 
 
Steps one through five are formulated within a system query. Using the Fish Oil-Raynaud 
Syndrome study as an example, Figure 13 shows the portion of the system query which 
searches for the UMLS and MeSH concepts. 
query = 'UMLS_CONCEPT_NAME: "Fish Oils" | UMLS_CONCEPT_NAME: "Eicosapentaenoic Acid" | 
UMLS_CONCEPT_NAME: "Raynaud Disease" | UMLS_CONCEPT_NAME: "Raynaud Phenomenon" ' 
exploreQuery("subgraphTextQueryId") { solr(q: query) } 
//Search UMLS Concepts for the above query terms 
entity("umlsconcept") { 
  identifier 'UMLS_QUERY_ID' 
  search("solr") { queryId subgraphTextQueryId" } 
} 
//Find corresponding MeSH terms for the provided search concepts (UMLS) 
entity("mesh") { 
  identifier 'MESH_QUERY_ID' 
  constraint { 
    type "PROJECTION" 
    projection { 
      relationshipName "umls_to_mesh" 
      sourceIdentifier "UMLS_QUERY_ID" 
    } 
  } 
} 
Figure 13. Step 1 – Search for concepts 
 
When executed, the results return a total of four UMLS concepts, and three MeSH 
concepts. This is because both Raynaud Disease (C0034734) and Raynaud Phenomenon 
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(C0034735) within the UMLS are mapped to the single MeSH concept Raynaud Disease 
(D011928) (Figure 14).  
Retrieved umlsconcept results: (4) 
[UMLS_CONCEPT_ID:[C0000545], UMLS_CONCEPT_NAME:[Eicosapentaenoic Acid], 
MESH_ID:[D015118], INV_DOCUMENT_FREQ:[8.333311917991818]] 
[UMLS_CONCEPT_ID:[C0016157], UMLS_CONCEPT_NAME:[Fish Oils], MESH_ID:[D005395], 
INV_DOCUMENT_FREQ:[8.119986372349722]] 
[UMLS_CONCEPT_ID:[C0034734], UMLS_CONCEPT_NAME:[Raynaud Disease], MESH_ID:[D011928], 
INV_DOCUMENT_FREQ:[9.758878686545028]] 
[UMLS_CONCEPT_ID:[C0034735], UMLS_CONCEPT_NAME:[Raynaud Phenomenon], MESH_ID:[D011928], 
INV_DOCUMENT_FREQ:[8.87448928343275]] 
 
Retrieved mesh results: (3) 
[DESCRIPTOR_IDENTIFIER:[D005395], DESCRIPTOR_NAME:[Fish Oils], 
MESH_TREE_NUMBER:[D10.627.430]] 
[DESCRIPTOR_IDENTIFIER:[D011928], DESCRIPTOR_NAME:[Raynaud Disease], 
MESH_TREE_NUMBER:[C14.907.617.812]] 
[DESCRIPTOR_IDENTIFIER:[D015118], DESCRIPTOR_NAME:[Eicosapentaenoic Acid], 
MESH_TREE_NUMBER:[D10.212.302.380.410.385 D10.251.355.255.200 D10.251.355.337.290
 D10.627.430.450.390]] 
Figure 14. Results of step 1 system query 
 
Although MEDLINE documents have MeSH concepts assigned to them directly, 
content curators will only mark those concepts which are deemed significant. This is in 
contrast to SemRep predications that use UMLS concepts, which are extracted via NLP. 
As either approach might miss the presence of a topic, the second step requires fetching 
the appropriate references for our search terms from either of these initial sets.  The query 
is a simple projection (Figure 15).  
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//Find which predicates contain the given UMLS Concepts 
entity("predicate") { 
  identifier 'PREDICATE_QUERY_ID' 
  constraint { 
    type "PROJECTION" 
    projection { 
      relationshipName "predicate_to_umls" 
      sourceIdentifier "UMLS_QUERY_ID" 
    } 
  } 
} 
//Find set of references S which contain EITHER the MeSH term or a predicate 
//which contained the UMLS Concept. 
entity("reference") { 
  identifier 'REFERENCE_QUERY_ID' 
  constraint { 
    type "PROJECTION" 
    projection { 
      relationshipName "reference_to_mesh" 
      sourceIdentifier "MESH_QUERY_ID"          
    } 
  } 
  constraint { 
    type "PROJECTION" 
    projection { 
      relationshipName "predicate_to_document" 
      sourceIdentifier "PREDICATE_QUERY_ID" 
    } 
  } 
  or() 
} 
Figure 15. Step 2 – Search for the set S of references 
 
For each retrospective study we collected together the MEDLINE articles cited by the 
original LBD paper. We will refer to these as core papers as they were directly cited by 
the LBD researcher. Then, for each core paper, all cited MEDLINE papers were also 
added to our corpus. Although each of the studies focused on different areas, some 
overlap was found. This is due to both the inherent interconnectedness of biomedical 
science as well as later LBD papers citing earlier work. 
  Our example query results in a total of 193 documents from our corpus (Figure 
16). Those marked in red are from the Fish Oils-Raynaud Disease study and comprise the 
majority of the hits as expected. Those in blue come from a study around Magnesium-
Migraine Disorders, those in green come from a study about the Obesity Paradox, and 
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those in yellow are from the Somatomedins-Arginine papers. Additionally, bold pubmed 
id numbers are from a core paper and those in italics were cited from a core paper but are 
directly hit by the search terms. 
6109 561947 2983350 4106870 6097237 6166048 6300604 6376801 6812750 7362667 
53042 591484 2985986 4121220 6098049 6168223 6301111 6377247 6816332 7364865 
58309 594750 2989401 4218716 6098051 6192302 6302714 6383036 6821892 7378283 
72898 616031 2996169 4327362 6100033 6209510 6303363 6383760 6890719 7427564 
73104 636997 2997286 4544972 6102181 6229551 6307322 6432198 7025341 7435433 
89498 661616 3010003 4604746 6104008 6247744 6308046 6449756 7031981 7442530 
121610 698554 3030173 4693099 6104986 6247778 6314583 6469703 7037038 7459607 
215027 760690 3115623 4740483 6106100 6247894 6316965 6540787 7039582 12854830 
218223 762741 3157318 4792656 6107739 6252872 6318123 6540986 7082969 13851885 
277163 849637 3551081 4792657 6114257 6266305 6320840 6613908 7161779 13884560 
376042 878907 3711250 4808710 6117898 6266735 6320945 6617097 7195627 14061587 
388720 881094 3724238 5006758 6118628 6278536 6321621 6636033 7208950 14289442 
419455 884936 3797213 5083413 6123019 6281800 6329189 6639916 7212523 16963250 
428147 952739 3883365 5090397 6128596 6281802 6330926 6707529 7240991  
465096 1069432 3888229 5410395 6130329 6285445 6337664 6712540 7259326  
471766 1135634 3977414 5414890 6131248 6293041 6339921 6775675 7263863  
519354 1162080 3990714 5488384 6134122 6294902 6339937 6782927 7275566  
531220 2412071 4002440 5547282 6135105 6295686 6340424 6788326 7284246  
550156 2536517 4015748 5791479 6136879 6298902 6352267 6803303 7295999  
554069 2857265 4082084 6087007 6158764 6298968 6365102 6810413 7311739  
Figure 16. Results of step 2 system query  
 
Later, in chapter four, when we discuss each retrospective study we will examine the 
effectiveness of closed discovery and ensure that no results are skewed to this overlap. 
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The next step of our process gathers all of the cited references from these 193 
documents. The query is shown in Figure 17 and yields a total of 520 documents within 
our corpus. 
entity("reference") { //The set of references S’ = cited by the set of references S. 
  identifier 'CITED_REF_QUERY_ID' 
  constraint { 
    type "PROJECTION" 
    projection { 
       relationshipName "reference_to_cited_reference" 
       sourceIdentifier "REFERENCE_QUERY_ID"                
    } 
  }         
} 
Figure 17. Step 3 – Search for the set S’ of cited references 
 
In total this makes 561 unique references as many papers have overlapping references.  
The fifth step of the query takes this list of references and collects the predicates that 
were extracted from those documents via SemRep (Figure 18). For our example study 
this amounted to 2097 predicates.  
 
entity("predicate") { //Find the set of unique predicates that come from either S or S’ 
  identifier 'SUBGRAPH-QUERY-RESULTS' 
  constraint { 
    type "PROJECTION" 
    projection { 
      relationshipName "predicate_to_document" 
      sourceIdentifier "REFERENCE_QUERY_ID" 
    } 
  } 
  constraint { 
    type "PROJECTION" 
    projection { 
      relationshipName "predicate_to_document" 
      sourceIdentifier "CITED_REF_QUERY_ID" 
    } 
  } 
  or() 
} 
Figure 18. Steps 4 and 5 – Search for predicates from the union of S and S’ 
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3.4.2 Closed Graph Generation and Display 
 Our system query results will be a list of all predicates that have been derived 
from the documents related to the original query. For closed discovery, graph algorithms 
are then applied to distill all possible paths up to the specified length between the 
concepts of the A set and the concepts of the C set. Then, one or more directed 
predications graphs are created in which nodes are UMLS concepts and edges are UMLS 
predicates. An example graph can be seen in Figure 19.  
 
Figure 19. All paths of length two between Magnesium and Migraine Disorders 
 
 
 For ease of implementation, the points of the graph are distributed randomly in a 
three dimensional box with edges drawn between their corresponding vertices. This was 
accomplished using the THREE.js JavaScript framework. The image can be rotated, 
zoomed, and navigated to help fully understand all of the predicate relationships. This 
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particular graph is a candidate graph containing all possible paths between the two sets. 
Each graph edge represents one or more predicates that associate two concepts. The blue 
dots along the edge represent each type of connection such as treats, causes, isa, etc. 
Clicking on one of the blue dots navigates to a new page with every document that 
generated the predicate in question. Additionally when there are multiple predicate types 
that connect two concepts, multiple blue dots may appear.  
 It should be obvious that representing all of the resulting paths within a single 
graph will quickly become unusable with larger numbers of concepts and graph edges. As 
such, it is necessary to divide this resulting graph into multiple subgraphs and impose 
criteria to rank the results. This will be discussed later in this chapter. 
 
3.5 Open Search Algorithm 
 The closed discovery process is based around having some hypothesis to be 
explored. This creates the initial search concepts which generate the resulting connection 
graphs. At that point the user is left to explore the concepts which appear and the listings 
of references which produced the predicate graph edges.  An open discovery approach 
needs to be more dynamic and flowing as its purpose is to help uncover possibilities. As 
such we find that there needs to be a difference between the initial search starting the 
open discovery and the subsequent exploratory queries. 
 
3.5.1 Initial Open Discovery System Query Construction 
 Our exploratory approach, or open discovery, is started where a user specifies a 
single concept. However, this could prove to be intractable by itself as there are likely to 
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be a large number of other concepts that appear in a predication with the selected 
concept. Thus, the user must also specify an initial relationship of interest, such as treats  
or causes. The initial search is described as follows:  
 
● Step 1 - User specifies a single concept C and relationship R. 
● Step 2 - Define the set of predicates P as the set of all predicates that have the 
relationship R and where one of the concepts is C. 
● Step 3 - Create resulting display graph from the predicates within P.  
 
Here, as we are interested in predicates that specifically contain the provided concept and 
relationship there is no need to include additional documents via citational association or 
to gather up other predicates within the documents. Using the same example as before, 
perhaps we wish to start our exploration for things that are known to treat the condition 
known as Raynaud Disease. The query for this is simple and is shown in Figure 20. 
 
query = '(SUBJECT_NAME: "Raynaud Disease" | OBJECT_NAME: "Raynaud Disease") & 
(PREDICATE_DESCRIPTOR: "TREATS") ' 
exploreQuery("subgraphTextQueryId") { solr(q: query) } 
//Search Predicates directly for the above query terms 
entity("predicate") { 
  identifier 'SUBGRAPH-QUERY-RESULTS' 
  search("solr") { queryId subgraphTextQueryId" } 
} 
Figure 20. Open search query for predicates 
 
The results of the query will be a series of predicates, each with one of the concepts as  
the specified search concept, Raynaud Disease.  
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3.5.2 Open Graph Generation and Display 
The resulting predicates are shown directly connected to the user’s single search 
concept (Figure 21).  
 
Figure 21. Example open discovery for Raynaud Disease 
 
Unlike the closed discovery graphs, here, concepts can also be selected to further 
exploration. If the user starts their open discovery with Raynaud Disease, they can then 
select Epoprostenol as an exploration target. It then makes sense that the system will then 
display Epoprostenol in the center along with a new arrangement of related concepts 
(Figure 22). A breadcrumb trail is displayed showing the user their exploration path, also 
providing a quick method to return back to a previous concept or conduct a closed 
discovery search between their initial search concept and the current one. 
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Figure 22. Open discovery for Raynaud Disease –> Epoprostenol 
 
3.5.3 Subsequent Open Discovery System Query Construction 
 Subsequent exploration queries could continue to search for “all” predicates 
containing a single concept each time. However, this will be little coherence between the 
results from one search to the next subsequent search. By selecting a subsequent concept 
the user is essentially exploring the connection to that concept, not just the concept. Thus, 
it is important to take into consideration the result context when performing the next 
search. Our algorithm is as follows: 
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● Step 1 - Define the concept C’ as the previously selected concept within this open 
discovery exploration. 
● Step 2 - User selects concept C within results of an open discovery search. 
● Step 3 - Define the set S as the set of all documents within the corpus that contain 
a predicate that associates C with C’. 
● Step 4 - Define the set S’ as the set of all documents cited by documents within 
the set S. 
● Step 5 - Define the resulting set of documents S’’ = S ∪ S’ 
● Step 6 - Define the set of predicates P as the set of all predicates defined for each 
document in S’’. 
● Step 7 - Define the set of predicates P’ as the set of all predicates within P where 
one of the concepts is the selected concept C. 
● Step 8 - Create resulting display graph from the predicates within P’. 
 
The initial search (Figure 23) looks for predicates that connect concept C and C’ together.  
 
query = '(SUBJECT_NAME: ""Epoprostenol" & OBJECT_NAME: "Raynaud Disease") | 
(SUBJECT_NAME: "Raynaud Disease" & OBJECT_NAME: "Epoprostenol") ' 
exploreQuery("subgraphTextQueryId") { solr(q: query) } 
//Search predicates for the above query terms 
entity("predicate") { 
  identifier 'BASE_PREDICATE_QUERY_ID' 
  search("solr") { queryId subgraphTextQueryId" } 
} 
Figure 23. Steps 1-2 – Search for predicates that connect concept C’ and C 
 
The rest of the query steps follow a similar series of steps to our closed discovery 
implementation, collecting the predicates from the documents and cited documents. 
These can be seen together in Figure 24. 
  
 
 
 
55 
 
 
 
 
//Find the set of documents S that contain the predicates 
entity("reference") { 
  identifier 'REFERENCE_QUERY_ID' 
  constraint { 
    type "PROJECTION" 
    projection { 
      relationshipName "predicate_to_document" 
      sourceIdentifier "BASE_PREDICATE_QUERY_ID" 
    } 
  } 
} 
//Find the set of references S’ which are cited by the set of references S. 
entity("reference") { 
  identifier 'CITED_REF_QUERY_ID' 
  constraint { 
    type "PROJECTION" 
    projection { 
       relationshipName "reference_to_cited_reference" 
       sourceIdentifier "REFERENCE_QUERY_ID"                
    } 
  }         
} 
//Find the set of unique predicates that come from either S or S’ 
entity("predicate") { 
  identifier 'SUBGRAPH-QUERY-RESULTS' 
  constraint { 
    type "PROJECTION" 
    projection { 
      relationshipName "predicate_to_document" 
      sourceIdentifier "REFERENCE_QUERY_ID" 
    } 
  } 
  constraint { 
    type "PROJECTION" 
    projection { 
      relationshipName "predicate_to_document" 
      sourceIdentifier "CITED_REF_QUERY_ID" 
    } 
  } 
  or() 
} 
Figure 24. Rest of predicate query for subsequent open discovery 
 
3.6 System Query Post-Processing 
During the execution of our retrospective studies, it was noticed that a number of 
concepts and predicates would appear within the results that had little to no value. The 
SemRep tool produces a large variety of predications, each with a semantic type that 
associates the two concepts. Some types such as treats, stimulates, or causes provide 
useful meaning, while others such as administered_to, diagnoses, and location_of are of 
less usefulness for our purposes. Additionally, concepts such as Patients or Human which 
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are so pervasive within the literature also provide little to no meaning. Two types of 
filters were placed during post-processing to account for these situations: one for 
predicates and one for concepts. 
 
3.6.1 Concept Filtering 
 The standard approach for examining the “value” of concepts/words is to start by 
calculating the Inverse-Document Frequency (IDF) of each concept. This is normally 
computed during the compilation of the corpus. The difficulty for our study arises from 
two aspects. The first is the smaller total number of documents within our corpus 
(thousands of documents rather than millions).  The second comes from the challenge of 
using NLP to associate words from titles and abstracts to the UMLS concepts within our 
results. Due to these restrictions the IDF was instead calculated based upon the 
predications data from SemRep for all of MEDLINE – consisting of 85.7 million 
predicates extracted from 16 million documents.  For a given UMLS concept, if it exists 
within a predicate, then it is counted as existing within that document. 
From Equation 2.1, the more times a particular term shows up across the corpus, 
the smaller the IDF value will be. For a given closed search, each predicate returned from 
a system query contains two concepts. The set of unique concepts returned can then be 
examined. An examination of the IDF scores for the Magnesium – Migraine Disorders 
study is illustrated in Figure 25. Table 3 then shows the lowest ten concepts, all with little 
semantic meaning. 
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Figure 25. Histogram for concepts returned for Magnesium – Migraine Disorders 
 
 
 
Table 3. Lowest concepts by IDF score returned for Magnesium – Migraine Disorders 
Concept IDF score 
Patients 1.449559652 
Therapeutic procedure 2.345444877 
Human 2.821365442 
Cells 2.903629008 
Rattus norvegicus 2.996794117 
Disease 3.147157075 
Child 3.273016623 
Woman 3.545474848 
Mus 3.584664126 
Pharmaceutical Preparations 3.64006119 
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The web tier can cull any predicates that contain a concept with a score lower than a 
given threshold. For experimental purposes we utilized a value that was two standard 
deviations below the mean score. 
 A second approach to remove uninformative relationships involves MeSH tree 
numbers. Each MeSH concept is organized into a hierarchy consisting of sixteen root 
categories listed in Appendix F. Category A contains anatomic terms, B is for organisms, 
C for diseases, D for drugs/chemicals, etc. With each category descriptors are arranged 
hierarchically from most general to most specific. As an example, the MeSH tree number 
for Raynaud Disease is C14.907.617.812, laying in category C because it is classified as 
a disease. Above it in the hierarchy is C14.907.617 for peripheral vascular diseases, 
C14.907 for vascular diseases, and C14 is for Cardiovascular diseases (Figure 26). A 
concept’s tree number can help identify how general or specific it is, and some LBD 
studies have made use of this to remove suggestions that were too general (Zhang, 
Fiszman, Shin, Wilkowski, and Rindflesch 2013; Fiszman, Rindflesch, and Kilicoglu 
2004; Swanson, Smalheiser, and Torvik, V. I. 2006). 
 
Figure 26. Sample MeSH Tree  
C - Diseases 
C14 - Cardiovascular Diseases C2 - Virus Diseases 
C14.907 - Vascular Diseases C14.280 - Heart Diseases 
C14.280.358 - Heart Aneurysm C14.907.617 - Peripheral Vascular Diseases 
C14.907.617.812 - Raynaud Disease C14.907.617.500 - Erythromelalgia 
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 Our primary results rely on semantic predications which relate two UMLS 
concepts. As not all UMLS concepts have an associated MeSH descriptor, they will also 
not have a corresponding MeSH Tree number. For those that do, having a shorter tree 
number indicates a more general concept and potentially is less useful. An examination of 
the average IDF values as a function of the MeSH tree depth shows just this. For the three 
studies Fish Oils-Raynaud Disease, Magnesium-Migraine Disorders, and Somatomedins-
Arginine the list of predicates resulting from the search query was captured. For each 
study the list of unique concepts was extracted and divided into groups by MeSH tree 
number length. If a concept had more than one tree number, the closest integer average 
length was used.  
 
Figure 27. Average IDF value of concepts as a function of MeSH tree depth 
 
 As can be seen in Figure 27, more general concepts (i.e. shorter tree number 
length) have a smaller average IDF score than more specific terms. A closer examination 
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of the concepts shows us more concrete examples to determine an appropriate cutoff.  
Table 4 shows a listing of concepts with a tree depth of one for the same three studies 
along with their UMLS concept identifier and the MeSH Tree Number.  
Table 4. Concepts with MeSH tree depth of one for three studies 
C0043250 Injury wounds [C26] C0013227 
Pharmaceutical 
Preparations [D26] 
C0007613 Cell physiology [G04] C0007634 Cells [A11] 
C0007222 Cardiovascular Diseases [C14] C0087111 Therapeutic procedure [E02] 
C0023779 Lipids [D10] C0751282 
Macromolecular 
Complexes [D05] 
C0040300 Body tissue [A10] C0005515 Biological Factors [D23] 
C0027361 Persons [M01] C0021053 Immune System Diseases [C20] 
C0543467 
Operative Surgical 
Procedures [E04] C0007004 Carbohydrates [D09] 
C0013227 
Pharmaceutical 
Preparations [D26] C0007613 Cell physiology [G04] 
C0007634 Cells [A11] C0043251 Wounds and Injuries [C26] 
C0087111 Therapeutic procedure [E02] C0023779 Lipids [D10] 
C0029224 Organic Chemicals [D02] C0004611 Bacteria [B03] 
C0014130 
Endocrine System 
Diseases [C19] C0011900 Diagnosis [E01] 
C0027765 nervous system disorder [C10] C0040300 Body tissue [A10] 
C0007004 Carbohydrates [D09] C0027361 Persons [M01] 
C0007613 Cell physiology [G04] C0006826 Malignant Neoplasms [C04] 
C0007222 Cardiovascular Diseases [C14] C0543467 
Operative Surgical 
Procedures [E04] 
C0023779 Lipids [D10] C0013227 
Pharmaceutical 
Preparations [D26] 
C0006826 Malignant Neoplasms [C04] C0007634 Cells [A11] 
C0543467 
Operative Surgical 
Procedures [E04] C0087111 Therapeutic procedure [E02] 
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As before, those in red are from the query results of the Fish Oils-Raynaud 
Disease study, those in blue come from a study around Magnesium-Migraine Disorders, 
and those in yellow are from the Somatomedins-Arginine papers. A glance over these 
concepts shows that all of them are too general to be useful as potential intermediates as 
we are interested in more specific biochemical connections. The same is also true for 
those concepts with a depth of two. At a depth of three we find a mixture of useful 
concepts such as Hypertension (C0020542) [C08.381.423] and less useful like Human 
Volunteers (C0020155) [M01.774.500].  The above analysis led to the culling of any 
predicates that contain a concept with either a tree depth of one or two.  
 
3.6.2 Predicate Filtering 
 Most of the post-processing is accomplished via an examination of the concepts 
within each predicate. However, each predicate also has one of thirty semantic types 
which characterizes the relationship between the two concepts (Table 5). In addition, all 
but three of the types can appear in a negated form that have the prefix “NEG_”. The 
semantic meaning of these connections may not be applicable for all studies attempting to 
uncover hidden knowledge.  
The types administered_to, location_of, process_of, method_of, part_of, and uses 
consistently appear at the bottom of IDF scoring of predicates by group. This is caused by 
the prevalence of more generic concepts within such groupings: such as “water - 
administered_to - patients”, “heart - location_of - fatty acids”, “anemia - process_of - 
patients”, and so on. In addition, some types such as diagnoses and occurs_in are less 
useful to us because such relations discuss procedures, in the case of diagnoses, and 
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population groups in the other. For our studies, where we wish to examine biochemical 
interactions, we filter out predicates with these eight semantic types.  
 
Table 5. Predicate Semantic Types 
Clinical Biologic General 
ADMINISTERED_TO ASSOCIATED_WITH AFFECTS 
COMPLICATES AUGMENTS CAUSES 
DIAGNOSES CONVERTS_TO COEXISTS_WITH 
MANIFESTATION_OF DISRUPTS COMPARED_WITH 
OCCURS_IN INHIBITS HIGHER_THAN 
PREDISPOSES INTERACTS_WITH ISA 
PREVENTS STIMULATES LOCATION_OF 
PROCESS_OF  LOWER_THAN 
TREATS  METHOD_OF 
  PART_OF 
  PRECEDES 
  PRODUCES 
  SAME_AS 
  USES 
 
 For closed discovery, the remaining predicates are then used to form a graph 
which can be very large and challenging to explore. Paths are computed from any source 
concept within (A set) to any target concept (C set), for path lengths up to the specified 
length.  
 Recall the earlier description of document sets S and S’ (Figure 2). By definition 
the document set S contains all documents which contain at least one concept from the 
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union of the sets A and C. Therefore, all predicates that contain either an A or C concept 
must also come from those documents in S. 
 
 
Figure 28. Predicates within document sets S and S’ 
 
A revisualization of this is shown in Figure 28. Predicates containing either an A or C 
concept must be within S, but past that there are no restrictions (i.e. all other possible 
concepts and predicates that connect those concepts may be in S, S’, both, or neither). 
When we consider paths of length two with a single intermediate concept [A-B1-C], then 
predicates will originate from papers containing the original search terms as each of the 
two predicates contain at least one search concept (Figure 29).  
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Figure 29. Paths of length two within document sets S and S’ 
 
Once you consider paths of length three [A-Bm-Bn-C], you allow for one predicate that 
does not contain a search term [Bm-Bn]. By observation the starting predicate [A-Bm] and 
the ending predicate [Bn-C] must be found within S, and therefore all four concepts must 
also be found within S.  However, the connecting predicate [Bm-Bn] can also be found 
outside S – which in our case, will be S’ (Figure 30).  
 
Figure 30. Paths of length three within document sets S and S’ 
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We can further extend this analogy to paths of lengths four [A-Bm-Bn-Bo-C] 
which can be seen in Figure 31. It is at this point possible for a path to be formed that 
includes a concept that is not present within any of the documents of S. This analogy can 
be continued to further increase the possible number paths found, however, increasing 
path lengths will, at some point, cause each pair of concepts in the graph database to be 
connected as greater and greater numbers of predicates are included. As such, there is an 
expectation that the number of paths will grow quickly and the average value of those 
paths to decrease. 
 
Figure 31. Paths of length four within document sets S and S’ 
 
Using the Fish Oil-Raynaud Disease study as an example, the total number of 
paths found and the average path IDF score were calculated as the maximum path length 
was varied from two to five. The average IDF score for a given path was calculated as the 
average of the IDF scores of each of the concepts that comprised the path. The average 
was then computed across all paths returned (Figure 32).  
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Figure 32. Paths found and average path IDF varying with maximum path length 
 
From this it can be seen that the graph complexity (number of paths) grows quickly as a 
function of path length. Additionally, the average IDF value for those paths declines as 
additional ‘low value’ connections are made. These two facts match the intuitive idea that 
a more direct connection has more meaning. 
The studies detailed in the next chapter are based upon previous work within the 
field. The seminal papers from which the discoveries were originally made tend to 
provide supporting evidence in the form of citations. Considering the ABC model for 
simplicity, in many cases the authors point out those documents supporting where either 
‘half’ of the connection is derived (e.g. [A-B] or [B-C]). If a perfect set of semantic 
predicates were to be generated from all of those documents, then merely examining 
paths of length two would be sufficient to recover the connections. However, if our 
predicates are not a perfect representation of the semantic knowledge contained within 
those documents, then we want to make use of their citations as an alternative means of 
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summarization. As a compromise between graph complexity and desiring the information 
gain from citations, our trials are conducted utilizing path lengths of three by default, two 
when possible. 
3.7 Subgraph Generation 
As we’ve seen, even with a small corpus a search may result in hundreds or 
thousands of possible paths. This has caused researchers to explore approaches to filter, 
compare, and organize their concepts or predicates.  
 
3.7.1.1 Degree Centrality   
Graph theory defines degree centrality as a measure of connectedness of the 
vertices within a graph. By definition, a vertex with more edges than other vertices has 
higher degree centrality. Researchers have hypothesized that this equates to the 
importance of the corresponding concepts (Wilkowski et al. 2011; Zhang et al. 2011; 
Zhang, Fiszman, Shin, Wilkowski, and Rindflesch 2013). In their 2011 study “Degree 
centrality for semantic abstraction summarization of therapeutic studies” Zhang et al. 
used this method on SemRep predications to summarize the most important information 
from a collection of documents. They achieved better results when compared to term 
frequencies. Wilkowski et al. also used degree centrality when comparing possible paths, 
reducing large graphs by retaining only paths which contained highly connected 
concepts.  
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3.7.1.2 Fact Checking 
When considering knowledge in general, statements of facts are in the same form 
as our predications: (subject, predicate, object) triples. If these then existed within a 
perfect knowledge graph, fact checking would be as trivial as checking for the existence 
of an edge. Unfortunately, our graphs of knowledge not only have limited information 
but also suffer from missing or incorrect assertions (Shi and Weninger 2016). When 
considering the knowledge contained within a large body of scientific papers there will 
exist duplicate or even contradictory assertions, not to mention that what can be regarded 
as true in one moment may change over time. 
The frequency in which a given piece of knowledge appears within a corpus has 
been used as a measure of its validity for information retrieval (Kan, McKeown, and 
Klavans 2001; Zhang et al. 2013). In a newer study, NLP has been used to attempt to 
extract a factuality measure along with the predications Kilicoglu, H., Rosemblat, G., & 
Rindflesch, T. C. (2017). The basis of their work is formed on the idea that most 
biomedical knowledge claims are expressed in the form of hypotheses or speculation 
rather than explicit statements of fact. Additional linguistic analysis examine the words 
used (e.g. “Nifedipine increase blood flow”, “our findings support the hypothesis”, “may 
benefit”, “does not support”, etc.) and attempts to assign a factuality score: Fact, 
Probable, Possible, Counterfact, Conditional, etc.). These approaches attempt to order 
possible results by the degree of measured or implied factuality. 
 
3.7.1.3 Concept Similarity 
One of the strengths of utilizing predicates is the inherent semantic meaning 
contained with a path relating two concepts. A reasonable goal would be to cluster 
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together predicates that are more closely related to that higher level concept. For 
example, in the Fish Oils-Raynaud Disease study we could expect one grouping around 
the topic of Platelet Aggregation and a different one around the topic of Blood Viscosity 
– similar to how latent semantic analysis attempts to produce collections of terms around 
higher order themes. 
One of the simplest measures to compare concepts is a technique based on the 
reciprocal of the shortest path length between a pair of concepts within an ontology 
(Rada, Mili, Bicknell, and Blettner 1989; Lee, Kim, and Lee 1993). For instance, in 
Figure 26 the similarity score between Raynaud Disease and Vascular Disease is the 
same as between Erythromelalgia and Vascular Disease because the distance is the same. 
A weakness of this approach lies in the assumption that the link or association 
between a concept and its parent are uniform distances. In 1995, Resnik introduced an 
equally simply but alternative measure based upon the concept of information content. 
Resnik stated that “one key to the similarity of two concepts is the extent to which they 
share information in common” (Resnik 1995). That is the connecting path between the 
concepts must go through a concept that is abstract enough to contain them both. For our 
earlier example (Figure 26) Erythromelalgia and Raynaud Disease are connected through 
Peripheral Vascular Diseases while Virus Diseases and Raynaud Disease are only 
connected through the root Diseases. 
Resnik also suggested the association of probabilities with the concepts to avoid 
the unreliability of edge distances. Each concept was assigned a value that equates to the 
probability of encountering an instance of that concept. In information theory, 
information content is defined as the amount of information gained when a random 
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variable or signal is sampled (Ross 2014). In this case, the information gained for a 
concept (E) with probability P is simply: 
I(C) := -log(P) (3.1) 
This should make intuitive sense: as the probability increases (the more abstract the 
concept), the lower its potential information content (Figure 33). 
 
 
Figure 33. Information Content as a function of probability 
 
Resnik, taking into account multiple inheritance, defined his similarity as the information 
content of the least common subsumer of both concepts. In a more general sense, the 
semantic similarity between two concepts is proportional to the amount of information 
they share (Resnik 1995; Jiang and Conrath 1997; Lin 1998). 
 
3.7.2 Path Relatedness 
A fundamental requirement for clustering paths based upon semantic meaning is 
the ability to define how similar two paths are to each other. According to Cameron, 
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assertions in scientific literature which are related will usually occur in similar contexts, 
and that the context of a path is the aggregation of the context of each assertion or 
predication within the path (Cameron 2014). 
To define the context of a single semantic predication Cameron made two 
assumptions. The first is that as MEDLINE articles are manually assigned a list of MeSH 
descriptors, these form a semantic summary of the full text of the article comprised of 
concepts. In addition, the predications themselves form a relational semantic summary by 
associating one concept to another. As both capture the implicit context of the reference, 
the concept-level semantic summary (MeSH descriptors) and relational semantic 
summary (predications) are interchangeable, albeit not equal, perspectives. 
The essence of the second assumption is succinctly stated by the English linguist 
John Rupert Firth: “You shall know a word by the company it keeps” (Firth 1957). In 
other words, that the “context of an individual predication across the entire corpus could 
be represented more comprehensively, as the aggregation of the MeSH descriptors 
assigned to each document in which it occurs” (Cameron 2014).  
Cameron continued this reasoning to define the context of a path as the 
summation of the contexts of its predicates. While standard distributional approaches 
would assign frequency vectors as the context of each predicate and then to use cosine 
similarity to compare paths, this is a poor fit as the goal is to cluster paths based upon 
relatedness and not similarity. Additionally, because the concept descriptors are arranged 
in a hierarchical structure, concepts will have one or more tree numbers that indicate their 
relative positioning within the tree. If two different concepts share some common parents 
they will share some semantic meaning. For example, the MeSH term Fish Oils 
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(D005395) has a tree number of D10.627.430. The D signifies Chemicals and Drugs, 
D10 is the identifier for lipids, and D10.627 identifies oils. Thus, another concept such as 
Fatty Acids, Omega-3 with a tree number of D10.627.430.450 signifies that it is closely 
related to the concept of Fish Oils.  
The Sørensen–Dice coefficient, or Dice similarity, is a statistic used to measure 
the similarity between two sets (Eq 3.2). 
 
(3.2) 
 
(3.3) 
This measure has long been applied to terms within a taxonomy leveraging information 
measures and the least common parent that subsumes both terms (Lin 1998). Cameron’s 
suggestion was that the dice similarity between two MeSH descriptors mi and mj could be 
computed based upon the sets A(mi) and A(mj) respectively where A(m) is the set of all 
ancestors of the MeSH descriptors m (Eq 3.3). For example, the dice similarity between 
Fish Oils (D10.627.430) and Fatty Acids, Omega-3 (D10.627.430.450) is calculated as 
follows:  
A(Fish Oils) = {D10.627.430, D10.627, D10} 
A(Fatty Acids, Omega-3) = {D10.627.430.450, D10.627.430, D10.627, D10} 
A(Fish Oils) ∩ A(Fatty Acids, Omega-3) = {D10.627.430, D10.627, D10} 
dice (Fish Oils, Fatty Acids, Omega-3) = (2 x 3) / (4 + 3) = 6/7 
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The range of similarity values is [0,1] where the maximum similarity occurs when the 
two descriptors are equal. Cameron further defines a normalized dice similarity score by 
using a similarity threshold (𝜏𝜏 sim = 0.75) in an effort to maximize the weight of in-context 
descriptors and minimize the weight of out-of-context descriptors (Eq 3.4). 
 
(3.4) 
 
(3.5) 
The semantic relatedness sr’’(pi,pj) between two paths pi and pj, is then computed as the 
sum of the pairwise normalized dice similarity between the context sets C(pi) and C(pj) 
(Eq 3.5). Take the following two paths from our results explained later as an example: 
 
pi Eicosapentaenoic Acid INTERACTS_WITH Epoprostenol TREATS 
Raynaud 
Phenomenon 
pj Eicosapentaenoic Acid STIMULATES Epoprostenol TREATS 
Raynaud 
Disease 
 
The first predicate (pred1), Eicosapentaenoic Acid - INTERACTS_WITH - Epoprostenol 
appears only in [PMID6252872] which is in our corpus because it is cited by three core 
references [PMID6302714, PMID6318123, PMID6321621]. The second predicate (pred2), 
Epoprostenol - TREATS - Raynaud Phenomenon appears in three core papers 
[PMID3883365, PMID6788326, PMID7037038]. The third predicate (pred3), 
Eicosapentaenoic Acid - STIMULATES - Epoprostenol comes from [PMID6098049]. The 
last predicate (pred4), Epoprostenol - TREATS - Raynaud Disease appears in the core 
reference [PMID3883365] and one of the papers it cites [PMID7025341].  
 
 
 
74 
 
 
 
 The context set for each of these predicates is simply the aggregate of the MeSH 
descriptors of all the documents from which it is present. Table 6 shows the context sets 
for these four predicates along with the document identifiers where each concept 
originated.  The context set for each path is then simply the unique set of MeSH 
descriptors aggregated from its predicates. For pi, this is the 27 unique terms resulting 
from the union of C(pred1) and C(pred2), and for pj, this is the 26 unique terms resulting 
from the union of C(pred3) and C(pred4).  
For the 702 pairs only 32 cross the similarity threshold (Table 7). Of these 18 are 
self matches, leaving only 14 that are more interesting. An example calculation of one 
pair is as follows for the case mi = Epoprostenol [D10.251.355.255.550.550.500] and 
mj = Prostaglandins [D10.251.355.255.550]: 
 
A(Epoprostenol) = {D10.251.355.255.550.550.500, D10.251.355.255.550.550, 
D10.251.355.255.550, D10.251.355.255, D10.251.355, D10.251, D10} 
A(Prostaglandins) = {D10.251.355.255.550, D10.251.355.255, D10.251.355, D10.251, 
D10} 
A(Epoprostenol) ∩ A(Prostaglandins) = A(Prostaglandins) 
dice (Epoprostenol, Prostaglandins) = (2 x 5) / (7 + 5) = 10/12 = 0.833 
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Table 6. Context set for example predicates 
C(pred1) C(pred2) C(pred3) C(pred4) 
Arachidonic Acids 
(PMID6252872) 
6-Ketoprostaglandin F1 alpha 
(PMID3883365) 
Arachidonic Acids 
(PMID6098049) 
6-Ketoprostaglandin F1 alpha 
(PMID3883365) 
Blood Vessels 
(PMID6252872) 
Adult  
(PMID3883365,PMID7037038) 
Eicosapentaenoic Acid 
(PMID6098049) 
Adult 
(PMID3883365) 
Eicosanoic Acids 
(PMID6252872) 
Aged 
(PMID7037038) 
Endothelium 
(PMID6098049) 
Ambulatory Care  
(PMID7025341) 
Eicosapentaenoic Acid 
(PMID6252872) 
Epoprostenol  
(PMID3883365, PMID6788326, 
PMID7037038) 
Epoprostenol 
(PMID6098049) 
Buffers 
 (PMID7025341) 
Epoprostenol 
(PMID6252872) 
Erythrocyte Deformability 
(PMID3883365) 
Fatty Acids, Unsaturated 
(PMID6098049) 
Clinical Trials 
(PMID7025341) 
Fatty Acids, Unsaturated 
(PMID6252872) 
Erythrocytes 
(PMID6788326) 
Humans 
(PMID6098049) 
Epoprostenol (PMID3883365, 
PMID7025341) 
Humans 
(PMID6252872) 
Female 
(PMID3883365, PMID6788326, 
PMID7037038) 
Indomethacin 
(PMID6098049) 
Erythrocyte Deformability 
(PMID3883365) 
Platelet Aggregation 
(PMID6252872) 
Humans 
(PMID3883365, PMID6788326, 
PMID7037038) 
Platelet Aggregation 
(PMID6098049) 
Female  
(PMID3883365, PMID7025341) 
Prostaglandins 
(PMID6252872) 
Infrared Rays  
(PMID7037038) 
Umbilical Veins 
(PMID6098049) 
Fingers  
(PMID7025341) 
Thromboxanes 
(PMID6252872) 
Infusions, Parenteral 
(PMID7037038) 
 Hand  
(PMID7025341) 
Umbilicus 
(PMID6252872) 
Male 
(PMID3883365, PMID6788326, 
PMID7037038) 
 
Humans  
(PMID3883365, PMID7025341) 
 
Middle Aged 
(PMID7037038) 
 Injections, Intravenous 
(PMID7025341) 
 
Prostaglandins  
(PMID6788326, PMID7037038) 
 Lupus Erythematosus, Systemic 
(PMID7025341) 
 
Prostaglandins E 
(PMID6788326) 
 Male 
 (PMID3883365) 
 
Radiometry 
(PMID7037038) 
 Prostaglandins  
(PMID7025341) 
 
Raynaud Disease  
(PMID3883365, PMID6788326, 
PMID7037038) 
 
Raynaud Disease 
 (PMID3883365, PMID7025341) 
 
Scleroderma, Systemic  
(PMID3883365, PMID6788326) 
 Scleroderma, Systemic 
(PMID3883365) 
 
Thermography 
(PMID7037038) 
 
Thermography (PMID7025341) 
 
Time Factors 
(PMID7037038) 
 
Time Factors (PMID7025341) 
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Table 7. MeSH descriptors pairs mi x mj that exceed 𝜏𝜏sim 
mi mj ∑(diceN(mi,mj
)) 
Epoprostenol Epoprostenol, Prostaglandins 2 
Eicosapentaenoic Acid Eicosapentaenoic Acid, Arachidonic Acids,  
Prostaglandins 
3 
Thromboxanes Arachidonic Acids 1 
Fatty Acids, Unsaturated Fatty Acids, Unsaturated 1 
Humans Humans 1 
Arachidonic Acids Eicosapentaenoic Acid, Arachidonic Acids,  
Prostaglandins 
3 
Platelet Aggregation Platelet Aggregation 1 
Prostaglandins Eicosapentaenoic Acid, Arachidonic Acids, 
Prostaglandins, Epoprostenol,  
6-Ketoprostaglandin F1 alpha 
5 
Erythrocyte Deformability Erythrocyte Deformability 1 
Female Female 1 
Raynaud Disease Raynaud Disease 1 
Male Male 1 
6-Ketoprostaglandin F1 6-Ketoprostaglandin F1, Prostaglandins 2 
Scleroderma, Systemic Scleroderma, Systemic 1 
Adult Adult 1 
Time Factors Time Factors 1 
Middle Aged Adult 1 
Thermography Thermography 1 
Aged Adult 1 
Prostaglandins E Prostaglandins, Epoprostenol,  
6-Ketoprostaglandin F1 alpha 
3 
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 Cameron noted that a broad range of scores may exist for this approach and 
additionally suggested using a log reduction in addition to the normalized dice similarity 
scores. This was accomplished by adding an additional step to compute the relatedness 
between a single MeSH descriptor to the context set of descriptors for a path (Eq 3.6). 
 
(3.6) 
 
(3.7) 
Using this new equation for the semantic relatedness between two paths (Eq 3.7), and 
data calculated in Table 7, for our example we see that: 
  
  
3.7.3 Cluster Similarity 
 If the desired goal is to achieve one or more result graphs with semantically 
related paths, then there is an additional measure we require. Equation 3.7 measures how 
much two single paths are related to each other, but another statistic is required when 
comparing one cluster to another. Hierarchical clustering algorithms measure this 
similarity in one of four ways (Manning, Raghavan, and Schütze 2008). 
 The first, single-link similarity, simply uses the similarity between the pair most 
similar between the two clusters. The second, complete-link similarity, uses the pair most 
dissimilar. The third is centroid, or average inter-similarity across all pairs between the 
two clusters. Lastly, the fourth is the average of all similarities between all pairs 
including those pairs from the same cluster. Cameron noted that centroid similarity is 
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ideal for the merging of two groups of paths as it will maintain the greatest amount of 
relatedness. As such he defines the inter-cluster similarity between two buckets Ba and Bb 
each containing one or more paths:  
 
(3.8) 
 
3.7.4 Subgraph Clustering 
 Cameron used a hierarchical agglomerative clustering (HAC) algorithm to 
construct coherent subgraphs based on the context relatedness of the individual paths 
(Cameron 2014). Initially starting with a number of buckets equal to the total number of 
possible paths, they iteratively calculate the relatedness between a set of paths from one 
bucket to each other. If the score exceeds a threshold the buckets are combined. 
Repeating the process until no more buckets are merged. This can result in one or more 
subgraphs whose paths share greater semantic meaning, and thus should appear less 
cluttered. The steps for Cameron’s algorithm are shown in Table 8. 
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Table 8. Hierarchical Agglomerative Clustering algorithm used by Cameron et al. 
Step 1: For each path generate an empty bucket and place the path within. Call this  
collection buckets 
Step 2: Compute path relatedness threshold as two standard deviations above the mean  
of the path relatedness scores. 
Step 3: Computer the inter-cluster similarity score between each pair of buckets b1 and  
b2 in buckets compute the similarity score (Equation 3.8). For each pair whose  
similarity score exceeds the threshold, mark the two buckets for merging. 
Step 4: For each pair marked for merging, create a new bucket consisting of all paths  
from the two buckets. Place this new bucket in mergedBuckets. If a bucket has  
not been marked for deletion or merging, add it to mergedBuckets by itself. 
Step 5: Repeat this algorithm until number of buckets in the previous iteration is equal  
to the number of buckets from the current one - that is, there are no more  
changes. 
 
As noted by Cameron et al. (2015) the time to complete this step could take from minutes 
to hours and produced between one and two hundred graphs and singleton paths for each 
of their studies. Although this can produce more semantically meaningful results, this is 
problematic for two reasons. One, there are two sets of results: subgraphs consisting of 
more than one path and singletons. If we wish to ascertain quantifiable measurements 
about the efficacy of the system in terms of precision and recall then only a single 
ordered list of the results should be returned to the researcher.  
Secondly, there may be many paths that are extremely similar. This can arise from 
several different cases: differences in predicate semantic types only, differences only in 
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the starting and/or ending concepts, and paths that are a longer version of an existing 
path. Despite their similarities, they will have slightly different contexts which could 
cause them to not be combined together during clustering. But to the user viewing the end 
results, the extra graphs will seem redundant and of little use. 
When searching the Fish Oils-Raynaud Disease study with a path length of two, 
there are eleven paths found (Table 9). The first case can be seen when comparing the 
first and third listed paths. The paths differ only in that with one Epoprostenol TREATS 
Raynaud Phenomenon and in the other, it is ASSOCIATED_WITH.  
If we consider these cases as similar and treat them as a single merged path, then 
after combining a single path is left as a placeholder for the grouping, and for our Fish 
Oils example this leaves only three paths remaining (Table 10). 
Zhang et al. describes a similar approach, where at a higher level, a predicatation 
can be considered as a metapredication in the form {Semantic Concept Group - Predicate 
Group - Semantic Concept Group} (Zhang et al. 2013). In their study predicate types are 
grouped together (e.g. INHIBITS, STIMULATES, and INTERACTS_WITH into an 
“Interaction” group). They use these grouping to form graph clusters.  
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Table 9. Fish Oils – Raynaud Disease paths with max length two 
Eicosapentaenoic Acid INTERACTS_WITH Epoprostenol TREATS 
Raynaud 
Phenomenon 
Eicosapentaenoic Acid INTERACTS_WITH Epoprostenol TREATS Raynaud Disease 
Eicosapentaenoic Acid INTERACTS_WITH Epoprostenol ASSOCIATED_WITH 
Raynaud 
Phenomenon 
Eicosapentaenoic Acid NEG_INHIBITS Epoprostenol TREATS 
Raynaud 
Phenomenon 
Eicosapentaenoic Acid NEG_INHIBITS Epoprostenol TREATS Raynaud Disease 
Eicosapentaenoic Acid NEG_INHIBITS Epoprostenol ASSOCIATED_WITH 
Raynaud 
Phenomenon 
Eicosapentaenoic Acid INHIBITS Thromboxane A2 CAUSES 
Raynaud 
Phenomenon 
Eicosapentaenoic Acid INTERACTS_WITH Thromboxane A2 CAUSES 
Raynaud 
Phenomenon 
Eicosapentaenoic Acid STIMULATES Epoprostenol TREATS 
Raynaud 
Phenomenon 
Eicosapentaenoic Acid STIMULATES Epoprostenol TREATS Raynaud Disease 
Eicosapentaenoic Acid STIMULATES Epoprostenol ASSOCIATED_WITH 
Raynaud 
Phenomenon 
 
 
Table 10. Condensed Fish Oils – Raynaud Disease paths with max length two 
Eicosapentaenoic Acid * Epoprostenol * 
Raynaud 
Phenomenon 
Eicosapentaenoic Acid * Epoprostenol * Raynaud Disease 
Eicosapentaenoic Acid * Thromboxane A2 CAUSES 
Raynaud 
Phenomenon 
 
 The second case can be seen in the first and second lines of Table 10. Here, an 
assumption is made that the researcher using the system considers the starting set of 
concepts together conceptually and the same for the target set of concepts. In other 
words, as long as the “core” of the path (everything not including the start and end) is 
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identical, we can consider the paths the same and plot them together. Figure 34 shows an 
illustration of these eleven paths being condensed into two aggregate groupings.  
 
  
Figure 34. Example combined predicates for Fish Oils – Raynaud Disease 
 
The third case arises with longer path lengths. For example, take the following 
two paths (Table 11). The first path is just a longer version of the second path. As such, 
we use the shorter path for subgraph creation and add the longer path into whatever 
results include the shorter. 
 
Table 11. Sample of Fish Oils – Raynaud Disease paths with max length three 
Eicosapentaenoic 
Acid INHIBITS Arachidonic Acid STIMULATES 
Thromboxane 
A2 CAUSES 
Raynaud 
Phenomenon 
Eicosapentaenoic 
Acid INHIBITS Thromboxane A2 CAUSES 
Raynaud 
Phenomenon   
   
Using these three checks as additional post-processing we then can form the subgraphs 
with the resulting paths (Table 12): 
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Table 12. Clustering algorithm 
Step 1: For each path generate an empty bucket and place the path within. Call this  
collection buckets 
Step 2: Compute path relatedness threshold as two standard deviations above the mean  
of the path relatedness scores. 
Step 3: Remove the first bucket, b1, from buckets. Compare b1 with the remaining  
buckets in buckets by computing their similarity score. For each bucket b2  whose  
similarity score with b1 exceeds the threshold, add all paths contained within b2  
to listToCombine. 
Step 4: Create a new bucket consisting of all paths contained within b1 and from  
listToCombine. Place this new bucket in listsToAdd. If a bucket has not been  
marked for merging, add it to leftOvers by itself. 
Step 5: If buckets is not empty go back to step three.  
Step 6: Add all buckets within listToAdd to buckets.  
Step 7: If any buckets were combined, go back to step three.  
 
The results of this algorithm consists of an unordered set of subgraph results. Each result 
will consist of one or more paths as some will have been combined semantically.   
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3.8 Result Ordering 
With many possible subgraph results it is highly important to determine a sort 
order. Paths with the shortest length are likely to be of primary importance to the 
researcher using an LBD system. As such, the primary sorting criteria of the resulting 
subgraphs is the minimum path length contained. If there is a more direct relation 
between two concepts, a researcher is more likely to be interested in this than a path that 
goes through several intermediate concepts.  
The second sorting criteria is an ordering based upon the average frequency of 
occurrence of the found path predications. The more documents a predication has 
appeared within, generally implies a greater accepted belief of that statement. (Kan, 
McKeown, and Klavans 2001; Zhang, Fiszman, Shin, Wilkowski, and Rindflesch 2013)  
 
3.9 Result Evaluation 
 Put succinctly, evaluating LBD systems is a “fundamentally challenging task 
because if they are successful, by definition they are capturing new knowledge that has 
yet to be proven useful” (Yetisgen-Yildiz and Pratt 2008). This difficulty has been 
overcome by many researchers by replicating the historical discoveries to evaluate the 
performance of their systems (Lindsay and Gordon 1999; Weeber, Klein, de Jong‐van 
den Berg, and Vos 2001; Srinivasan 2004; Hristovski, Friedman, Rindflesch, and Peterlin 
2006; Cameron et al. 2015; Song, Heo, and Ding 2015). These historical studies have 
become known as the gold-standard for LBD systems and include many from Swanson 
and Smalheiser including Fish Oils – Raynaud Disease, Magnesium – Migraine 
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Disorders, Alzehimer’s Disease – Estrogen, Somatomedin C – Arginine, Alzeimer’s 
Disease – Indomethacin, and others. 
In general, these systems have reported qualitative success based solely upon the 
presence of the original connections within their results - usually claiming to have 
recovered some number of the intermediate concepts found in the original paper. This 
approach ignores the fact that in some cases these results are a few out of potentially 
hundreds of results (ignoring the rest), nor does it give a quantitative measure of the 
information retrieval (Yetisgen-Yildiz and Pratt 2008). 
  
3.9.1 Information Retrieval Metrics 
 At its heart LBD is a blend of summarization and information retrieval. A 
standard measure of IR system performance is not only the ability to return information 
relevant to the search, but also to not return non-relevant information. This has been 
quantized in two popular metrics: precision and recall (Baeza-Yates and Ribeiro-Neto 
1999). 
 For a standard document-based information retrieval system, precision is defined 
as the proportion of the relevant documents returned compared with the total number 
returned (i.e. what % of the returned results are correct). Recall is defined as the 
proportion of relevant documents returned compared with the total number of relevant 
documents in the system (i.e. what percentage of the correct results are returned). In 
contrast to these, LBD systems return terms instead of documents. As such, precision and 
recall for the evaluation of an LBD system are calculated with the following formulas:  
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(3.9) 
 
(3.10) 
Here, Ti is the set of intermediate terms generated by the LBD system for a given starting 
term(s) i, and Gi is the set of intermediate terms as defined by the gold standard 
(Yetisgen-Yildiz and Pratt 2008).  
 Within information retrieval systems a well-known challenge is the trade-off 
between the two metrics. A system designed for high precision can result in low recall, 
and vice versa. An additional measure was created to help address this issue, F-measure, 
which is a combined version of the two: 
 
(3.11) 
For F-measure, R is the recall, P is the precision, and β is a weighting factor between the 
two. The most commonly used case sets this to one, assigning equal value to precision 
and recall. 
 
3.9.2 Ranked Retrieval 
 Precision, recall, and the F-measure are all set-based measures calculated using a 
complete unordered set of results. With ordered (ranked) result sets, subsets of retrieved 
documents can be examined using the top k retrieved documents. For example, if a search 
had a total of seven ordered results (d0 through d6) and a maximum of three relevant 
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results, we can calculate both precision and recall after considering each result. These 
figures are shown in Table 13. 
  
Table 13. Example Ranked Retrieval Data 
Ranked Result  Precision Recall 
d0 Relevant 1.0 0.333 
d1 Relevant 1.0 0.667 
d2 Not Relevant 0.667 0.667 
d3 Not Relevant 0.5 0.667 
d4 Not Relevant 0.4 0.667 
d5 Not Relevant 0.333 0.667 
d6 Relevant 0.429 1.0 
 
 For each of these, the values of precision and recall can be plotted to 
provide a precision-recall curve. These curves have a distinctive saw-tooth shape due to 
the fact that if the (k+1)th result retrieved is non-relevant then recall is the same as for the 
top k documents, but precision has dropped. And if it is relevant, then both precision and 
recall increase causing the curve to increase up and to the right (Figure 35). 
 
Figure 35. Sample Precision – Recall Curve 
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A common combination of precision and recall is the F1 measure, defined as the 
harmonic mean of precision and recall (Eq. 3.12). 
𝐹𝐹1 = 2 ∗ 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑤𝑤𝑝𝑝𝑤𝑤𝑙𝑙𝑛𝑛 ∗ 𝑝𝑝𝑝𝑝𝑝𝑝𝑟𝑟𝑙𝑙𝑙𝑙
𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑤𝑤𝑝𝑝𝑤𝑤𝑙𝑙𝑛𝑛 + 𝑝𝑝𝑝𝑝𝑝𝑝𝑟𝑟𝑙𝑙𝑙𝑙  (3.12) 
𝐹𝐹1@𝑘𝑘 = 2 ∗ 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑤𝑤𝑝𝑝𝑤𝑤𝑙𝑙𝑛𝑛@𝑘𝑘 ∗ 𝑝𝑝𝑝𝑝𝑝𝑝𝑟𝑟𝑙𝑙𝑙𝑙@𝑘𝑘
𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑤𝑤𝑝𝑝𝑤𝑤𝑙𝑙𝑛𝑛@𝑘𝑘 + 𝑝𝑝𝑝𝑝𝑝𝑝𝑟𝑟𝑙𝑙𝑙𝑙@𝑘𝑘  (3.13) 
 
This can then be further extrapolated for ranked recall to a measure of “F1 at k” (Eq 3.13) 
which is a calculation of the F1 score as a function of the top k returned results. 
 
3.9.3 Natural Language Challenges 
 Suppose we try to strictly apply our measures of precision and recall. Using the 
Magnesium-Migraine Disorders study as an example, we run into an inherent problem. 
The usefulness of any term or predicate depends ultimately on the context of the articles 
within which it occurs. “Interpreting that context and its usefulness requires, in general, 
expert knowledge and human judgment” (Swanson, Smalheiser, and Torvik 2006). For 
example, magnesium acts like a Calcium antagonist, having been compared to both 
Verapamil and Nifedipine - two calcium channel blockers known to help treat migraines 
(Figure 36). 
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Figure 36. Magnesium as a Calcium antagonist 
 
Although our gold standard LBD studies identify a list of intermediates, such as Calcium 
Channel Blockers between Magnesium and Migraine Disorders, these are usually meant 
to identify “higher-level” concepts that relate the two. And here two classic problems 
arise in natural languages: synonymy and polysemy. Synonymy refers to a case where two 
different words (say Calcium Channel Blockers and Verapamil) have the same meaning. 
Polysemy, on the other hand, refers to the situation where a term has multiple meanings 
(e.g. bank). To account for this in our calculations of precision and recall the following 
rules are used: 
  
1. Multiple terms that are associated with a “gold-standard” intermediate are all 
counted as a single hit/true positive. (i.e. If the results contain Calcium Channel 
Blockers, Verapamil, Nifedipine, etc. then these all count as a single true positive 
for the idea of Calcium Channel Blockers). 
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2. If no terms are found to associate with a “gold-standard” intermediate, this is 
counted as a single miss/false negative. 
3. Each term appearing in the answers that cannot be associated with a “gold-
standard” intermediate will count as a false positive. 
 
Yet another difficulty that may arise is that the semantics of terms may evolve over 
time. For example, the term “virus” which initially only referred to an infectious 
biological agent now also is used to refer to those of a digital origin with similar 
properties (Xun, Jha, Gopalakrishnan, Li, & Zhang 2017). When creating associations the 
context of the surrounding words can matter to better identify the semantic meaning of 
the term. 
 
3.10 Summary 
 This chapter presents the system design of a performant LBD system and 
semantic-based search algorithms for both closed and open discovery approaches. A key 
contribution of this dissertation is the inclusion of citations within these algorithms. This 
is followed by a discussion on several filters based upon concept IDF scores and the 
MeSH term hierarchy that must be applied to cull terms which are too common or too 
general. Lastly we discuss how to generate subgraph results along with an evaluation 
approach to qualitatively compare the results with and without the use of citational 
references.   
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Chapter 4 
 
Results 
 
 
 Knowledge rediscovery, or retrospective analysis, is the standard for evaluating 
LBD systems. Initially the goal was to construct a LBD framework with an 
implementation of Cameron’s algorithms using the Fish Oils – Raynaud Disease study as 
a testbed. This was then expanded to make use of citational links between documents. 
Because these had positive results, additional studies were performed with the same 
algorithms to test the results to see if they were truly indicative of better results. To date, 
we have performed five projects using retrospective studies. These projects were based 
on the original studies: the Magnesium – Migraine Disorders discovery by Swanson, the 
connections between Somatomedins and Arginine also by Swanson, the association 
between Testosterone and Sleep by Miller, and Kostoff’s research on the common factors 
of Parkinson’s disease and Crohn’s disease.  
 
4.1 Retrospective Study: Fish Oils and Raynaud Disease 
 In this retrospective study the corpus consisted only of the papers that Swanson 
cited in his paper (Table A-1) as well as documents that those papers cited. A listing of 
the key predicates along with their corresponding sentences are recorded by document 
identifier within Table A-2. Appendix A also includes the topmost results of the search, 
first using citations and then again without. 
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 We seeded our search with two concepts as sources: Fish Oils (C0016157) and 
Eicosapentaenoic Acid (C0000545), and two concepts as targets: Raynaud Disease 
(C0034734) and Raynaud Phenomenon (C0034735). This is analogous to the search 
criteria as made by Cameron et al.  
 In the original study it was stated that dietary fish oil might prevent Raynaud’s 
syndrome. “This is because dietary fish oils (1) inhibit Platelet Aggregation, (2) increase 
the flow of blood (by reducing Blood Viscosity), and (3) have a regulatory effect on 
muscle (thereby preventing vasoconstriction and stimulating vasodilation)” (Cameron 
2015).  As such, rediscovery approaches consider these to be the primary three 
intermediate topics that should be found.  
 
4.1.1 Platelet Aggregation 
It is unsurprising that within our top results, the topic of Platelet Aggregation 
appeared several times under the guise of different MeSH terms, namely Figure A-2, 
Figure A-3, and Figure A-5. Particularly within biochemistry many things will be closely 
interrelated, and we can examine these connections via separate paths. The first two 
connect Fish Oils and Eicosapentaenoic Acid via Prostaglandins to Epoprostenol to 
Raynaud Phenomenon (Figure A-2 and Figure A-3). A third then connects 
Eicosapentaenoic Acid to Platelet aggregation to Alprostadil to Raynaud Phenomenon 
(Figure A-5). 
 
 
 
 
93 
 
 
 
4.1.2 Fish Oils to Raynaud Phenomenon Path via Prostaglandins 
 As shown in Figure 37, this path is present within our results. The stronger 
predicate [Fish Oils INHIBITS Prostaglandins] reported within Cameron’s results, 
does not exist within the export of SemRepDB and thus must be derived from the full-
text. 
 
Figure 37. Prostaglandins Subgraph 
 
 
In fact, none of the core papers have a predicate relating the two. However, 
multiple papers [PMID6302714, PMID6303363, PMID6301111] cite Culp et al. 
[PMID7208950] whose abstract states “The effect of altering the abundance of precursors 
and inhibitors of prostaglandin formation by dietary supplements of fish oil…” (Culp 
1980). This generates a lesser version of the predicate  [Fish Oils INTERACTS_WITH 
Prostaglandins], connecting the two concepts with INTERACTS_WITH rather than 
INHIBITS.  
 The second predicate [Prostaglandins ISA Epoprostenol] also does not exist 
in the core non full-text documents - nor does any predicate relating the two. A core 
paper [PMID6301111] cites both [PMID378308] by Bayer et al. and [PMID6773615] by 
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Pickard et al. In the abstract of the first paper, the authors state “due to the formation of 
platelet aggregates it is concluded that PGI2 is a most potent anti-aggregatory 
prostaglandin” (Bayer 1979), while in the abstract of the second paper the authors state 
“These results support our suggestion that a prostaglandin, in particular PGI2, is required 
for hypercapnia to produce full cerebral vasodilatation” (Pickard 1980). In both cases, the 
predicate [Prostaglandins ISA Epoprostenol] is derived, as Epoprostenol is also 
known as PGI2 or prostacyclin. 
 The next predicate, [Epoprostenol TREATS Raynaud Phenomenon] has multiple 
predicates within the non full-text core documents. It is present in [PMID6788326, 
PMID7037038, and PMID3883365]. 
 The analysis indicates that this particular path would not be found using only non 
full-text versions of the core documents, but is present in our results because our 
algorithm included the cited references.  
  
4.1.3 Eicosapentaenoic Acid to Raynaud Phenomenon Path via Prostaglandins 
 This path is largely the same as the previously described one, aside from the 
difference of the first graph edge (Figure 37). Here, the predicate [Eicosapentaenoic 
Acid CONVERTS_TO Prostaglandins] is found in two non full-text core documents  
[PMID6314583 and PMID6821892]. Despite this, because this path also utilizes the 
[Prostaglandins ISA Epoprostenol] step, this path would also not be found using 
only non full-text versions of the core documents, but is present in ours because 
bibliographic associations included the additional references.  
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4.1.4 Eicosapentaenoic Acid to Raynaud Disease Path via Platelet Aggregation 
 We can see a more obvious interaction using the MeSH concept Platelet 
Aggregation directly in our fourth graph result (Figure 38). The predicate 
[Eicosapentaenoic Acid DISRUPTS Platelet Aggregation] appears in the abstract 
of one core document [PMID6303363] where it was said that Eicosapentaenoic acid “has 
been reported to be a potent antagonist of platelet aggregation and also to reduce the 
incidence of cardiovascular disorders” (Terano et al. 1983). 
 
 
Figure 38. Platelet Aggregation Subgraph 
 
 From there, there are associations between Platelet Aggregation and both 
Epoprostenol and Alprostadil. Although the path between Epoprostenol and Raynaud’s 
Disease was previously discussed, the predicates [Epoprostenol DISRUPTS Platelet 
Aggregation] and [Epoprostenol AFFECTS Platelet Aggregation] are new. These 
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are generated from one core paper and over ten cited articles. The title of the 1985 core 
paper [PMID2408588], “Inhibition of platelet aggregation by a new stable prostacyclin 
introduced in therapy of patients with progressive scleroderma”, produces the first 
predicate (Keller, J., Kaltenecker, A., Schricker, K. T., Neidhardt, B., & Hornstein, O. P. 
(1985). 
The second [Alprostadil DISRUPTS Platelet Aggregation] does not appear 
in the non full-text version of any core document. Core documents [PMID6301111 and 
PMID6302714] cite four different papers [PMID190267, PMID364545, PMID7003784, 
and PMID7427564] which generate this predicate, and one of which [PMID7427564] is hit 
on the search terms. As an example, Minkes et al. [PMID190267] state in their abstract 
“Furthermore, dBcAMP and PGE1 both inhibit platelet aggregation” (Minkes 1977) 
while Whittle et al. [PMID364545] state “The activity of prostacyclin (PGI2), PGE1 or 
PGD2 as inhibitors of platelet aggregation” in theirs (Whittle 1978). As Prostaglandin E1 
(PGE1), is also known as Alprostadil, these yield the predicate in question. 
The final predicate that has not been discussed, [Alprostadil TREATS 
Raynaud’s Disease], appears in two core references [PMID3977414, PMID7259326]. 
The 1981 paper [PMID7259326] by Martin et al. concludes that Alprostadil “may 
therefore be suitable treatment for Raynaud's phenomenon and the vascular insufficiency 
of systemic sclerosis and other connective tissue diseases” (Martin et al. 1981) 
 
4.1.5 Blood Viscosity 
The second intermediate Blood Viscosity was found by Cameron et al. (2015) via 
the following predicates: [Eicosapentaenoic Acid DISRUPTS Blood Viscosity], 
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[Fish Oils AFFECTS Blood Viscosity], [Ketanserin DISRUPTS Blood 
Viscosity], and [Ketanserin TREATS Raynaud Phenomenon]. This shows up in our 
15th result (Figure 39). 
 
 
Figure 39. Blood Viscosity Path 
 
 The predicates are mostly found directly within the titles and abstracts of core 
documents. The predicate [Eicosapentaenoic Acid DISRUPTS Blood Viscosity] is 
from [PMID6303363] where Terano et al. state that “We recently reported that EPA also 
reduces whole blood viscosity” (Terano 1983). Similarly, the predicate [Fish Oils 
AFFECTS Blood Viscosity] is contained within the title of Woodcock et al.’s paper 
[PMID6320945]: “Beneficial effect of fish oil on blood viscosity in peripheral vascular 
disease” (Woodcock 1984). [Ketanserin TREATS Raynaud Phenomenon] is lastly found 
in multiple core documents [PMID6812750, PMID6365102, PMID6432198].  
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 The one exception, [Ketanserin DISRUPTS Blood Viscosity] is not found 
within any of the non full-text documents. Instead, only a weaker relation [Ketanserin 
AFFECTS Blood Viscosity] exists within Walker et al.’s paper [PMID2412054] where 
they state “Ketanserin given intravenously for seven days to patients with very severe leg 
ischaemia, significantly improves whole blood viscosity...” (Walker 1985). 
 For this path, there is no additional benefit from utilizing bibliographic citations 
and the only change from not using full-text is the weaker relation between Ketanserin 
and Blood Viscosity. 
 
4.1.6 Vascular Reactivity 
 Cameron et al. reported that they were unable to retrieve the intermediate concept 
of Vascular Reactivity directly. They later observed that SemRep erroneously parsed the 
phrase Vascular Reactivity (C1660757) into two tokens: Vascular (Blood Vessels-
C0005847) and Reactivity (Reactive-C0205332) (Cameron 2016). Only after adjusting 
the predicates manually were they able to achieve the results in Figure 40. 
 
 
Figure 40. Vascular Reactivity Path from Cameron et al. 
Epoprostenol 
Vascular 
Reactivity
RD/RP EPA 
TREATS 
INHIBITS_MAN 
AFFECTS_MAN 
AFFECTS_MAN CAUSES 
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 In their results, multiple predicates had to be manually adjusted, indicated with 
the suffix notation of “_MAN” in the graph. Here, these are from [Eicosapentaenoic 
Acid AFFECTS_MAN Vascular constriction], [Epoprostenol INHIBITS_MAN 
Vascular constriction] and [Epoprostenol TREATS Raynaud Syndrome].  
However, our results (Figure 41) generated a path without any modification to the 
predicates or utilizing full-text. A particular predicate, [Epoprostenol ISA 
Vasodilator Agents] can be found within two documents [PMID7003784 and 
PMID114606]. The first states that “Prostaglandins E1 (PGE1) and I2 (prostacyclin, PGI2) 
are potent vasodilators and inhibitors of platelet aggregation “, while the second states 
“As PGI2 is the most potent cerebral vasodilator drug tested”. Both of these are cited by 
one of the core documents [PMID6301111].  
 The second predicate [Vasodilator Agents TREATS Raynaud Disease] is also 
only included via citation. The core document by Belch et al. [PMID3883365] cites an 
earlier paper by Belch et al. [PMID7025341] where they measured the effects of 
“prostacyclin (PGI2) a potent antiplatelet and vasodilator agent in 5 female patients with 
Raynaud's syndrome” with positive results (Belch et al. 1981). Thus, the entire path is 
generated due to the inclusion of bibliographic citations. 
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Figure 41. Vascular Reactivity Path 
 
 
4.1.7 Retrospective Study: Fish Oils and Raynaud Disease - Conclusions 
 In work later performed by Cameron as part of his dissertation, he attempted to 
rediscover Swanson’s Raynaud Syndrome–Dietary Fish Oils hypothesis without the use 
of full-text. Through a similar predicate analysis he noted that “these results collectively 
suggest that titles and abstracts alone, might NOT be sufficient” (Cameron et al. 2016). 
As such, this matches the results of this project in that several of his resulting paths were 
only available due to the usage of predicates generated from full-text. This project, 
however, shows that it is possible to reproduce the results of Swanson’s Raynaud 
Syndrome–Dietary Fish Oils hypothesis (using a similar corpus) without the use of full-
text by modifying Cameron et al.’s approach by incorporating bibliographically related 
documents.  
 
 
 
101 
 
 
 
 In Appendix A, Table A-3 details the precision and recall at each ranked result 
when using citations. Table A-4 does the same when not using citations but otherwise 
follows the same algorithm. A graph of the results can be seen here in Figure 42.  
 
Figure 42. Precision Recall Curve for Fish Oils – Raynaud Disease Study 
 
The shape of this graph departs from the typical sawtooth shape of precision-recall 
curves. When considering standard document relevancy, a document result is unique and 
can be considered relevant or not. Here, each result is a subgraph which may contain 
more than one possible path, and each path could contain several concepts. For example, 
the very first result using citations was shown in Figure 41. In this graph paths may go 
through Epoprostenol, Alprostadil, Vasodilator Agents, and Systemic Scleroderma, the 
precise meaning of which may vary:  Epoprostenol and Alprostadil generally imply an 
association with Platelet Aggregation, Vasodilator Agents refers to Vascular Reactivity, 
and Systemic Scleroderma, although related to Raynaud’s Disease isn’t a direct 
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connection. This implies that the first search result has a recall of 0.667 having two of the 
three intermediate topics, and a precision of 0.667 for having two relevant and one non-
relevant topics. 
A second factor that is different from standard document information retrieval 
approaches is that a subgraph result may technically contain new information but no new 
relevancy information. Consider the first (Figure 41) and the second (Figure 37) returned 
results. The second result has a new concept, Prostaglandins, when compared to the first 
result, but semantically this is still referring to the topic of Platelet Aggregation. It 
provides additional information into the interconnectedness between the concepts but at 
the same time does not demonstrate increased recall.  
An alternative is to examine the F1 measure as a function of the top k results 
(Figure 43). The search without citations only returned a total of eight results, but up to 
that point using citational information produced a better F1 score.  
 
 
Figure 43. F1 @ K measure for Fish Oils – Raynaud Disease Study 
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Beyond the behavior of the graphs themselves, the most noticeable difference is 
that without using citations, one of the three intermediate concepts (Vascular Reactivity) 
was unable to be recovered.  
 
4.2 Retrospective Study: Magnesium and Migraine Disorders 
 In his 1987 paper, “Migraine and Magnesium: Eleven Neglected Connections” 
Swanson described his discovery of how Magnesium deficiency might exacerbate 
Migraines via eleven different interrelated mechanisms (Swanson 1988). These are listed 
below in Table 14. We attempted to reproduce these results via the approach described 
previously. 
 
Table 14. Swanson’s Eleven Intermediates for Magnesium-Migraine Disorders 
Calcium Channel Blockers 
Vascular Mechanisms 
Prostaglandins 
Epilepsy 
Serotonin 
Inflammation 
Spreading Cortical Depression 
Hypoxia 
Platelet Aggregation 
Stress/Type A personality 
Substance P 
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 Our corpus consisted of 131 of the original MEDLINE documents cited by 
Swanson (Table B-1) along with the other MEDLINE documents they cited, totaling 
approximately 2,900 references. Some documents were missing abstracts (and thusly 
missing SemRep abstract-generated predicates), for these abstracts/introductions were 
located and added manually along with any generated predicates. A listing of the 
predicates along and their corresponding sentences are recorded by document identifier 
within Table B-2.  
 Unless specified otherwise, each search was performed with a source concept of 
Magnesium (C0024467) and a destination of Migraine Disorders (C0149931). Even 
today the exact nature of migraine hasn’t been completely solved and there is debate if it 
is primarily a vascular (pertaining to blood vessels), neurological (pertaining to neurons), 
or a mixture of the two. We examined each of the eleven intermediates that Swanson 
discovered to determine if our system has recovered the discovery. In addition, we will 
discuss a twelfth intermediate concept, Diabetes, not identified by either Swanson or 
Cameron.  
 
4.2.1 Calcium Channel Blockers 
It stands that if the source of pain is caused by vasoconstriction, then a vasodilator 
should provide relief.  Peroutka explained that “calcium channel antagonists are a 
recently developed class of vasodilators that prevent the influx of calcium into vascular 
smooth muscle. The unique pharmacologic effects of these agents provide a theoretical 
basis for their use in the treatment of migraine” (Peroutka 1983).  
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Figure 44. Calcium Channel Blockers 
 
Our second search result using citations are shown in Figure 44. Known calcium 
channel blockers, Verapamil and Nifedipine, both treat Migraine as suggested by 
multiple articles. The article by Markley, Cheronis, and Piepho [PMID6539877] entitled 
“Verapamil in prophylactic therapy of migraine” states “Verapamil significantly reduced 
both headache frequency and duration with few side effects” (Markley, Cheronis, and 
Piepho 1984). The article by Meyer and Hardenberg [PMID6358126] indicates that 
“Nifedipine and verapamil provided equivalent relief for cluster but produced more side 
effects, and were less effective, than nimodipine in control of migraine” (Meyer and 
Hardenberg 1983).  Similar statements to the use of Verapamil and Nifedipine in the use 
of migraines can be found in other documents. [PMID2425960, PMID6339937, 
PMID2425960] All of these produce at least one of the two predicates 
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[C0042523|Verapamil - TREATS - C0149931|Migraine Disorders] and 
[C0028066|Nifedipine - TREATS - C0149931|Migraine Disorders]. 
The presence of Magnesium acts like a Calcium antagonist, having been 
compared to both Verapamil and Nifedipine. The predicates connecting 
Magnesium(C0024467) to Verapamil(C0042523) and Nifedipine(C0028066) can be 
found in two documents [PMID7297597, PMID3458981]. In the paper by Sjögren A. and 
Edvinsson L. [PMID3458981] it was indicated that “the order of potency for eliciting 
relaxation was: nifedipine greater than verapamil greater than magnesium” (Sjögren and 
Edvinsson 1986). While in the second reference by Turlapaty, Weiner, and Altura 
[PMID7297597] it is noted that a deficiency of magnesium induces vascular constriction:  
“Previous studies on isolated blood vessels indicate that [a] withdrawal of magnesium 
([Mg2+]0) induces calcium-dependent contractile responses” (Turlapaty, Weiner, and 
Altura 1981). 
 In Andersson’s 1986 paper [PMID2424267] he calls out several calcium channel 
blockers in his statement: “The cardiovascular effects of different calcium channel 
blockers (CCB), exemplified by nifedipine, verapamil and diltiazem, are not identical” 
(Andersson 1986). Other papers also illustrate this relationship [PMID2981405, 
PMID6202853, PMID6708731, PMID6869560, PMID7195070] (Figure 45). 
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Figure 45. Calcium Channel Blockers Subgraph 
  
 Multiple documents associate Calcium Channel Blockers with Migraine 
Disorders, including the paper by Peroutka mentioned earlier [PMID6358127, 
PMID3521194, PMID6715160]. Taken together these explicitly show that both Nifedipine 
and Verapamil are Calcium Channel Blockers and that the blockers as a whole are used 
as treatment for migraines. 
 
4.2.2 Vascular Mechanisms 
 Multiple subgraphs were examined connecting Magnesium and Migraine 
Disorders via vascular mechanisms. In the following sections we examine Dilatation, 
Blood Vessels, Contraction, and Vasospasm to understand the underlying connections. 
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4.2.2.1 Dilatation 
The 1977 paper by Hachinski et al. [PMID597797] attempted to examine regional 
cerebral blood flow (rCBF) and dilation during migraines. One theory of migraine at the 
time conjectured that the primary mechanism consists of a series of events initiated by 
vasospasm of the cerebral arteries followed by a reactive vasodilation. The distension of 
the vessels was assumed to be the source of the headache pain. Although their findings 
did not support the speculation, it did not discount distention of the intracranial arteries 
during migraine headache (Hachinski et al. 1977). The predicate seen in the fourth search 
result (Figure 46), [C0012359|Pathological Dilatation - COEXISTS_WITH - 
C0149931|Migraine Disorders], was extracted from Hachinski’s paper, signifying one 
of the underlying possibilities for migraines.  
 
Figure 46. Vascular Mechanisms (Dilatation) Subgraph 
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The interaction along calcium channels has already been discussed, both in terms of 
Verapamil and Magnesium acting as a vasodilator, or in the case of Magnesium 
deficiency, acting as a vasoconstrictor.  
 
4.2.2.2 Vascular Mechanisms - Summary 
 Our resulting subgraphs have shown vascular connections between Magnesium 
and Migraine Disorders using a path length of three using our constrained corpus. If we 
were to extend our corpus to include the additional documents that Cameron utilized 
within his study then several additional predicates would have appeared and allowed a 
connection at a path length of two. The 1972 article [PMID4260015] “Magnesium 
metabolism from the viewpoint of cardioangiology. II. Findings in magnesium 
metabolism in vascular diseases” by Wustenberg et al. generates the predicate 
[C0024467|Magnesium - ASSOCIATED_WITH - C0042373|Vascular Diseases]. 
Although ASSOCIATED_WITH is not as strong of a direct implication as INHIBITS, 
implied by Swanson, its existence would have been sufficient reason to investigate paths 
of length three. Additionally, the predicate [C0149931|Migraine Disorders - ISA - 
C0042373|Vascular Diseases] would have been generated from Domzal’s 1975 article 
[PMID1153064], wherein he states “EEG changes suggest--according to the author--that 
migraine is a primary cerebral and only secondarily a vascular disorder” (Domzal 1975). 
 
4.2.3 Prostaglandins 
As is common with many biochemical systems, a particular chemical can have 
one effect in larger concentrations, while a deficiency will provoke the opposite response 
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as a means of regulation. As Horrobin’s experimental results showed this was the case for 
prostaglandins - indicating that higher concentrations can cause vascular dilation, while 
the opposite was true in low concentrations (Horrobin 1977). Various experiments have 
shown that the administration of Prostaglandins could cause migraine-like symptoms, 
such as in Carlson’s study where Prostaglandin E1 was infused intravenously into eight 
healthy male subjects with no prior history of migraine - all experienced symptoms with a 
sufficient dosage (Carlson, Ekelund, and Orö 1968).    
 
 
Figure 47. Prostaglandins Subgraph – Path Length of 2 
 
The title of their article, “The effect of infused prostacyclin in migraine and 
cluster headache”, by Peatfield et al. [PMID7026501] implies some relationship between 
prostacyclin (Epoprostenol), a type of Prostaglandin, and migraines. They noted that “We 
have assessed the role of prostacyclin by infusing it into eight patients with migraine and 
eight with cluster headache. Most of the subjects developed a dull throbbing headache 
during the infusion” (Peatfield, Gawel, and Rose 1981). The title itself generates two 
different predicates: [C0033567|Epoprostenol - AFFECTS - C0009088|Cluster 
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Headache] and [C0033567|Epoprostenol - AFFECTS - C0149931|Migraine 
Disorders].  
Meanwhile, Prostacyclin was noted by Briel, Lippert, and Zahradnik 
[PMID3898850] to be a “potent naturally occurring vasodilator and inhibitor of platelet 
aggregation”, then continue to state that “Magnesium is known to exert an inhibitory 
effect on coagulation and platelet function”, thus prompting them to investigate the 
effects of “magnesium sulfate on vascular prostacyclin synthesis and platelet prostacyclin 
interaction” (Briel, Lippert, and Zahradnik 1985). This last statement having generated 
the predicate [C0024467|Magnesium - INTERACTS_WITH - C0033567|Epoprostenol] 
in Figure 47. 
 
 
Figure 48. Prostaglandins Subgraph – Path Length of 3 
 
Using a path length of three we can see some of the additional details that we would 
expect (Figure 48). 
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 The predicate [C0033567|Epoprostenol - ISA - C0033554|Prostaglandins] 
is derived from the sentence “Prostacyclin appears to be the most active of the 
vasodilating prostaglandins with inflammatory and hyperalgesic properties” in the article 
by Peatfield et al. [PMID7026501] (Peatfield et al. 1981). Two documents [PMID4016946, 
PMID89390] also generate the predicate [C0033554|Prostaglandins - 
ASSOCIATED_WITH - C0149931|Migraine Disorders]. Both articles make a claim that 
“Prostaglandins (PG), particularly PGE, may be linked to the pathophysiology of 
migraine”, namely because “PGEs cause vasodilation and hyperalgesia, both typical 
reactions of inflammation”. This view that vascular headache is an "inflammatory 
reaction" explains the “local role of PGs and the effectiveness of PG-inhibitors in the 
treatment of migraine” (Parantainen, Vapaatalo, and Hokkanen 1985). 
 It has been shown that Magnesium Deficiency can increase prostaglandin 
production. This was noted by Soma et al. in their 1988 paper [PMID3238000] wherein 
their findings suggested “that the biosynthesis of eicosanoids, mainly PGI2, is stimulated 
in Mg deficiency, and this may provide protection against intracellular Mg depletion and 
Ca accumulation, so as to counteract to the constricted and hyperreactive state of the 
vasculature in such a condition” (Soma et al. 1988.)  
 
4.2.4 Epilepsy  
 Migraines have been a mystery for decades due to the mixture of vascular and 
neurogenic symptoms. Swanson noted that “a connection between migraine and epilepsy 
has been suspected for most of the past century” (Swanson 1988). In 1969, Basser wrote 
his paper [PMID4978139] entitled “The Relation of Migraine and Epilepsy” which 
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illustrated their study into a potential relationship between the two: “It is the purpose of 
this paper to examine the question of the relation of migraine and epilepsy by an analysis 
of 1,800 cases of migraine seen at the Northcott Neurological Centre since 1951 with 
particular reference to those cases in which migraine and epilepsy were manifested in the 
same individual” (Basser 1969). Our first search result (Figure 49) shows the predicate 
[C0014544|Epilepsy - COEXISTS_WITH - C0149931|Migraine Disorders] derived 
from this. 
 
 
Figure 49. Epilepsy Subgraph – Path Length of 2 
 
 Canelas et al. wrote a paper in 1965 [PMID14338128] entitled “Disorders of 
Magnesium Metabolism in Epilepsy”, from which the predicate [C0024467|Magnesium 
- ASSOCIATED_WITH - C0014544|Epilepsy] was derived. As an interesting note, in 
their introductory paragraph they state that “The possibility that convulsions may occur in 
Mg deficiency led some investigators to study the metabolism of this metal in the 
epilepsies, and a trend to low blood concentrations was usually found” (Canelas, De 
Assis, and De Jorge 1965). A second article, [PMID108361], also generated this predicate. 
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4.2.5 Serotonin 
 Serotonin is present in both blood platelets and blood serum that acts as a 
neurotransmitter and causes vascular constriction. Swanson noted that Hilton and 
Cumings discovered “increased platelet aggregability and sensitivity to serotonin release 
in headache-free migraine patients”, and that many researchers have also suggested that 
platelets and serotonin have some association with migraines (Swanson 1988). Several 
studies within our corpus have associated Serotonin to migraines [PMID6275679, 
PMID5658323, PMID5297855, PMID1254466, PMID1146499]. Each producing a 
predicate to connect the two concepts (Figure 50).  
“Serotonin is released from platelets during a migraine attack, thus causing a 
transient increase in plasma serotonin which, through its vasoconstrictive action, is then 
thought to play a role in the development of the headache phase of the attack. Plasma 
serotonin is rapidly metabolized, leading to a drop in blood levels of serotonin as a 
consequence of a migraine episode” (Swanson 1988). It has been further suggested that a 
serotonin releasing factor is present within the blood of migraine patients. Free fatty acids 
(Figure 51) have been suggested for this (Anthony 1982). 
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Figure 50. Mg - Migraine search result 14 Figure 51. Mg – Migraine search result 5 
 
  Our corpus contained six references that connected Serotonin to vasoconstriction 
[PMID6948814, PMID6538269, PMID4814375, PMID379918, PMID7060640, 
PMID1262918]. One example [PMID6948814] of which states that “In isolated human pial 
arteries (diameter 0.4-0.5 mm), contractions were produced by potassium, noradrenaline, 
serotonin, and prostaglandin F2 alpha” (Brandt, Andersson, Edvinsson, and Ljunggren 
1981). Given that serotonin is a known vasoconstrictor this is no surprise. We have also 
previously noted the vasodilator effects of Magnesium and Calcium Channel Blockers. 
The predicate [C0036751|Serotonin - STIMULATES - C0042523|Verapamil] is 
derived from [PMID7150872] in the sentence “The calcium channel blocking agent, 
verapamil (10(-6)M), inhibited completely contractile responses to KCl; contractile 
responses elicited by angiotensin II and 5-HT were attenuated by verapamil” (Altura and 
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Turlapaty 1982).  This matches our expectations (Figure B-5). The same is true for the 
predicate [C0028066|Nifedipine - INHIBITS - C0036751|Serotonin] derived from 
[PMID450213] and is seen in Figure B-3.  
Our results (Figure 50 and Figure 51) have shown interconnections between 
Magnesium and Migraine Disorders via Serotonin using a path length of three within our 
constrained corpus. Cameron states that the 1987 article [PMID3629724] by Pertseva et al. 
produces the predicate [Magnesium - INTERACTS_WITH - Serotonin] (Cameron 2014). 
In this case, by extending our corpus to include the additional document that Cameron 
utilized within his study then we gain an additional predicate that would have appeared 
and allowed a connection at a path length of two. However, upon inspection, the abstract 
of the article states “A stimulating effect of serotonin, guanine nucleotides and sodium 
fluoride is found as well as a dependence of the catalytic activity of adenylate cyclase on 
magnesium and manganese ions” (Pertseva and Soltitskaia 1987). This produces the 
predicate [C0001492|Adenylate Cyclase - INTERACTS_WITH - 
C0024467|Magnesium], which is different than expected.  
 
4.2.6 Inflammation 
In his paper Swanson posits that “pain is a classic sign of inflammation, and 
migraine has been described as a sterile inflammatory disease of cranial blood vessels” 
(Swanson 1988). Acute inflammation is generally characterized by vasodilation, 
increased permeability, and increased blood flow. In 1979 Moskowitz et al. [PMID90971] 
proposed a mechanism for pain in headache based upon the abnormal release of 
Substance P from trigeminal nerve terminal terminals. The trigeminal nerve is the largest 
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of the cranial nerves and provides the primary pathway for the transmission of head pain. 
Moskowitz also hypothesized that pain was the result of an induced release of 
vasodilators such as Substance P from the nerve fibers (Moskowitz, Romero, Reinhard, 
Melamed, and Pettibone 1979).  
 
Figure 52. Inflammation Subgraph 
 
The relationship between Pain and Migraine Disorders is fairly common as one 
would expect. The titles of several articles indicate as such: [PMID3585352, 
PMID6830162, PMID7310427, PMID20784580], each generating the predicate 
[C0030193|Pain - ASSOCIATED_WITH - C0149931|Migraine Disorders]. However, 
given the complexity of migraine, the explanation is not as straightforward. 
 Sicuteri, Renzi, and Geppetti wrote an article in 1986 [PMID2433912] where they 
construct the predicate [C0037659|Somatostatin - TREATS - C0030193|Pain] for 
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headaches and further implicate the involvement of Substance P. “Opiates and 
somatostatin inhibit the release of substance P from primary sensory neurones and relieve 
both pain and autonomic symptoms of cluster headache attack” (Sicuteri, Renzi, and 
Geppetti 1986).  
 To complete the association as shown in Figure 52, we have to determine the 
relationship between Magnesium and Somatostatin. An article within our corpus sheds 
some light onto this and provides the necessary predicate. Curry and Bennett’s article 
[PMID6141690] “Magnesium requirement for somatostatin inhibition of insulin secretion” 
suggests from the title alone that Magnesium is necessary for Somatostatin to function 
properly - at least in certain capacities. The predicate relationship, INHIBITS, in this case 
is misleading but upon examination fits into our expectations. As we’ve seen so far it is 
the case of Magnesium deficiency which is in relation to Migraine conditions. Here, a 
lack of Magnesium causes Somatostatin to not function properly. 
 
4.2.7 Spreading Cortical Depression 
 Spreading Cortical Depression (SCD), or Spreading Depression of Leao is 
described as a self-propagating wave of depolarization across the cerebral cortex. 
Experimentally it could be induced by means of a stimulus applied to the cerebral cortex, 
and results showed that it was accompanied by vasodilation of the arteries. SCD has also 
been found to be induced by hypoxic conditions and has been implicated in migraines. 
(Swanson 1988). Additional research into spreading depression has shown two different 
types, one based upon glutamate and the other on potassium. The introduction of 
Magnesium ions were able to block the potassium based SCD [PMID739264, 
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PMID6150068] (Van Harreveld 1978, 1984), while a deficiency induced spreading 
depression in some situations [PMID3763042, PMID3801897] (Walther, Lambert, Jones, 
Heinemann, and Hamon 1986; Anderson, Lewis, Swartzwelder, and Wilson 1986). 
Unfortunately, our system was unable to produce a subgraph that could relate 
Magnesium and Migraine Disorders via Spreading Cortical Depression using a path 
length of 3 or less. It is expected that clinical verbiage used within abstracts did not use a 
consistent terminology to be able to produce the necessary predicates, which is consistent 
with the results of Cameron et al. 
 
4.2.8 Brain Hypoxia 
Hypoxia is defined as a deficiency in the amount of oxygen reaching a particular 
section of tissue. In 1974, Bucking and Baumgartner suggested [PMID4842482] that 
migraine and spreading depression might be initiated by cerebral hypoxia. They found 
that experimentally induced hypoxia caused a burst of cerebral electrical activity that 
resembled spreading depression (Bücking and Baumgartner 1974). It was later suggested 
that the mechanisms of both SCD and brain hypoxia/anoxia are related in the ionic 
permeability of brain cells (Hansen and Zeuthen 1981). 
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Figure 53. Hypoxia Subgraph 
 
As can be seen in Figure 53, the predicate [C0024467|Magnesium - 
ASSOCIATED_WITH - C0151744|Myocardial Ischemia] is generated by another article 
by Altura and Altura [PMID6149922]. They note that “Mg++ ions are essential for 
regulation of Na+ and K+ transport across cell membranes” and “under conditions where 
cellular Mg++ is depleted (e.g. hypoxia, ischaemia, anoxia)” (Altura and Altura 1984). 
Additionally of note, they state “A reduction in the extracellular Mg++ concentration can 
produce hypertension, coronary vasospasm and potentiation of vasoconstrictor agents by 
allowing excess entry of Ca++; concomitantly, the potency of vasodilator agents is 
reduced” (Altura and Altura 1984). The predicate [C0151723|Hypomagnesemia - 
PREDISPOSES - C0151744|Myocardial Ischemia] comes from similar statements in 
[PMID527222]. 
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Both Altura BM’s 1979 article [PMID390330] on ischemic heart disease and the 
1976 reference by Hearse et al. [PMID939020] produce the associations between Ischemia 
and Myocardial Ischemia. Of lesser interest, but related biochemically we see Cerebral 
Vasospasm. Previously we have seen a connection between Magnesium and Cerebral 
Vasospasm. For Figure 53, all three predicates [C0024467|Magnesium - DISRUPTS - 
C0265110|Cerebral Vasospasm], [C0265110|Cerebral Vasospasm - 
COEXISTS_WITH - C0151723|Hypomagnesemia], and [C0265110|Cerebral Vasospasm 
- COEXISTS_WITH - C0022116|Ischemia] come from [PMID6680619] by Altura and 
Altura. 
The final link, [C0022116|Ischemia - CAUSES - C0149931|Migraine 
Disorders], can be found in two documents. The first by Skinhoj E and Paulson OB 
[PMID5803690], comes from the following statement:  “According to the classical theory 
the first (prodromal) phase in migraine is caused by ischemia within the internal carotid 
system and the second phase (headache) by a vasodilation, especially within the external 
carotid system” (Skinhoj and Paulson 1969). The second from Welch et al. [PMID184066] 
where they state that  “Since biochemical abnormalities reported herein were common to 
occlusive CVD and migraine headache, it seems probable that they are due to ischemia 
associated with both conditions and possibly related to the resultant disorder of cerebral 
energy metabolism” (Welch et al. 1976). 
 
4.2.9 Platelet Aggregation  
The hypothesis that migraine is a platelet disorder was proposed by Hanington 
citing evidence in the difference in the behavior of platelets in migraine patients 
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(Hanington, Jones, Amess, and Wachowicz 1981; Hannington 1986). Other research has 
since disputed this (Steiner, Joseph, and Rose 1985; Joseph and Welch 1987), instead 
suggesting that differences in platelet behavior is a consequence to other changes such as 
stress, the release of catecholamines, FFAs, serotonin, and prostaglandins (Swanson 
1988).  
 Previously we have seen that Prostacyclin (Epoprostenol) inhibits platelet 
aggregation and that Magnesium can enhance this effect when present, or inhibit it during 
the case of Magnesium deficiency (Figure 48).   
A more direct connection to the concept Platelet Aggregation shows up at length 
4 (Figure 54), but there are many paths of little value generated at this length. In his paper 
Cameron mentions a 1987 article by Briel et al. [PMID2440758] that confirms the 
predicate [Magnesium - INHIBITS - Platelet Aggregation]. However, this paper does not 
generate the predicate with SemRep.  
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Figure 54. Platelet Aggregation Subgraph – Path Length of 4 
 
 The other paths of note in Figure 54 connect Prostaglandins and Platelet 
Aggregation. We can find the predicate [C0033567|Epoprostenol - DISRUPTS - 
C0032176|Platelet aggregation] from “Prostacyclin (PGI2), a strong vasodilator of 
cerebral vessels and potent inhibitor of platelet aggregation” inside [PMID7048862] 
(Quintana, Konda, Ishibashi, Yoshimoto, and Suzuki 1982) and other documents 
[PMID7014260, PMID6992233, PMID6117893, PMID6110816, PMID6117893]. The 
other predicate [C0033554|Prostaglandins - DISRUPTS - C0032176|Platelet 
aggregation] is derived from both [PMID372242] and [PMID361756]. 
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4.2.10 Stress / Type A Personality  
Swanson noted that the “descriptions of migraine-associated personality in the 
older literature bear a close resemblance to descriptions of what is now called the type A 
personality” (Swanson 1988). Several studies have reported a correlation between those 
of type A personality and frequency of headaches.  
 
Figure 55. Stress Subgraph 
 
 Our study shows a meaningful path connecting Magnesium and Migraine 
Disorders that related to Stress/Type A personality by means of Hypertensive disease.  
In the 1954 article by Friedman et al. [PMID13214278] entitled “Migraine and tension 
headaches; a clinical study of two thousand cases” the authors state “Among this group 
are headaches associated with hypertension, arteriosclerosis, infection, brain tumor, 
hematoma, allergy, and cranial trauma” which generates the predicate 
[C0018681|Headache - ASSOCIATED_WITH - C0020538|Hypertensive disease] in 
Figure 55 (Friedman, Von Storch, and Merritt 1954). 
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 Swanson explained that “stress causes an increases in blood levels of free fatty 
acids, which in turns induces loss of blood magnesium”, or in other words, “type A 
behavior in effect entails a virtual deficiency of Magnesium” (Swanson 1988). This is 
backed up by McCarron [PMID6847018] who states that “Many studies suggest that 
reduced consumption of calcium or magnesium is associated with an increased risk of 
developing hypertension and cardiovascular disease” (McCarron 1983) which generates 
the predicate [C0024467|Magnesium - PREDISPOSES - C0020538|Hypertensive 
disease]. 
  
4.2.11 Substance P 
 During our prior analysis of a connection involving inflammation/pain, the 
neuropeptide “Substance P” was referred to as another possible factor in the genesis of 
migraines. Our study did not find a meaningful path connecting Magnesium and 
Migraine Disorders that related to Substance P. However, an exploratory analysis did 
find a connection utilizing the concept Cluster Headache.  
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Figure 56. Substance P Subgraph – Path Length of 3 
 
Two papers within our corpus related Substance P to Cluster Headache. The first, 
was a 1983 paper by Sicuteri et al. [PMID6193886] where their title, “Substance P and 
endogenous opioids: how and where they could play a role in cluster headache” generates 
the graph predicate. They state that “Substance P appears to be involved in the 
transmission of pain signals from the periphery to the spinal cord and brain stem” and 
that “Substance P containing neurons are responsible for the neurogenic vasodilation” 
(Sicuteri, Rainò, and Geppetti 1983). The second paper, “Substance P in the human iris: 
possible involvement in echothiophate-induced miosis in cluster headache” by 
Fanciullacci et al. [PMID2452018], also connects the two concepts by title alone 
(Fanciullacci et al. 1988). 
 The predicate [C0038585|Substance P - CAUSES - C0019595|Histamine 
Release] are produced from the sentence “Substance P (SP) induces histamine release 
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from isolated rat peritoneal mast cells at concentrations of 0.1-10 muM” written in an 
article by Fewtrell et al. [PMID6184468] (Fewtrell et al. 1982). In the same avenue, the 
connection between Substance P and Blood Vessels comes from sentence “Indirect 
evidence has abundantly been presented to support the view that substance P (SP) is 
involved in the vasodilatation following activation of fine calibre pain fibres”, by Rosell 
et al. [PMID6171999] (Rosell et al. 1981). Both of these connections fit our earlier 
reasoning that inflammation, pain, and Substance P are interrelated.  
 The one new connection in Figure 56 is [C0024467|Magnesium - DISRUPTS - 
C0019595|Histamine Release]. This predicate also comes from Fewtrell et al. 
[PMID6184468] where they state that “Extracellular calcium (0.1-1 mM), magnesium (1-
10 mM) and cobalt (0.01-0.1 mM) all inhibit SP-induced histamine release when added 
before the peptide” (Fewtrell et al. 1982). It therefore stands that if the presence of 
Magnesium inhibits SP-induced histamine, then a magnesium deficiency would cause 
help provoke headaches in this context. 
 
4.2.12 Diabetes  
 In addition to the aforementioned eleven connections (Table 14) there was one 
unexpected concept that showed up in our initial graph (Figure 57) of length two paths - 
Insulin. The predicate [C0024467|Magnesium - COEXISTS_WITH - 
C0021641|Insulin] is derived from Flink et al. [PMID572225] where the authors note 
that “FFA fell by a maximum of 65% or 0.44 meq/liter and Mg fell by a maximum of 
0.31 meq/liter during the glucose-insulin infusions” (Flink, Shane, Scobbo, Blehschmidt, 
and McDowell 1979). The other predicate [C0021641|Insulin - ASSOCIATED_WITH - 
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C0149931|Migraine Disorders] came from [PMID65562], a paper by Hsu et al. (Hsu et 
al. 1977). In our result set for paths of length three this relationship appears in the third 
answer, shown in Figure 58. 
 
 
 
Figure 57. Insulin Subgraph Figure 58. Insulin (Glucose) Subgraph 
 
 Performing a search between {Magnesium, Hypomagnesemia} and Migraine 
Disorders yields Figure 59. Of primary interest is the predicate 
[C0151723|Hypomagnesemia - COEXISTS_WITH - C0011849|Diabetes Mellitus] 
which comes from four documents [PMID7068108, PMID6802656, PMID5682248, 
PMID527222] where each group of authors found a connection. Fujii et al. [PMID7068108] 
state that “Hypomagnesemia has been reported to occur in diabetes mellitus in the course 
of recovery from ketoacidoses, as well as during insulin maintenance therapy” (Fujii, 
Takemura, Wada, Akai, and Okuda 1982). McNair et al. [PMID6802656] found that “net 
tubular reabsorption of magnesium is decreased in diabetic patients in presence of 
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hyperglycaemia, leading to hypermagnesiuria and hypomagnesaemia” (McNair, 
Christensen, Christiansen, Madsbad, and Transbøl 1982). Jackson and Meier, in their 
1968 paper [PMID5682248] “Routine serum magnesium analysis. Correlation with clinical 
state in 5,100 patients”, show that “Diabetes mellitus was the most common condition 
associated with hypomagnesemia” (Jackson and Meier 1968). If the conditions of 
Diabetes as a disease make magnesium deficiency prevalent, then it is also likely that 
migraines are also common for individuals with Diabetes.  
 
Figure 59. Diabetes Subgraph 
 
 In the paper “Increased platelet aggregation in early diabetes mellitus” by Sagel et 
al. [PMID1138583], they note a “tendency toward vascular disease in diabetes mellitus” 
and conclude that “platelet aggregation may be increased early in diabetes mellitus” 
(Sagel, Colwell, Crook, and Laimins 1975). Additionally. Rayssiguier notes in his 1984 
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paper [PMID6399344] studying the role of magnesium in arteriosclerosis that “magnesium 
and potassium depletion have also been reported in diabetes and the vascular implications 
of this should be considered” (Rayssiguier 1984). More recent studies have started to 
investigate the connections between Diabetes and headaches/migraines [Aamodt, 
Stovner, Midthjell, Hagen, and Zwart 2007; Berge et al. 2013; Fagherazzi et al. 2019; 
Haghighi et al. 2015; López-de-Andrés et al. 2018]. 
 It should be noted that the connection [C0042373|Vascular Diseases - 
COEXISTS_WITH - C0011849|Diabetes Mellitus] which completes the path is only 
found by including cited documents. This document [PMID1138583] does not have any of 
the search MeSH terms, and is only included via the citation from a paper by Joseph and 
Welch [PMID3308769], cited by Swanson which details a study on platelets and migraines 
(Swanson 1988). 
  
4.2.13 Retrospective Study: Magnesium and Migraine Disorders - Conclusions 
 The goal of this retrospective study and comparison with Cameron’s results is 
twofold: 1) A further test of reproducibility - that is, in general, similar results can be 
achieved, and 2) answer the question if the inclusion of citational information improves 
upon the prior results. The results are summarized in Table 15. For the eleven 
intermediate concepts, all of the seven that Cameron found were found in our reduced 
corpus with path lengths less than or equal to three. For the four concepts (Hypoxia, 
Stress, Substance P, Spreading Depression) noticed by Swanson that Cameron did not 
find, we were able to discover three. Substance P was discovered via discovery browsing 
of related concepts, so it is possible they could have been found within Cameron’s system 
under a different search. Both Stress/Type A Personality and Hypoxia were found within 
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our default search. This implies that overall the results were similar and differences are 
likely due to the differences in datasets due to updates to documents, MeSH terms, and a 
different version of the SemRep tool. Our results include a twelfth concept, Diabetes, 
undiscovered by Swanson and Cameron, where some predicates could only be uncovered 
via including cited documents.  
 
Table 15. Comparison of rediscoveries with those of Cameron (Magnesium) 
Intermediate Fleig Cameron 
Calcium Channel Blockers Found at 2 Found at 2 
Prostaglandin Found at 2 Found at 2 
Epilepsy  Found at 2 Found via discovery browsing. 
Serotonin  Found at 3 Found at 2 
Vascular  Found at 3 Found at 2 
Inflammation  Found at 3 Found via discovery browsing. 
Hypoxia  Found at 3 Did not find 
Platelet Aggregation Found at 3 Found via discovery browsing? 
Stress (Type A personality) Found at 3. Did not find 
Substance P Found (at 3) via discovery browsing. Did not find 
Spreading Cortical 
Depression 
Not Found Did not find 
Diabetes Found at 2 Did not find 
 
 
In Appendix B, Table B-3 details the precision and recall at each ranked result when 
using citations. Table B-4 does the same when not using citations but otherwise follows 
the same algorithm. A graph of the Precision-Recall curve can be seen here in Figure 60, 
and the F1@K measure in Figure 61.  
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Figure 60. Precision – Recall Curve for Magnesium – Migraine Disorder Study 
 
 
Figure 61. F1 @ K measure for Magnesium – Migraine Disorder Study 
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Comparison results show that using citations in the initial search does not uncover 
one of the expected intermediates that could not be found without their use as there was 
sufficient justification for several of the terms to account for the discovery. But, the 
inclusion of citations does cause the relevant results to appear higher in the ordered result 
set, yield additional results with exploratory searches, and illuminate one new 
intermediate concept. Analysis of the data indicates this stems from two factors. The first 
is caused by additional predicates that although yield no new intermediates in this case, 
may enhance the clustering. The second is caused by a higher IDF threshold.  
The IDF threshold is calculated independently for each search, based upon the 
unique concepts that are returned. Without citations the query result set contains 962 
unique UMLS concepts with a mean of 8.11 and a calculated cutoff at 3.945. When using 
citations the query result set contains 1943 unique UMLS concepts with a mean of 8.49 
and calculated cutoff at 4.566. Several of the non-relevant concepts appearing within the 
non-citation search fall below this higher value. This trend continues for all five of the 
studies performed (Table 16). 
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Table 16. Number of unique concepts and average IDF by study 
Number of Unique Concepts Avg IDF Std Dev Origin Study 
449 7.872367037 2.164025258 Fish Oils (W/o Citations) 
962 8.119543301 2.13191342 Magnesium (W/o Citations) 
967 8.177050274 2.137530552 Fish Oils (With Citations) 
1276 8.242275259 2.123573465 Arginine (W/o Citations) 
1686 8.492098715 2.107634478 Testosterone (W/o Citations) 
1943 8.489334596 2.011232172 Magnesium (With Citations) 
2163 8.508816686 2.072720142 Arginine (With Citations) 
2260 8.628326503 2.091449369 Parkinson’s (W/o Citations) 
2745 8.700485948 2.064198644 Testosterone (With Citations) 
3077 8.73736814 2.06278992 Parkinson’s (With Citations) 
 
This behavior is to be expected given the nature of language. Zipf’s law states 
that, when given a corpus comprised of natural language, the frequency of any word is 
inversely proportional to its rank in the frequency table for that corpus. In other words, 
that the most frequent word will occur about twice as often as the second most frequent 
word, three times that of the next and so on and so forth (Zipf 1949). This distribution 
follows that of a power law probability distribution. Previously we stated that IDF values 
for each unique concept were calculated based upon the 85.7 million predicates generated 
from Semrep. Plotting the document frequencies for each concept in rank order we find 
that they behave as expected by Zipf’s law (Figure 62).  
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Figure 62. Log – Log Plot of Concepts Illustrating Zipf’s Law 
 
The probability density for the Zipf distribution has been defined as Equation 4.1, where 
ζ(s) is the Riemann zeta function (Eq 4.2), k is the rank position, and s characterizes the 
distribution.  
 
𝑓𝑓(𝑘𝑘|𝑝𝑝) = 𝑘𝑘−𝑠𝑠
𝜁𝜁(𝑝𝑝) (4.1) 
𝜁𝜁(𝑝𝑝) = ∑ 1
𝑛𝑛𝑠𝑠
∞
𝑛𝑛=1  , s > 1 (4.2) 
 
The shape of this probability curve is known as a Pareto distribution and can be seen in 
Figure 63.  
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Figure 63. Example Pareto Distribution  
 
When considering the set of unique concepts within a document set, such as our 
search results without using citations, that set will contain some distribution of concepts 
out of the entire corpus following Zipf’s law. That is to say we expect, on average, more 
concepts with a lower IDF score. By expanding the search to include citationally related 
documents a greater number of concepts are returned, thereby increasing the average IDF 
score. Following the probability distribution selecting random sets shows us this behavior 
and explaining the additional differences between results (Figure 64). 
 
Figure 64. Average IDF for Random Selection of Unique Concepts 
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4.3 Retrospective Study: Somatomedin and Arginine 
In his 1990 paper, “Somatomedin C and Arginine: Implicit Connections between 
Mutually Isolated Literatures” Swanson described four connections between the protein 
Somatomedin C, also termed Insulin-Like Growth Factor 1 IGF), and the dietary amino 
acid Arginine. These were: stimulus of Growth Hormones, the promotion of Wound 
Healing, recovery from malnutrition, and the general improvement of Body Mass/Weight 
(Swanson 1990). We attempted to reproduce these results via the approach described 
previously. 
         Our corpus consisted of 150 of the original MEDLINE documents cited by 
Swanson (Table C-1) along with the other MEDLINE documents they cited, totaling 
2,125 references. Some documents were missing abstracts (and thusly missing SemRep 
abstract-generated predicates), for these abstracts/introductions were located and added 
manually along with any generated predicates. A listing of the pertinent predicates along 
and their corresponding sentences are recorded by document identifier within Table C-2. 
         Unless specified otherwise, each search was performed with source concepts of 
Somatomedins (C0037657) and Insulin-Like Growth Factor I (C0021665), along with a 
destination of Arginine (C0003765). As an example, Figure 65 shows a complete graph 
of all paths of length two returned. Of the four intermediates we immediately see three of 
them, along with a new intermediate, Diabetes.  
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Figure 65. Somatomedin – Arginine paths of length 2 
  
 4.3.1 Growth Hormone 
The first intermediate, Growth Hormone (GH), is also known as somatotropin or 
human growth hormone (HGH). It stimulates both growth and the regeneration and 
reproduction of cells. Arginine, Somatomedin, and IGF all have direct associations to 
somatotropin as can be seen in Figure 66 where our results with a path length of two are 
shown.  
The article entitled “Effect of arginine on serum levels of insulin and growth 
hormone in obese subjects” [PMID6027286] by Copinschi, Wegienka, Hane, and Forsham 
(1967) suggests [C0037663|Somatotropin - INTERACTS_WITH - 
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C0003765|Arginine] by title alone. Three other articles also provide similar associations 
[PMID4201417, PMID5571779, PMID3683183]. 
 
  
Figure 66. Growth Hormone Subgraph 
  
 Multiple sources provide the relationships between Somatotropin and IGF1. 
Manson, Smith, and Wilmore wrote in their article “Growth hormone stimulates protein 
synthesis during hypocaloric parenteral nutrition” [PMID2899993] that “GH was 
associated with an increase in insulin and insulin-like growth factor-I concentrations” 
(Manson, Smith, and Wilmore 1988). This sentence produces the predicate 
[C0037663|Somatotropin - STIMULATES - C0021665|Insulin-Like Growth 
Factor I]. This is similarly echoed in other references: “Levels of circulating IGF I and 
IGF II are affected by growth hormone” [PMID3322823] (Hammerman 1987),  “By 
contrast, both GH and PL stimulate IGF-I synthesis” [PMID6338399] (Adams, Nissley, 
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Handwerger, and Rechler 1983), and “There was also a significantly enhanced increase 
of SM-C/IGF I in the presence of GH” [PMID6385593] (Stracke, Schulz, Moeller, Rossol, 
and Schatz 1984).  
 The explicit relationship between Somatomedins to GH/Somatotropin is clear in 
the article “Specific binding of a somatomedin-like polypeptide in rat serum depends on 
growth hormone” [PMID967246] by Moses, Nissley, Cohen, and Rechler, where they 
state that “Somatomedins are growth hormone-dependent polypeptides” (Moses, Nissley, 
Cohen, and Rechler 1976). In addition to this, in 1980 Hintz et al. wrote  in their article 
“Interaction of somatomedin-C with an antibody directed against the synthetic C-peptide 
region of insulin-like growth factor-I” [PMID6153391]  that “Insulin-like growth factor-I 
is a human plasma peptide with strong structural homology to human prosinsulin. This 
peptide has been classified as a somatomedin on the basis of its biological actions and 
growth hormone dependence” (Hintz, Liu, Marshall, and Chang 1980). Additional 
references also produce the predicates relating Somatomedin and Somatotropin: 
[PMID4506104, PMID3803997, PMID6639868]. 
 
4.3.2 Malnutrition 
 The second intermediate, Malnutrition, is discovered through Kwashiorkor which 
is a type of severe form of protein malnutrition and Protein-Energy Malnutrition. The 
subgraph illustrating these relationships is shown in Figure 67. 
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Figure 67. Malnutrition Subgraph 
 
 Several predicates relating Arginine and Kwashiorkor, Marasmic Kwashiorkor, 
and Protein-Energy Malnutrition were generated from the 1986 article entitled “Serum 
insulin-like growth factors I and II concentrations and growth hormone and insulin 
responses to arginine infusion in children with protein-energy malnutrition before and 
after nutritional rehabilitation” by Soliman et al. [PMID3099250]. They stated that “GH 
responses to arginine were depressed in the three malnourished groups and improved 
significantly in marasmic-kwashiorkor and marasmic children after nutritional 
rehabilitation” (Soliman et al. 1986). They then further state that “insulin responses to 
arginine were impaired in kwashiorkor, and marasmic-kwashiorkor children and 
improved significantly after refeeding”.  
 In “Effects of dietary composition on somatomedin activity in growing rats” 
[PMID107298], Reeves et al. studied how diet affects somatomedin activity. The predicate 
[C0037657|Somatomedins - ASSOCIATED_WITH - C0022806|Kwashiorkor] was 
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produced by their conclusion that “these data suggest that dietary composition has a 
direct effect on plasma somatomedin activity and that the severe growth retardation 
associated with protein malnutrition may be related to its additional effect on serum 
somatomedin” (Reeves et al. 1979). Three other references produce like predicates: 
[PMID96201, PMID6792631, PMID467343]. 
Finally, two other papers [PMID412936, PMID105670] examined Somatomedins 
in relation to malnutrition. As an example, in the first paper, Hintz et al. stated that their 
“study was undertaken to define the interrelationships of somatomedin, growth hormone, 
and an inhibitor of SM in protein-calorie malnutrition” (Hintz, Suskind, Amatayakul, 
Thanangkul, and Olson 1978).  
 
4.3.3 Wound Healing 
 Our results show that Wound Healing is directly connected to each of Arginine, 
Somatomedins, and Insulin-Like Growth Factor I. Each of these is illustrated in Figure 
68. The predicate [C0003765|Arginine - AFFECTS - C0043240|Wound Healing] is 
derived from the 1985 article by Barbul et al [PMID3923266] where their conclusions 
“indicate that high arginine levels in IVH solutions improve wound healing and thymic 
immune function following injury” (Barbul et al. 1985). 
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Figure 68. Wound Healing Subgraph 
  
 Spencer, Skover, and Hunt investigated the relationship between Wound Healing 
and Somatomedins from which the predicate [C0037657|Somatomedins - AFFECTS - 
C0043240|Wound Healing] is derived. In their 1988 article “Somatomedins: do they 
play a pivotal role in wound healing?” [PMID3380847] they state that “An understanding 
of the role of somatomedins in normal wound healing might be able to help us understand 
abnormalities of the repair process such as keloid formation” (Spencer, Skover, and Hunt 
1988). 
 Although these two predicates are sufficient to prove the intermediate Wound 
Healing, the additional predicate [C0021665|Insulin-Like Growth Factor I - 
AFFECTS - C0043240|Wound Healing] is also present within the subgraph. The 
originating article “Regenerating endothelial cells express insulin-like growth factor-I 
immunoreactivity after arterial injury” [PMID3690631] by Hansson, Jennische, and 
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Skottner concludes that “IGF-I is likely to be involved in the repair of the intima in 
injured arteries” (Hansson, Jennische, and Skottner 1987). 
 
4.3.4 Diabetes 
In addition to the aforementioned three connections there were a few unexpected 
intermediate concepts that showed up: these include Insulin, Diabetic, and Diabetes 
Mellitus (Figure 69). Although these were not called out as intermediates in Swanson’s 
original paper (Swanson 1990) it should be noted that Cameron et al. also uncovered 
Insulin. 
In 1980 Binoux, Hossenlopp, Lassarre, and Seurin studied the production of 
Somatomedin [PMID6986740].  Their findings suggested that “insulin plays an important 
role in SM generation, as it itself is capable of both stimulating the release of SM and 
amplifying the stimulatory effect of GH” (Binoux, Hossenlopp, Lassarre, and Seurin 
1980).  This conclusion produces the predicate [C0021641|Insulin - INTERACTS_WITH 
- C0037657|Somatomedins]. This interplay is also backed up by the predicate 
[C0021641|Insulin - COEXISTS_WITH - C0037657|Somatomedins] from Kogawa et 
al. [PMID6751804] where “the addition of human growth hormone and/or insulin to the 
perfusates caused a significant increase in somatomedin after 120 minutes of 
recirculation” (Kogawa, Takano, Hizuka, Asakawa, and Shizume 1982). Other sources 
also show relationships between the two concepts: [PMID6368579, PMID1261514, 
PMID132381] 
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Figure 69. Diabetes Subgraph 
    
 The predicate relating Arginine and Insulin, [C0003765|Arginine - 
COEXISTS_WITH - C0021641|Insulin], comes from “Sex-determined variation in 
serum insulin and growth hormone response to amino acid stimulation” [PMID5917038], a 
study by Merimee, Burgess, and Rabinowitz. They state that “during the course of 
experience with subjects who were given infusions of arginine, we observed that female 
subjects showed a greater rise in serum insulin and in serum HGH than did males of a 
comparable age” (Merimee, Burgess, and Rabinowitz 1966). Three other studies 
[PMID6027286, PMID4903729, PMID6754563] also generate predicates linking 
Arginine and Insulin. 
 The relations between either Somatomedins or Arginine and Diabetic/Diabetes 
Mellitus are generated from a few sources.  The observation “of a growth hormone-
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resistant decrease in somatomedin activity associated with conditions of insulinopenia 
suggest that somatomedin and growth might be related to metabolic control in diabetes 
mellitus” from Phillips and Orawski [PMID142677] produces [C0037657|Somatomedins 
- ASSOCIATED_WITH - C0011849|Diabetes Mellitus] (Phillips and Orawski 1977). 
The next, [C0037657|Somatomedins - AFFECTS - C0241863|Diabetic], is likewise 
generated by the observation in [PMID2413420] that “diabetic children, treated 
conventionally, have normal circulating IGF levels, but both growth rate and serum IGF 
concentration may increase dramatically when diabetic control is optimized” (Hill and 
Milner 1985). Finally, the 1979 study “Prolactin nonresponsiveness to arginine in 
diabetes mellitus” examined the interaction of Arginine within diabetic patients (Le 
Roith, Shapiro, Jabotinsky, and Spitz 1979). 
 
4.3.5 Body Weight (Growth) 
  Performing a closed discovery yields a subgraph result that includes Growth 
(Figure 70). Multiple studies generate predicates associating Arginine and Growth: 
“Dietary arginine may play a critical role in growth of normal as well as neoplastic 
tissue” [PMID430251] (Milner and Stepanovich 1979), “The diet supplemented with 
arginine and glycine improved growth before and after trauma” [PMID430225] (Pui and 
Fisher 1979), “The rôle of arginine in growth” [PMID20276173] (Borman et al. 1946), and 
“Effect of arginine deficiency on growth and intermediary metabolism in rats” 
[PMID4430939] (Milner, Wakeling, and Visek 1974). 
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Figure 70. Growth (Body Weight) Subgraph 
 
   
 The inter-relationship between Growth and Somatotropin has been known for 
over half a century as evident by the well-known study by Salmon and Daughaday where 
they hypothesized the existence of a mediating factor (Salmon and Daughaday 1957). 
Multiple documents generate predicates relating the two. The predicate 
[C0037663|Somatotropin - AUGMENTS - C0018270|Growth] comes from 
[PMID6243390] where the authors acknowledge the earlier work: “It is now over 20 years 
since Salmon and Daughaday hypothesized that stimulation of growth by growth 
hormone (somatotropin) was mediated by a circulating 'sulfation factor'” (Phillips, 
Vassilopoulou-Sellin, and Reichard 1979). Similar quotes can be found in other 
references: “Somatomedin (SM) is a growth hormone (GH)-dependent peptide, 
circulating in normal serum, which directly causes skeletal growth” [PMID1128255] 
(Daughaday, Phillips, and Herington 1975), “The significance of pituitary growth 
hormone (GH) for the regulation of skeletal growth is uniformly recognized” 
[PMID4538721] (Hall 1972), and “In the whole animal a major function of GH is to 
stimulate the longitudinal growth of the skeleton, and GH acts by controlling the 
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production of a second series of hormones, the somatomedins” [PMID1128683] (Francis 
and Hill 1975). 
 The other predicates shown in Figure 70 have already been discussed in our 
examination of previous intermediates. These include the association of Somatropin to 
both Somatomedin and Insulin-Like Growth Factor I. 
 
4.3.6 Retrospective Study: Somatomedin and Arginine - Conclusions 
 The goal of this retrospective study is the same as our previous ones and the 
results are summarized in Table 17. We were able to successfully uncover all five of the 
expected intermediate concepts. In comparison, Cameron’s study was not able to find 
Wound Healing. 
 
Table 17. Comparison of rediscoveries with those of Cameron (Somatomedins) 
Intermediate Fleig Cameron 
Growth Hormone Found at 2 Found at 2 
Body Weight Found at 2 Found at 2 
Malnutrition Found at 2 Found via discovery browsing. 
Wound Healing Found at 2 Not Found 
Diabetes Found at 2 Found at 2 
 
 
In Appendix C, Table C-3 details the precision and recall at each ranked result when 
using citations. Table C-4 does the same when not using citations but otherwise follows 
the same algorithm. A graph of the Precision-Recall can be seen here in Figure 71.  
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Figure 71. Precision – Recall Curve for Somatomedins – Arginine Study 
 
 
 As we were able to uncover all of the expected intermediates with just a path 
length of two, the slight improvement in our Precision-Recall curve when using citations 
is purely due to the higher IDF threshold which we discussed previously. Figure 72 
shows the F1@K graphs for each approach and their expected similarity.  
 
Figure 72. F1 @ K measure for Somatomedins – Arginine Study 
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4.4 Retrospective Study: Testosterone and Sleep 
In their 2012 paper, “A Closed Literature-Based Discovery Technique Finds a 
Mechanistic Link Between Hypogonadism and Diminished Sleep Quality in Aging Men” 
Miller et al. described their insights into the associations between Hyogonadism and 
diminishing sleep quality in men. It had been known that the process of aging in healthy 
adults causes a reduction in sleep quality due to decreased REM sleep, more frequent 
awakenings, and total sleep duration (Espiritu 2008). It had also been previously 
suggested that hormonal changes could be responsible for a shorter sleep duration 
(Trenell, Marshall, and Rogers 2007), though no mechanism was known. 
Miller et al. stated that a consequence of hypoganism is high levels of Cortisol, 
and therefore theorized that as men age and testosterone levels decrease their cortisol 
levels increase due to the onset of hypogonadism. (Miller et al. 2012).  As such we expect 
to find the intermediate Cortisol/Hydrocortisone. We attempted to reproduce these results 
via the approach described previously. 
         Our corpus consisted of 52 of the original MEDLINE documents cited by Miller 
et al. (Table D-1) along with the other MEDLINE documents they cited, totaling 2,039 
references. A listing of the pertinent predicates along and their corresponding sentences 
are recorded by document identifier within Table D-2. Our search was performed with 
the source concept Testosterone (C0039601) and the destination of Sleep (C0037313, 
C0037322, C0234451), finding results at path lengths of one and two.  
Multiple papers call out the direct association between Testosterone and Sleep 
directly. Andersen and Tufik’s 2008 paper [PMID18519168] states it directly in their title 
“The effects of testosterone on sleep and sleep-disordered breathing in men: its 
bidirectional interaction with erectile function” (Andersen and Tufik 2008). In the 1997 
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paper [PMID9329339] by Leibenluft et al. they claim that their results indicated that 
“testosterone has relatively specific and discrete effects on sleep and hormonal rhythms 
in men” (Leibenluft et al. 1997). Lastly Axelsson et al. wrote in their 2005 paper 
[PMID15914523] that “testosterone increased during sleep and fell during waking, 
whereas circadian effects seemed marginal” (Axelsson, Ingre, Åkerstedt, and Holmbäck 
2005). Our first search result illustrates this (Figure 73).  
 
Figure 73. Direction relationship between Testosterone and Sleep 
 
 Several results also appear which continue to emphasize that a relationship exists, 
but does not provide a deeper semantic meaning. These include Gonadal Steroid 
Hormones (Figure D-3), Hormones (Figure D-5), Aging (Figure D-7), Growth Hormone 
Secretion (Figure D-8), Circadian Rhythms (Figure D-9), and Estrogens (Figure D-13).  
 
4.4.1 Hydrocortisone (Cortisol) 
Hydrocortisone does show up in our ninth search result (Figure 74), the 
association having been generated from multiple source references.  Cortisol is a 
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glucocorticoid secreted by the adrenal cortex in response the physical and psychological 
stress. Glucocorticoids are involved in the metabolism of carbohydrates, proteins, and 
fats and have anti-inflammatory properties. The release of Cortisol affects the 
metabolism by attempting to help maintain blood glucose levels during physical exercise. 
Testosterone is an anabolic hormone important in the growth and maintenances of 
muscle, bone, and red blood cells. Similar to Cortisol, Testosterone levels increase in 
response to exercise and stress. 
 
 
 
Figure 74. Relationship between Testosterone and Sleep via Hydrocortisone 
 
Previous research has established that under particular circumstances Cortisol and 
Testosterone exhibit a negative relationship. In the paper [PMID15724043] “Fetal plasma 
testosterone correlates positively with cortisol” Gitau et al. noted that “unlike the norm in 
the adult, where testosterone production is often inhibited by cortisol, in the fetus there is 
a positive link between the two” (Gitau, Adams, Fisk, and Glover 2005). Doerr and Pirke 
concluded that the “administration of cortisol leading to plasma levels as seen under 
treatment with ACTH suppresses testosterone by abolishing or flattening the nocturnal 
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rise” in their paper [PMID956348] “Cortisol-induced suppression of plasma testosterone 
in normal adult males” (Doerr and Pirke 1976). Two additional papers also discuss the 
relationship: [PMID15886244, PMID15841103]. 
 The paper [PMID10841212] "Sleep impairments in healthy seniors: roles of 
stress, cortisol, and interleukin-1 beta” by Prinz, Bailey, and Woods noted that “healthy 
older women and men with higher levels of free cortisol under a mild stress condition had 
impaired sleep” (Prinz, Bailey, and Woods 2000). The researchers Kern, Dodt, Born, and 
Fehm also corroborates this [PMID8548511] in the results where “changes in sleep-
dependent secretion of GH and cortisol correlated significantly with an age-dependent 
decrease in slow wave sleep” (Kern, Dodt, Born, and Fehm 1996). Five other papers also 
discuss the relationship between Cortisol and Sleep: [PMID3790626, PMID3661052, 
PMID2541159, PMID8077308, PMID6822642]. 
 
4.4.2 Alzheimer’s Disease 
 One of our results indicated a potential connection via the intermediate 
Alzheimer’s Disease (Figure 75). Upon inspection this path exists due to two cited papers 
included within the corpus. The first [PMID16344336], entitled “Effects of testosterone 
on cognition and mood in male patients with mild Alzheimer disease and healthy elderly 
men”, by Lu et al. concluded that “testosterone replacement therapy improved overall 
quality of life in patients with AD” but had “minimal effects on cognition” (Lu et al. 
2006).  
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Figure 75. Relationship between Testosterone and Sleep via Alzheimer’s disease 
 
The second was a paper [PMID12531038] by McCurry et al. titled “Treatment of sleep 
disturbance in Alzheimer's disease” only suggested that “sleep problems in AD are multi-
factorial, and influenced by a variety of demographic, physical, psychiatric and 
situational factors” (McCurry, Reynolds, Ancoli-Israel, Teri, and Vitiello 2000). The 
predicates in question were generated from very general relationships and thus are 
inconclusive, but does leave open the possibility that sleep problems in some Alzheimer’s 
patients could be due to decreased Testosterone.  
 
4.4.3 Interleukin-1 Beta 
 Interleukin-1 beta is a cytokine protein and is a pro-inflammatory cytokine 
involved in the body’s inflammatory response to infections or conditions associated with 
an inflammatory state. From [PMID15240608], Testosterone has been shown to have 
“immune-modulating properties” and evidence suggests that it “may suppress the 
expression of the pro-inflammatory cytokines” (Malkin et al. 2004). Previously we noted 
the relationship between reduced testosterone and greater amounts of cortisol, a known 
glucocorticoid. This is further evidenced by a paper by Chang and Opp [PMID 
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10956236] entitled “IL-1 is a mediator of increases in slow-wave sleep induced by CRH 
receptor blockade”. Therein they describe that “IL-1 promotes sleep, and glucocorticoids 
inhibit IL-1 synthesis” (Chang and Opp 2000). 
 
Figure 76. Relationship between Testosterone and Sleep via IL-1 beta 
 
 Several other papers provide support for the role of IL-1 in sleep. In [PMID 
9781819] Taishi et al. state that “much evidence implicates interleukin-1beta (IL-1beta) 
in sleep regulation” (Taishi et al. 1998). In the same year Fang, Wang, and Krueger 
[PMID9530230] wrote that “Interleukin-1 beta (IL-1 beta) is a well characterized sleep 
regulatory substance” (Fang, Wang, and Krueger 1998). A later study [PMID12000022]. 
in 2001 by some of the same individuals continued to support the earlier work (Krueger, 
Obál, Fang, Kubota, and Taishi 2001).  
 The original paper by Miller et al. did not state IL-1 (or any other cytokine) as a 
potential intermediate. However, given the papers just mentioned, it seems likely that 
these proteins could be potentially involved within the biochemical interactions involving 
sleep and the role of testosterone (Figure 76). 
 
4.4.4 Parkinson’s Disease 
 Within our results, one answer showed Parkinson’s Disease as an intermediate 
(Figure D-6). This path is due entirely to ten papers which studied the effects of 
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Parkinson’s Disease with either Testosterone or Sleep. These are documents included in 
our local corpus that were cited from core papers in our final study involving the 
connections between Parkinson’s Disease and Crohn’s Disease. It should be noted that, as 
such, we would not have this result from just the corpus constructed from Miller et al.’s 
work.  The paper by Okun et al. [PMID16682542] indicates that “testosterone deficiency 
has been reported in patients with Parkinson disease (PD), Alzheimer disease, and 
Huntington disease” (Okun et al. 2006). And numerous papers illustrate the relationship 
between sleep disorders and PD: [PMID2259351, PMID18591114, PMID17942122, 
PMID15389999, PMID12621636, PMID12438461, PMID11798367, PMID10752568]. 
 
4.4.5 Retrospective Study: Testosterone and Sleep - Conclusions 
We were able to successfully uncover the single expected intermediate concept, 
Cortisol/Hydrocortisone. As we were able to recover the concept with a path length of 
two, as expected, Cameron’s study was also able to recover the concept. Additionally, 
because we found the solutions at path lengths of two and less we expect there to be little 
difference between the citational and non-citational approaches. In fact, the resulting 
subgraphs were identical between the two trials, yielding the same P-R (Figure 77) and 
F1@K (Figure 78) curves. 
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Figure 77. Precision – Recall Curve for Testosterone – Sleep Study 
 
 
Figure 78. F1 @ K measure for Testosterone – Sleep Study 
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4.5 Retrospective Study: Parkinson’s Disease and Crohn’s Disease 
 Parkinson’s disease (PD) is a neurodegenerative disorder that affects dopamine-
producing neurons within the brain. In turn, dopamine activates the nerve cells that 
coordinate normal muscle activity. In patients with PD, there is a reduction in the supply 
of dopamine which impairs their ability to control movement.  
 Crohn’s disease (CD) is a type of chronic inflammatory bowel disease (IBD) that 
affects the lining of the digestive tract. CD is also considered an autoimmune disease as 
the immune system attacks the gastrointestinal tract causing abdominal pain, diarrhea, 
vomiting, and other complications.  
 In 2014 Kostoff published a study titled “Literature-related discovery: common 
factors for Parkinson’s Disease and Crohn’s Disease” where in the interconnections 
between these two diseases were explored via LBD. Kostoff concluded that there were 
three major themes that unified the PD and CD literatures: these were Genetics, 
Neuroimmunology, and Cell Death. Additionally, he noted that these three themes are not 
independent from each other. In one example Kostoff states “there are genetic 
determinants of the inflammatory response” which are immunological in nature, and that 
“naturally occurring genetic variants in important inflammatory mediators such as TNF-
alpha appear to alter inflammatory responses” (Kostoff 2014). 
Reproducing Kostoff’s study, our corpus consisted of 32 of the original 
MEDLINE documents cited by Miller et al. (Table E-1) along with the other MEDLINE 
documents they cited, totaling 1,974 references. A listing of the pertinent predicates 
along and their corresponding sentences are recorded by document identifier within Table 
E-2. Our search was performed with the source concept Parkinson Disease (C0030567) 
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and the destination of Crohn’s Disease (C0010346), finding results at path lengths of two 
and three. 
4.5.1 Immunology 
 Inflammation is a normal response for the body’s immune system when tissues 
are injured by trauma, toxins, bacteria, or other causes. Chemicals such as histamine are 
released by the damaged cells which lead into the surrounding area causing swelling. 
This is a signal to the body’s white blood cells to help protect the area from foreign 
substances.  
 Performing a closed search with a max path length of two we find that four of the 
eight results match this case: Inflammation (Figure E-2), Chronic Inflammation (Figure 
E-5), Immune Response (Figure E-6), and Anti-Inflammatory Agents (Figure E-8). Past 
research has well documented this generalized connection. Whitton’s paper 
“Inflammation as a causative factor in the aetiology of Parkinson's disease” 
[PMID17339843] considers the “possible use of anti-inflammatory drugs in PD” 
(Whitton 2007). Additionally, “accumulating evidence has suggested that inflammation 
in the brain participates in the pathogenesis of Parkinson's disease” (Li, Wang, Pei, Liu, 
and Hong 2005). Similar statements connect PD to Inflammation in [PMID19221310, 
PMID15869932, PMID15109580, and PMID17156147].   
 Crohn’s disease is, by definition, an inflammatory bowel disease “characterized 
by transmural inflammation” (Vallance et al. 2005) and Burke et al. noted 
[PMID17156147] that the “pathogenesis of inflammation in CD has been extensively 
investigated” (Burke et al. 2007). Additional statements that connect Inflammation to CD 
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can be found in [PMID12474223, PMID15058528, PMID11052175, and 
PMID11743591]. 
 Another result (Figure E-7), Cytokine, connects PD to CD and yields more direct 
information. Cytokines are a broad category of proteins important to cell signaling. More 
directly for our study, they can be involved with immune responses and inflammation. 
Wahner et al. noted in 2007 [PMID17984451] that “markers of neuroinflammation, 
including activated microglia and increased levels of circulating proinflammatory 
cytokines, have been observed in the brains and CSF of patients with Parkinson disease” 
(Wahner, Bronstein, Bordelon, & Ritz 2007). Mogi et al. also noticed the connection 
[PMID10400088]:  “the levels of proinflammatory cytokines such as tumor necrosis 
factor (TNF)-alpha are increased in the striatum and cerebrospinal fluid from patients 
with Parkinson's disease (PD)” (Mogi et al. 1999).  Similar observations were made in 
[PMID9550432] connecting cytokines in the pathogenesis of Crohn’s Disease. 
 Performing a closed search with a path length of three, and limiting paths that go 
through one of these intermediates (Figure E-10), we can see additional details to these 
associations. The first result of the search (Figure 79) shows a number of new potential 
intermediate terms of interest: Peroxisome Proliferator-Activated Receptors (PPAR), 
Inflammatory Bowel Diseases (IBD), Interleukin-1 beta, Ulcerative Colitis (UC), Tumor 
Necrosis Factor-alpha (TNF alpha), and the TNF gene. 
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Figure 79. Relationship between PD and CD (Inflammation) 
 
 Although these concepts seem like a good fit, and many are associated with 
Inflammation and Crohn’s Disease, none are directly linked to Parkinson’s disease in the 
graph. Thankfully, however, the subsequent results provide more detail.  
 
 
Figure 80. Relationship between PD and CD – TNF protein 
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 While Tumor Necrosis Factor-alpha and TNF gene both appeared in Figure 79, 
we find TNF protein (Figure 80) in the second search result. The predicate 
[C1448177|TNF protein – ASSOCIATED_WITH – C0030567|Parkinson Disease] 
comes from [PMID12205053], a paper by Sriram. Therein they studied the potential role 
for TNF-alpha in PD, stating that “the proinflammatory cytokine TNF-alpha is an 
obligatory component of dopaminergic neurodegeneration” and that “enhanced 
expression of the proinflammatory cytokine, tumor necrosis factor (TNF)-alpha, has been 
found in association with glial cells in the substantia nigra of patients with PD” (Sriram 
2002).  Similar predicates come from other documents [PMID14724828, 
PMID17483119]. 
 
 
Figure 81. Relationship between PD and CD – IL-10 
 
 Another related result from the search (Figure 81) shows the intermediate 
Interleukin-10. The predicate [Interleukin-10 – ISA – cytokine] was extracted 
from a 2005 paper [PMID15879017] (Chevrier et al. 2005). The subsequent association 
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with Crohn’s Disease stems from [PMID16461743] where they conclude “the NOD2fs 
mutation results in a loss-of-function phenotype in human myeloid DC and imply 
decreased immune regulation by IL-10 as a possible mechanism for this mutation in CD” 
(Kramer, Netea, De Jong, Kullberg, and Adema 2006). Of note, their paper associates 
this immune regulating cytokine with Crohn’s Disease, but it is also within the context of 
a genetic variation.  
 
4.5.2 Cell Death 
 The last two results of the Inflammation search (Figure E-19 and Figure E-21) 
show a relation with the concept of Cell Death via Immunology – specifically Cytokine or 
Inflammation. The first of the two, shown here as Figure 82, indicated that Parkinson’s 
Disease is related to Apoptosis. Apoptosis is a regulated form of pre-programmed cell 
death which can occur either because it senses some amount of stress (internal) or 
because it of external signals from other cells.  
 
Figure 82. Relationship between PD and CD – Apoptosis 
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 In 2005, Maraganore et al. performed a genetic study of Parkinson’s Disease, in 
their paper [PMID16252231] “High-resolution whole-genome association study of 
Parkinson disease”, where we extracted [C0030567|Parkinson Disease – AFFECTS – 
C0162638|Apoptosis]. They identified eleven single nucleotide polymorphisms 
(variation in a single nucleotide that occurs at a specific position) associated with PD and 
discovered that “the protein encoded by this gene plays an important role in neurogenesis 
and in neuronal apoptosis, which is consistent with existing hypotheses regarding PD 
pathogenesis” (Maraganore et al. 2005). TNF-alpha is a cytokine known to be a large 
mediator of apoptosis, and three additional papers in our corpus then further relate 
Cytokine to Apoptosis: [PMID16493072, PMID11922776, PMID9422513].  
 
 
Figure 83. Relationship between PD and CD – Cell Death (Inflam) 
 
 
 Figure 83 shows Cell Death explicitly as a connection. This is derived from two 
references. The first, [C0030567|Parkinson Disease -  AFFECTS - C0007587|Cell 
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Death] is from a paper [PMID17908040] by Tweedie, Sambamurti, and Greig who detail 
that “TNF-alpha has been demonstrated to play a major role in central nervous system 
(CNS) neuroinflammation-mediated cell death in AD, PD and amyotrophic lateral 
sclerosis (ALS) as well as several other CNS complications” (Tweedie, Sambamurti, and 
Greig 2007). The same predicate is also extracted from a second paper [PMID8196673].  
 The predicates connecting Cell Death to Inflammation/Anti-inflammatory Agents 
is supported by two studies [PMID15109580, PMID17984451]. One of which indicates 
that “antiinflammatory agents inhibit dopaminergic cell death in animal models of PD, 
and there is one epidemiological report that their use significantly diminishes the risk of 
PD”  (McGeer and McGeer 2004).  
 Further evidence of Cell Death being a common factor lies hidden in one of 
results from the original search (Figure E-3), shown in Figure 84 below. When the 
connections are examined, the listed concept Anti-Anxiety Agents (C0040616) is found 
to be a misnomer. The predicate [C0040616|Anti-Anxiety Agents – TREATS – 
C0030567|Parkinson Disease] is extracted from Olanow’s 2006 paper 
[PMID16717254], stemming from the sentence “this raises the possibility that anti-
apoptotic agents might be neuroprotective in PD” (Olanow 2006).  
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Figure 84. Relationship between PD and CD – Cell Death (apoptosis) 
 
 A similar problem occurred in two documents making the connection with  
Crohn’s Disease: [C0040616|Anti-Anxiety Agents – TREATS – C0010346|Crohn’s 
disease].  Hanauer summarized [PMID15580149] that “the past decade has brought 
forth a series of novel biologic agents targeting tumor necrosis factor (TNF) for the 
treatment of Crohn's disease” and his review discussed “the results of controlled clinical 
trials of anti-TNF agents for Crohn's disease” (Hanauer 2004). In this case, “anti-TNF” 
was interpreted by SemRep as Anti-Anxiety Agents by mistake, and we’ve already noted 
how TNF is associated with apoptosis. The second article, [PMID17470824] by 
Sandborn also encountered the same issue with SemRep where “anti-TNF” was picked 
up as Anti-Anxiety Agents (Sandborn 2007).  
 With a better understanding of the connections found in Figure 84, this shows a 
more direct connection between Parkinson’s Disease and Crohn’s Disease via the higher 
order concept Cell Death. 
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4.5.3 Genetics 
 Previously we referenced a paper by Maraganore et al. [PMID16252231] in 
regards to the intermediate Apoptosis, wherein the authors stated they “identified 11 
Single Nucleotide Polymorphisms that were associated with Parkinson’s Disease” 
(Maraganore et al. 2005), generating the predicate [C0752046|Single Nucleotide 
Polymorphism – ASSOCIATED_WITH – C0030567|Parkinson Disease].  This same 
concept also appeared as one of the original search results (Figure 85). A large scale 
international study [PMID17052658] the next year by Elbaz et al. further corroborated 
this by identifying “13 single-nucleotide polymorphisms (SNPs) significantly associated 
with Parkinson's disease” (Elbaz et al. 2006).  
 
Figure 85. Relationship between PD and CD – Single Nucleotide Polymorphism 
 
 The predicate [C0752046|Single Nucleotide Polymorphism – 
NEG_ASSOCIATED_WITH – C0010346|Crohn’s disease] which connects Crohn’s 
Disease is extracted from [PMID15685540] where the authors wrote that “the G2677T 
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SNP was not associated with UC or CD” (Ho et al. 2005). This, unfortunately, is a weak 
association. Like before, we can dig for additional meaning by attempting a deeper 
search. A different search performed (Figure E-23) focused around Single Nucleotide 
Polymorphism between PD and CD, we find several genetic intermediates (Figure 86). 
 
Figure 86. Relationship between PD and CD, PL3 – Single Nucleotide Polymorphism 
 
 From the figure we find that ABCB1 gene connects to all three: Parkinson’s 
Disease, Crohn’s Disease, and Single Nucleotide Polymorphism. This is not a surprise as 
the last result of our original search connected PD and CD via ABCB1 gene (Figure E-9). 
Additionally P-Glycoprotein, also known as Multidrug Resistance Protein 1 (MDR1), is 
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encoded by the ABCB1 gene. Ishikawa et al. reported in [PMID15256718] that “genetic 
variations of the human ABCB1 (P-glycoprotein/MDR1) gene have been most 
extensively studied” and “more than fifty single nucleotide polymorphisms (SNPs) and 
insertion/deletion polymorphisms in the ABCB1 gene have been reported” (Ishikawa et 
al. 2004). 
 Other research has further connected the gene to each of the two diseases. In their 
paper “Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical 
relevance” [PMID14749689] Marzolini, Paus, Buclin, and Kim stated “An increasing 
number of studies have also implicated certain commonly occurring SNPs in MDR1 in 
problems including altered drug levels and host susceptibility to diseases such as 
Parkinson's disease, inflammatory bowel disease, refractory seizures, and CD4 cell 
recovery during human immunodeficiency virus therapy” (Marzolini, Paus, Buclin, and 
Kim 2004). Their work points an associating with both PD and IBD, but not directly with 
CD. This is connected in our graph by the paper “MDR1 gene: susceptibility in Spanish 
Crohn's disease and ulcerative colitis patients” [PMID16374256]. The authors concluded 
that “considering our results and those from others, the MDR1 gene behaves as a 
common risk factor for both CD and UC” (Urcelay et al. 2006) 
 
4.5.4 Retrospective Study: PD and CD – Conclusions 
 After consideration, the results of our search with a maximum path length of two 
(Figure E-1), cover all three expected high level concepts: Immunology, Cell Death, and 
Genetics. The search results are again identical between the citational and non-citational 
approaches, yielding the same P-R (Figure 87) and F1@K (Figure 88) curves.  
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Figure 87. Precision – Recall Curve for Parkinson – Crohn Study 
 
 
 
Figure 88. F1 @ K measure for Parkinson – Crohn Study 
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However, the details of those connections were not able to explain those 
associations and, as such, prompted several secondary searches to probe deeper. Of the 
concepts that appeared within the subsequent searches a number only appeared due to the 
use of citations.  
 With the Inflammation search (path length three) there were five separate 
concepts that only appeared when using citations given our corpus. Comparing Figure 
E-11 and Figure E-12, we find a difference for the concepts Interleukin-1 beta, TNF 
gene, and Peroxisome Proliferator-Activated Receptors (PPAR). Interleukin-1 beta is 
another cytokine, TNF gene is responsible for Tumor Necrosis Factor-alpha which we 
discussed previously, and Peroxisome Proliferator-Activated Receptors are a group of 
proteins that help regulate the expression of genes. Another cytokine, Interleukin-10, is 
yet another example that appears when using citations (Figure E-15 and Figure E-16). 
Lastly, the intermediate Apoptosis (Figure E-19) does not appear without citations. 
 With the Single Nucleotide Polymorphism the term P-Glycoprotein does not 
appear without citations as well. This can be seen in the comparison of Figure E-24 and 
Figure E-25. Although the ABCB1 gene was already present in the graph, the presence of 
the corresponding P-Glycoprotein helps complete the overall semantic picture. 
 
4.6 Summary 
 This chapter presented the results of five retrospective experiments performed to 
determine the validity of a semantic-based LBD approach that makes use of bibliographic 
citations. In two cases (e.g. the study of Somatomedin and Arginine and the study of 
Testosterone and Sleep), strong relationships were found by examining predicates of path 
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length two or less. In these situations we have shown that including citations does not 
improve the results. However, in the other three studies the inclusion of citations 
uncovered crucial or additional related concepts. In two of the three cases (Fish Oils and 
Magnesium studies) a portion of the intermediates were only uncovered with the use of 
citational information. In the last case, the Parkinson’s Disease – Crohn’s Disease study, 
although all of the expected concepts appeared within the graph at a path length of two, 
the supporting abstracts did not provide sufficient evidence to back the claim. This 
prompted additional searches with a path length of three wherein multiple concepts 
appeared due to using predicates included via citations. We conclude from these five 
studies that the use of information from citationally related documents improves the 
qualitative results as shown by F1 and Precision-Recall curves.  
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Chapter 5 
 
Summary 
 
5.1 Foundation of Work 
  Cameron et al. (2015) devised a closed-discovery context-driven LBD approach 
based upon the earlier graph-based semantic summarization methods. Their system 
automatically generates one or more graphs representing the semantic associations 
between two user-provided concepts. These graphs are then used to find semantically 
related pathways from one concept to another. They performed multiple retrospective 
studies, recovering many key intermediates while utilizing full-text. 
In work later performed by Cameron as part of his dissertation, he attempted to 
rediscover Swanson’s Raynaud Syndrome–Dietary Fish Oils hypothesis without the use 
of full-text. Through a similar predicate analysis he noted that “these results collectively 
suggest that titles and abstracts alone might NOT be sufficient” (Cameron et al. 2016). 
The results of this study have shown that some intermediates can additionally be 
uncovered by including cited documents when working with only titles and abstracts.  
 
5.2 Summary of Results 
We have performed five retrospective experiments performed to determine the 
validity of a semantic-based LBD approach that makes use of bibliographic citations. In 
two cases, such as the Somatomedin and Testosterone studies, strong relationships were 
found by examining predicates constructing a path with length two or less. In these 
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situations we have shown that including citations does not improve the results. However, 
in the other three studies the inclusion of citations uncovered crucial or additional related 
concepts.  
The first study of these successfully reproduced Swanson’s original Fish Oils – 
Raynaud Disease hypothesis without the use of full-text by modifying the approach by 
Cameron et al. to incorporate bibliographically related documents. A detailed 
examination shows that the intermediate Vascular Reactivity is not present in the core 
references and only appears by using full-text or by including cited documents.  
The Magnesium – Migraine Disorders discovery by Swanson was the second 
study. For the eleven expected intermediate concepts, all of the seven that Cameron 
found were found in our reduced corpus. For the other four concepts (Hypoxia, Stress, 
Substance P, Spreading Depression) noticed by Swanson that Cameron did not find, we 
were able to discover three - both Stress/Type A Personality and Hypoxia were found 
within our original search, and Substance P was discovered via discovery browsing of 
related concepts. Additionally, our results include a twelfth concept, Diabetes, 
undiscovered by Swanson and Cameron, only included via cited documents. 
The third study to yield strong results was a reproduction of Kostoff’s research on 
the common factors of Parkinson’s disease and Crohn’s disease. Here, all three high 
level concepts (Immunology, Cell Death, and Genetics), appeared in some fashion 
without the use of cited documents, but the details of those connections were not able to 
explain those associations. Thus, several secondary searches were used to probe deeper. 
Of the concepts that appeared within the subsequent searches a number only appeared 
 
 
 
175 
 
 
 
due to the use of citations. Between the three intermediate topics there were an additional 
six separate concepts that only appeared when using citations given our corpus.  
In conclusion, our findings conclude that the inclusion of citational relationships 
can be used to improve the results of LBD research. Quantitative and qualitative 
improvements are made by uncovering intermediates that would not be found otherwise. 
This not only can improve the resulting Precision-Recall curves for the results, but can 
provide additional meaning in cases where a supporting statement is too generic, such as 
within our Parkinson’s disease – Crohn’s disease study. 
 
5.3 Future Work 
This research’s contribution is the illustration of the information contained within 
citational references as it applies to LBD. While evidence suggests that it supports the 
validity of this approach, this is also the biggest limitation of this work. This is relevant in 
that although titles and abstracts for most documents tend to be easy to acquire due to 
modern digitalization efforts, citational information from one document to others is not. 
Further research leveraging these associations is possible, either in datasets where 
citations are available, or in a more complex manner as greater amounts of this 
information is recorded.  
Also, due to the nature of our five retrospective studies and their focus on 
bibliographic citations, each study was performed using a relatively small corpus. As 
noted previously, this corpus was constructed from the references listed in each of the 
original studies along with the papers that they themselves cited. As such, the entire 
corpus contained only thousands of papers. Thus, despite the fact that concept IDF values 
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were calculated using all of the MEDLINE papers, predicate graphs were constructed 
only using the reduced corpus. An investigation should be made into the efficacy of using 
bibliographic citations at full scale. 
Additionally there are systemic limitations that should be addressed. First, and 
foremost, is the reliance upon the generation of semantic predications from a NLP tool. 
Both as noted in this paper and in the work by Cameron et al. (2016), several predicates 
were found to be erroneous due to an incorrect concept. This is only one instance of the 
potential difficulties. Further difficulties arrive when contracting semantic predications 
are generated from text, either due to nuances in the way the text was composed, results 
may be based upon apriori assumptions or situations, or changing/conflicting scientific 
evidence.  
In a similar fashion a more specific improvement can also be made regarding the 
association of similar concepts. It was noticed several times during our exploratory 
studies that there are separate concepts that are very similar (e.g. Magnesium, Magnesium 
Deficiency, and Hypomagnesemia). When predicates are generated from documents 
different concepts might be used, making it challenging to find a connecting path. For 
example, perhaps there is a path connecting Magnesium Deficiency to Migraine 
Disorders but this won’t be found for a search based on Magnesium. An expert user that 
is well versed in the subject matter could be aware of such pitfalls and make searches 
accordingly but an average user would miss out on potential connections. Modifications 
could be made to treat concepts that are sufficiently similar but would need to do so 
within a given context (referring back to section 2.5.2 in regards to LSA). 
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 Appendix A
Fish Oils – Raynaud Syndrome Study 
 
Table A-1. Fish Oils – Raynaud Syndrome Core Corpus Medline IDs 
53042 4002440 6229551 6340424 6775675 
58309 4015748 6298902 6352267 6788326 
277163 4082084 6301111 6365102 6812750 
596950 6088955 6302714 6376801 6827988 
2408588 6097237 6303363 6424425 6890719 
2412054 6098049 6307322 6432198 7031981 
2412071 6098051 6314583 6449756 7037038 
2997286 6100033 6318123 6540787 7161779 
3157318 6128596 6320840 6613908 7259326 
3883365 6130329 6320945 6636033 7295999 
3888229 6134122 6321621 6639916 7364865 
3977414 6136879 6330926 6707529 7470209 
3990714 6209510 6339921 6718836 14289442 
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Figure A-1. Fish Oils – Raynaud Disease Search Parameters 
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Figure A-2. Fish Oils – Raynaud Disease result 1 (with citations) 
 
 
Figure A-3. Fish Oils – Raynaud Disease result 2 (with citations) 
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Figure A-4. Fish Oils – Raynaud Disease result 3 (with citations) 
 
 
 
Figure A-5. Fish Oils – Raynaud Disease result 4 (with citations) 
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Figure A-6. Fish Oils – Raynaud Disease result 5 (with citations) 
 
 
Figure A-7. Fish Oils – Raynaud Disease result 6 (with citations) 
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Figure A-8. Fish Oils – Raynaud Disease result 7 (with citations) 
 
 
Figure A-9. Fish Oils – Raynaud Disease result 8 (with citations) 
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Figure A-10. Fish Oils – Raynaud 
Disease result 9 (with citations) 
Figure A-11. Fish Oils – Raynaud Disease 
result 10 (with citations) 
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Figure A-12. Fish Oils – Raynaud Disease result 11 (with citations) 
 
 
 
Figure A-13. Fish Oils – Raynaud Disease result 12 (with citations) 
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Figure A-14. Fish Oils – Raynaud Disease result 13 (with citations) 
 
 
 
Figure A-15. Fish Oils – Raynaud Disease result 14 (with citations) 
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Figure A-16. Fish Oils – Raynaud Disease result 15 (with citations) 
 
 
Figure A-17. Fish Oils – Raynaud Disease result 16 (with citations) 
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Figure A-18. Fish Oils – Raynaud Disease result 1 (no citations) 
 
 
Figure A-19. Fish Oils – Raynaud Disease result 2 (no citations) 
 
 
 
 
188 
 
 
 
 
 
Figure A-20. Fish Oils – Raynaud Disease result 3 (no citations) 
 
 
Figure A-21. Fish Oils – Raynaud Disease result 4 (no citations) 
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Figure A-22. Fish Oils – Raynaud Disease result 5 (no citations) 
 
 
Figure A-23. Fish Oils – Raynaud Disease result 6 (no citations) 
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Figure A-24. Fish Oils – Raynaud Disease result 7 (no citations) 
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Figure A-25. Fish Oils – Raynaud Disease result 8 (no citations) 
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Table A-2. Fish Oils – Raynaud Disease generated predicates 
[PMID114606] 
Abstract 
“Both PGH2 and PGI2 could produce dose-dependent contraction or relaxation of 
isolated arteries.” 
[C0033567|Epoprostenol – CAUSES – C1140999|Contraction] 
Abstract 
“As PGI2 is the most potent cerebral vasodilator drug tested, it may be of clinical use 
in the treatment of cerebral vasospasm.” 
[C0033567|Epoprostenol – ISA – C0042402|Vasodilator Agents] 
[C0033567|Epoprostenol – TREATS(SPEC) – C0265110|Cerebral Vasospasm] 
[C0042402|Vasodilator Agents – TREATS – C0265110|Cerebral Vasospasm] 
[PMID190267] 
Abstract 
“In contrast, when arachidonic acid is added directly to platelets, prior incubation with 
dBcAMP or PGE1 does not inhibit production of the prostaglandins or their 
metabolites.” 
[C0002335|Alprostadil – NEG_INHIBITS – C0033554|Prostaglandins] 
[C0003695|Arachidonic Acid – NEG_INHIBITS – C0033554|Prostaglandins] 
Abstract 
“Furthermore, dBcAMP and PGE1 both inhibit platelet aggregation induced by either 
arachidonic acid or prostaglandin H2 without affecting the production of prostaglandin 
metabolites from these compounds.” 
[C0002335|Alprostadil – DISRUPTS – C0032176|Platelet aggregation] 
[C0003695|Arachidonic Acid – AUGMENTS – C0032176|Platelet aggregation] 
[C0072288|Prostaglandin H2 – AUGMENTS – C0032176|Platelet aggregation] 
[PMID2408588] 
Title 
“Inhibition of platelet aggregation by a new stable prostacyclin introduced in therapy of 
patients with progressive scleroderma.” 
[C0033567|Epoprostenol – DISRUPTS – C0032176|Platelet aggregation] 
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[PMID2412054] 
Abstract 
“The effects of serotonin and its pharmacological antagonists on the physical flow 
properties of the blood have been studied far less than their effects on blood vessels, 
although they may be equally important.” 
[C0036751|Serotonin – AFFECTS – C0005847|Blood Vessels] 
Abstract 
“Indirect evidence suggests that in pathological circumstances serotonin may locally 
increase whole blood viscosity, particularly at low shear rates, decrease red cell 
deformability and increase the adhesiveness of white cells.” 
[|C0036751|Serotonin – AUGMENTS – C0005848|Blood Viscosity] 
Abstract 
“Specific serotonergic-antagonists, administered either orally or intravenously, 
normalize the increased whole blood viscosity and decreased blood filterability found 
in essential hypertension, following myocardial infarction and in severe leg ischaemia” 
[C0948013|Increased blood viscosity – COEXISTS_WITH – C0085580|Essential Hypertension] 
Abstract 
“8 Ketanserin given intravenously for seven days to patients with very severe leg 
ischaemia, significantly improves whole blood viscosity, increases red cell transit time 
and most dramatically decreases pore clogging.” 
[C0022616|Ketanserin – AFFECTS – C0005848|Blood Viscosity] 
[PMID364545] 
Abstract 
“The activity of prostacyclin (PGI2), PGE1 or PGD2 as inhibitors of platelet 
aggregation in plasma from human, dog, rabbit, rat, sheep and horse was investigated.” 
[C0002335|Alprostadil – DISRUPTS – C0032176|Platelet aggregation] 
Abstract 
“5 Theophylline or dipyridamole potentiated the inhibition of human platelet 
aggregation by prostacyclin, PGE1 or PGD2.” 
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[C0002335|Alprostadil – DISRUPTS – C0032176|Platelet aggregation] 
[C0033567|Epoprostenol – DISRUPTS – C0032176|Platelet aggregation] 
[PMID378308] 
Abstract 
“...due to the formation of platelet aggregates it is concluded that PGI2 is a most potent 
anti-aggregatory prostaglandin…” 
[C0033567|Epoprostenol – ISA – C0033554|Prostaglandins] 
[PMID3883365] 
Abstract 
“As prostacyclin (PGI2) is of benefit in the treatment of RS in SS, we have measured 
endogenous stable metabolites of PGI2 (PGI2m) in 42 patients with Raynaud’s 
Phenomenon (RP) of varying aetiology (15 SS patients, 15 patients with Raynaud’s 
Disease (RD) but no other symptoms, and 12 other RS patients with probable 
connective tissue disorder).” 
[C0033567|Epoprostenol – TREATS - |C0034734|Raynaud Disease] 
[C0033567|Epoprostenol – TREATS(INFER) – C0034735|Raynaud Phenomenon] 
[C0034734|Raynaud Disease – COEXISTS_WITH – C0036421|Systemic 
Scleroderma] 
[PMID3977414] 
Abstract 
“An improved thermographic response to cold stress testing after treatment of 
Raynaud’s syndrome with PGE1 has also been shown for the first time.” 
[C0002335|Alprostadil – TREATS – C0034734|Raynaud Disease] 
[PMID531220] 
Abstract – Taken from publisher’s site. 
“In human platelet-rich plasma (PRP) eicosapentaenoic acid (EPA) inhibited platelet 
aggregation induced by a stable analogue of PGH2 (U46619), arachidonic acid, 
collagen or ADP.” 
[C0000545|Eicosapentaenoic Acid – DISRUPTS – C0032176|Platelet aggregation] 
[C0917834|U-44619 – ISA – C0072288|Prostaglandin H2] 
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Abstract – Taken from publisher’s site. 
“EPA incubated with PRP did not induce the generation of a thromboxane (TXA)-like 
activity; indeed it prevented the formation of TXA2 induced by arachidonic acid or by 
collagen.” 
[C0000545|Eicosapentaenoic Acid – NEG_STIMULATES – 
C0040061|Thromboxanes] 
[C0003695|Arachidonic Acid – STIMULATES – C0040057|Thromboxane A2] 
Abstract – Taken from publisher’s site. 
“The anti-aggregatory activity of EPA was not influenced by inhibitors of cyclo-
oxygenase and lipoxygenase.” 
[C0000545|Eicosapentaenoic Acid – INHIBITS – C0023837|Lipoxygenase] 
[C0000545|Eicosapentaenoic Acid – INHIBITS – C0033551|Prostaglandin-
Endoperoxide Synthase] 
[PMID6303363] 
Abstract 
“Eicosapentaenoic acid (EPA), which is abundant in seafood, has been reported to be a 
potent antagonist of platelet aggregation and also to reduce the incidence of 
cardiovascular disorders.” 
[C0000545|Eicosapentaenoic Acid – DISRUPTS – C0032176|Platelet aggregation] 
Abstract 
“We recently reported that EPA also reduces whole blood viscosity.” 
[C0000545|Eicosapentaenoic Acid – DISRUPTS – C0005848|Blood Viscosity] 
[PMID6314583] 
Abstract 
“EPA was not able to be converted to any prostaglandins (PGs) in murine and porcine 
smooth muscle cells.” 
[C0000545|Eicosapentaenoic Acid – CONVERTS_TO – C0033554|Prostaglandins] 
Abstract 
“In rat, EPA was not only being converted to no PGI3, but also being a blocker to PGI2 
synthesis in vascular cells.” 
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[C0000545|Eicosapentaenoic Acid – CONVERTS_TO|C0072294|prostaglandin I3] 
[C0005773|Blood Cells – LOCATION_OF – C0033567|Epoprostenol] 
[C0072294|prostaglandin I3 – ISA – C0033567|Epoprostenol] 
Abstract 
“Moreover, the rat EPA has much less activity in inhibiting thromboxane A2 (TXA2) 
synthesis in platelets.” 
[C0000545|Eicosapentaenoic Acid – INTERACTS_WITH – C0040057|Thromboxane A2] 
Abstract 
“On the contrary, in human EPA was not only easily converted to PGI3 in vascular 
cells, but also blocking TXA2 synthesis in platelets.” 
[C0000545|Eicosapentaenoic Acid – CONVERTS_TO – C0072294|prostaglandin I3] 
[PMID6320945] 
Title 
“Beneficial effect of fish oil on blood viscosity in peripheral vascular disease.” 
[C0016157|Fish Oils – AFFECTS – C0005848|Blood Viscosity] 
[PMID6339921] 
Title 
“Controlled double-blind trial of nifedipine in the treatment of Raynaud’s 
phenomenon” 
[C0028066|Nifedipine – TREATS – C0034735|Raynaud Phenomenon] 
Abstract – Taken from publisher’s site. 
“The treatment of this condition is difficult.1 Nifedipine, a slow calcium-channel 
antagonist, causes vascular smooth-muscle relaxation and relief of arterial vasospasm.” 
[C0028066|Nifedipine – TREATS – C0085616|Vasospasm] 
Abstract – Taken from publisher’s site. 
“Nifedipine-induced vasodilation has been shown to result in a fall in peripheral 
vascular resistance and an increase in peripheral blood flow.” 
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[C0042401|Vasodilation – COEXISTS_WITH – C1258192|Total Peripheral 
Resistance] 
Abstract – Taken from publisher’s site. 
“Nifedipine increases the skin blood flow by 50 to 150 per cent in normal persons and 
has also been shown in vitro to inhibit norepinephrine-induced vasospasm of rabbit and 
human peripheral arteries and veins.” 
[C0028066|Nifedipine – AUGMENTS – C0232338|Blood flow] 
Abstract – Taken from publisher’s site. 
“The calcium-channel blockers nifedipine and verapamil have …” 
[C0028066|Nifedipine – ISA – C0006684|Calcium Channel Blockers] 
[PMID6365102] 
Title 
“Treatment of Raynaud’s phenomenon with ketanserin, a selective antagonist of the 
serotonin2 (5-HT2) receptor.” 
[C0022616|Ketanserin – TREATS – C0034735|Raynaud Phenomenon] 
Abstract 
“6 These findings lend support to the hypothesis that serotonin is an important element 
in the pathogenesis of systemic sclerosis.” 
[C0036751|Serotonin – CAUSES – C0036421|Systemic Scleroderma] 
[PMID6432198] 
Title 
“Treatment of Raynaud’s phenomenon with ketanserin in patients with connective 
tissue disorders.” 
[C0022616|Ketanserin – TREATS - |C0034735|Raynaud Phenomenon] 
Abstract 
“The results of this study suggest that orally administered ketanserin may be an 
effective and well tolerated treatment for Raynaud’s phenomenon associated with 
connective tissue disorders, especially scleroderma.” 
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[C0022616|Ketanserin – TREATS – C0034735|Raynaud Phenomenon] 
[PMID6773615] 
Abstract 
“These results support our suggestion that a prostaglandin, in particular PGI2, is 
required for hypercapnia to produce full cerebral vasodilatation.” 
[C0033554|Prostaglandins – COEXISTS_WITH – C0033567|Epoprostenol] 
[C0033567|Epoprostenol – ISA – C0033554|Prostaglandins] 
[PMID6788326] 
Title 
“Effect of prostaglandins I2 and E1 on red cell deformability in patients with 
Raynaud’s phenomenon and systemic sclerosis.” 
[C0033567|Epoprostenol – TREATS(INFER) – C0034735|Raynaud Phenomenon] 
[C0033567|Epoprostenol – TREATS(INFER) – C0036421|Systemic Scleroderma] 
[PMID6812750] 
Abstract 
“This study suggests that ketanserin may be useful in the treatment of Raynaud’s 
phenomenon” 
[C0022616|Ketanserin – TREATS – C0034735|Raynaud Phenomenon] 
[PMID6821892] 
Abstract 
“Formation of prostaglandins derived from eicosapentaenoic acid and interference of 
eicosapentaenoic acid with formation and action of prostaglandins derived from 
arachidonic acid were evident in vitro.” 
[C0000545|Eicosapentaenoic Acid – CONVERTS_TO – C0033554|Prostaglandins] 
[C0003695|Arachidonic Acid – CONVERTS_TO – C0033554|Prostaglandins] 
[PMID7003784] 
Abstract 
“Prostaglandins E1 (PGE1) and I2 (prostacyclin, PGI2) are potent vasodilators and 
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inhibitors of platelet aggregation which have been reported to be of value in the 
treatment of peripheral ischemia.” 
[C0002335|Alprostadil – DISRUPTS – C0032176|Platelet aggregation] 
[C0033567|Epoprostenol – ISA – C0042402|Vasodilator Agents] 
[PMID7025341] 
Title 
“Successful treatment of Raynaud’s Syndrome with prostacyclin.” 
[C0033567|Epoprostenol – TREATS – C0034734|Raynaud Disease] 
Abstract 
“We evaluated the effect of prostacyclin (PGI2) a potent antiplatelet and vasodilator 
agent in 5 female patients with Raynaud’s syndrome.” 
[C0033567|Epoprostenol – TREATS(INFER) – C0034734|Raynaud Disease] 
[C0042402|Vasodilator Agents – TREATS(INFER) – C0034734|Raynaud Disease] 
[PMID7037038] 
Title 
“Treatment of Raynaud’s phenomenon by intravenous infusion of prostacyclin (PGI2)” 
[C0033567|Epoprostenol – TREATS – C0034735|Raynaud Phenomenon] 
[PMID7208950] 
Abstract 
“The effect of altering the abundance of precursors and inhibitors of prostaglandin 
formation by dietary supplements of fish oil…” 
[C0033554|Prostaglandins – INTERACTS_WITH – C0016157|Fish Oils] 
[PMID7259326] 
Abstract 
“PGE1 may therefore be suitable treatment for Raynaud’s phenomenon and the 
vascular insufficiency of systemic sclerosis and other connective tissue diseases.” 
[C0002335|Alprostadil – TREATS – C0034735|Raynaud Phenomenon] 
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[PMID7427564] 
Abstract 
“Prostaglandin E1, a vasodilator and potent inhibitor of platelet aggregation, was 
administered to 26 patients with severe vasospastic disease of the hands.” 
[C0002335|Alprostadil – DISRUPTS – C0032176|Platelet aggregation] 
Abstract 
“Intensity of digital vasospasm induced by cold water challenge was not objectively 
affected by prostaglandin E1 despite an increased finger temperature after infusion.” 
[C0002335|Alprostadil – AFFECTS – C0085616|Vasospasm] 
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Table A-3. Precision and recall at each result using citations for Fish Oil study 
Result New Intermediate Terms Relevancy (Topic) Precision Recall 
d0 Epoprostenol 
Alprostadil 
Vasodilator Agents 
Systemic Scleroderma 
Platelet Aggregation 
Platelet Aggregation 
Vascular Reactivity 
Not Relevant 
0.667 0.667 
d1 Prostaglandins Platelet Aggregation 0.667 0.667 
d2 Thromboxane A2 Platelet Aggregation 0.667 0.667 
d3 Platelet Aggregation Platelet Aggregation 0.667 0.667 
d4 N/A  0.667 0.667 
d5 Aspirin Platelet Aggregation 0.667 0.667 
d6 N/A  0.667 0.667 
d7 Arachidonic Acid Not Relevant 0.5 0.667 
d8 N/A  0.5 0.667 
d9 Platelet Function Platelet Aggregation 0.5 0.667 
d10 Thromboxanes Platelet Aggregation 0.5 0.667 
d11 Myocardial Ischemia Not Relevant 0.4 0.667 
d12 Prostaglandin I3 Platelet Aggregation 0.4 0.667 
d13 Drug Interactions Not Relevant 0.333 0.667 
d14 Blood Viscosity 
Ketanserin 
Blood Viscosity 
Blood Viscosity 
0.429 1.0 
d15 Blood flow Blood Viscosity 0.429 1.0 
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Table A-4. Precision and recall at each result not using citations for Fish Oil study 
Result New Intermediate Terms Relevancy (Topic) Precision Recall 
d0 Epoprostenol 
Systemic Scleroderma 
Platelet Aggregation 
Not Relevant 
0.5 0.333 
d1 Thromboxane A2 Platelet Aggregation 0.5 0.333 
d2 Prostaglandins Platelet Aggregation 0.5 0.333 
d3 Arachidonic Acid Not Relevant 0.333 0.333 
d4 Platelet Aggregation 
Alprostadil 
Platelet Aggregation 
Platelet Aggregation 
0.333 0.333 
d5 N/A  0.333 0.333 
d6 Prostaglandin I3 Platelet Aggregation 0.333 0.333 
d7 Blood Viscosity 
Blood flow 
Blood Viscosity 
Blood Viscosity 
0.5 0.667 
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 Appendix B
Magnesium – Migraine Disorders Study 
 
Table B-1. Magnesium – Migraine Disorders Core Corpus Medline IDs 
90971 3523056 3897128 6116859 6784664 
96740 3523058 3898850 6141289 6826350 
108361 3524092 3908832 6146019 6836300 
330466 3530775 3918779 6150068 6861894 
414910 3530778 3946808 6163401 6869560 
418838 3531248 3962783 6170210 6870999 
630136 3536167 4016924 6172961 6878586 
739264 3537077 4016926 6206779 6881926 
750727 3582557 4016930 6230778 7085796 
1110377 3585352 4016941 6275679 7120030 
1262918 3607427 4016945 6296376 7181451 
2408700 3616619 4016946 6316376 7334315 
2425960 3705931 4019939 6339166 7348028 
2433912 3713254 4021225 6375330 7400981 
2435656 3715946 4167805 6392763 7402146 
2864494 3724238 4323509 6438124 7443079 
2867984 3733214 4725298 6464059 10303918 
3022872 3758107 4842482 6481797 13295838 
3107334 3758108 4978139 6503357 13597818 
3160475 3763042 4990911 6525007 13645235 
3300911 3771208 5514170 6609739 14212747 
3308769 3797213 5573439 6620432 14338128 
3458981 3801897 5703635 6643036 14399531 
3513507 3827683 5763574 6680619  
3514549 3827684 5956342 6689894  
3515057 3880896 6115200 6708731  
3521194 3881117 6116625 6751554  
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Figure B-1. Magnesium – Migraine Disorders search parameters 
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Figure B-2. Magnesium – Migraine Disorders result 1 (with citations) 
 
 
Figure B-3. Magnesium – Migraine Disorders result 2 (with citations) 
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Figure B-4. Magnesium – Migraine Disorders result 3 (with citations) 
 
 
Figure B-5. Magnesium – Migraine Disorders result 4 (with citations) 
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Figure B-6. Magnesium – Migraine Disorders result 5 (with citations) 
 
 
Figure B-7. Magnesium – Migraine Disorders result 6 (with citations) 
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Figure B-8. Magnesium – Migraine Disorders result 7 (with citations) 
 
 
Figure B-9. Magnesium – Migraine Disorders result 8 (with citations) 
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Figure B-10. Magnesium – Migraine Disorders result 9 (with citations) 
 
 
Figure B-11. Magnesium – Migraine Disorders result 10 (with citations) 
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Figure B-12. Magnesium – Migraine Disorders result 11 (with citations) 
 
 
Figure B-13. Magnesium – Migraine Disorders result 12 (with citations) 
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Figure B-14. Magnesium – Migraine Disorders result 13 (with citations) 
 
 
Figure B-15. Magnesium – Migraine Disorders result 14 (with citations) 
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Figure B-16. Magnesium – Migraine Disorders result 15 (with citations) 
 
 
Figure B-17. Magnesium – Migraine Disorders result 16 (with citations) 
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Figure B-18. Magnesium – Migraine Disorders result 17 (with citations) 
 
 
Figure B-19. Magnesium – Migraine Disorders result 18 (with citations) 
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Figure B-20. Magnesium – Migraine Disorders result 1 (no citations) 
 
 
 
Figure B-21. Magnesium – Migraine Disorders result 2 (no citations) 
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Figure B-22. Magnesium – Migraine Disorders result 3 (no citations) 
 
 
Figure B-23. Magnesium – Migraine Disorders result 4 (no citations) 
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Figure B-24. Magnesium – Migraine Disorders result 5 (no citations) 
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Figure B-25. Magnesium – Migraine Disorders result 6 (no citations) 
 
 
Figure B-26. Magnesium – Migraine Disorders result 7 (no citations) 
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Figure B-27. Magnesium – Migraine Disorders result 8 (no citations) 
 
 
Figure B-28. Magnesium – Migraine Disorders result 9 (no citations) 
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Figure B-29. Magnesium – Migraine Disorders result 10 (no citations) 
 
 
Figure B-30. Magnesium – Migraine Disorders result 11 (no citations) 
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Figure B-31. Magnesium – Migraine Disorders result 12 (no citations) 
 
 
Figure B-32. Magnesium – Migraine Disorders result 13 (no citations) 
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Figure B-33. Magnesium – Migraine Disorders result 14 (no citations) 
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Figure B-34. Magnesium – Migraine 
Disorders result 15 (no citations) 
Figure B-35. Magnesium – Migraine 
Disorders result 16 (no citations) 
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Table B-2. Magnesium – Migraine Disorders generated predicates 
[PMID108361] 
Title 
“Cerebrospinal fluid concentrations of magnesium and inorganic phophate in epilepsy.” 
[C0024467|Magnesium – ASSOCIATED_WITH – C0014544|Epilepsy] 
[PMID1138583] 
Title 
“Increased platelet aggregation in early diabetus mellitus”  
SemRep did not derive a predicate from this statement, but it is worth noting. 
Abstract 
“In view of the tendency toward vascular disease in diabetes mellitus, we studied 
platelet aggregation in 15 normal, 7 prediabetic, 12 latent, and 20 frankly diabetic 
subjects.” 
[C0042373|Vascular Diseases – COEXISTS_WITH – C0011849|Diabetes Mellitus] 
[C0042373|Vascular Diseases – COEXISTS_WITH – C0241863|Diabetic] 
Abstract 
“We conclude that platelet aggregation may be increased early in diabetes mellitus and 
may be involved in the genesis of diabetic microangiopathy.” 
[C0011849|Diabetes Mellitus – AFFECTS – C0025945|Microangiopathy, Diabetic] 
[PMID1146499] 
Title 
“The significance of blood serotonin levels in migraine.” 
[C1445983|Blood serotonin measurement – DIAGNOSES – C0149931|Migraine 
Disorders] 
Abstract  
“If serotonin is effective in relieving migraine pain, this is probably due to extracellular 
serotonin acting on the cardiovascular system.” 
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[C0036751|Serotonin – ASSOCIATED_WITH – C0030193|Pain] 
[C0036751|Serotonin – ASSOCIATED_WITH(SPEC) – C0149931|Migraine 
Disorders] 
[PMID1153064] 
Abstract 
“EEG changes suggest–according to the author–that migraine is a primary cerebral and 
only secondarily a vascular disorder.” 
[C0149931|Migraine Disorders – ISA – C0042373|Vascular Diseases] 
[PMID1254466] 
Title 
“Serotonin (5HT) in migraine: levels in whole blood in and between attacks.” 
[C0036751|Serotonin – ASSOCIATED_WITH – C0149931|Migraine Disorders] 
[PMID1262918] 
Title  
“Cerebral arterial spasm. Part 4: in vitro effects of temperature, serotonin analogues, 
large nonphysiological concentrations of serotonin, and extracellular calcium and 
magnesium on serotonin-induced contractions of the canine basilar artery.” 
[C0006675|Calcium – AFFECTS – C1140999|Contraction] 
[C0024467|Magnesium – AFFECTS – C1140999|Contraction] 
[C0036751|Serotonin – AFFECTS – C1140999|Contraction] 
Abstract  
“Extracellular magnesium, in contrast, was shown to inhibit serotonin-induced 
contractions.” 
[C0024467|Magnesium – DISRUPTS – C1140999|Contraction] 
[PMID13214278] 
Introductory Paragraph 
“Among this group are headaches associated with hypertension, arteriosclerosis, 
infection, brain tumor, hematoma, allergy, and cranial trauma.” 
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[C0018681|Headache – ASSOCIATED_WITH – C0020538|Hypertensive disease] 
[PMID14338128] 
Title 
“DISORDERS OF MAGNESIUM METABOLISM IN EPILEPSY.” 
[C0024467|Magnesium – ASSOCIATED_WITH – C0014544|Epilepsy] 
Introductory Paragraph 
“The possibility that convulsions may occur in Mg deficiency led some investigators to 
study the metabolism of this metal in the epilepsies, and a trend to low blood 
concentrations was usually found.” 
[C0009951|Convulsions – OCCURS_IN – C0024473|Magnesium Deficiency] 
[PMID184066] 
Abstract – Taken from publisher’s site. 
“Since biochemical abnormalities reported herein were common to occlusive CVD and 
migraine headache, it seems probable that they are due to ischemia associated with both 
conditions and possibly related to the resultant disorder of cerebral energy 
metabolism.” 
[C0022116|Ischemia – CAUSES – C0149931|Migraine Disorders] 
[PMID20784580] 
Title 
“The Pain Pathways in Migraine” 
[C0030193|Pain – ASSOCIATED_WITH – C0149931|Migraine Disorders] 
[PMID2424267] 
Abstract 
“The cardiovascular effects of different calcium channel blockers (CCB), exemplified 
by nifedipine, verapamil and diltiazem, are not identical.” 
[C0028066|Nifedipine – INTERACTS_WITH – C0006684|Calcium Channel Blockers] 
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[C0042523|Verapamil – INTERACTS_WITH – C0006684|Calcium Channel Blockers] 
[PMID2425960] 
Abstract 
“Three such drugs, nifedipine, verapamil, and diltiazem, are currently available in the 
United States, although none are specifically approved for use in migraine.” 
[C0028066|Nifedipine – TREATS – C0149931|Migraine Disorders] 
[C0042523|Verapamil – TREATS – C0149931|Migraine Disorders] 
Abstract  
“Nifedipine and nimodipine also appear to be valuable for the treatment of cluster 
headache.” 
[C0028066|Nifedipine – TREATS – C0009088|Cluster Headache] 
[C0028094|Nimodipine – TREATS – C0009088|Cluster Headache] 
Abstract 
“Two case reports describing favorable responses to flunarizine in childhood 
hemiplegic migraine are the only available data concerning the utility of these drugs in 
“complicated” migraine syndromes.” 
[C0016295|Flunarizine – TREATS – C0270862|Hemiplegic migraine] 
[PMID2433912] 
Abstract 
“Opiates and somatostatin inhibit the release of substance P from primary sensory 
neurones and relieve both pain and autonomic symptoms of cluster headache attack.” 
[C0037659|Somatostatin – TREATS – C0030193|Pain] 
Abstract 
“Plasma substance P-like immunoreactivity was decreased during spontaneous attack 
of cluster headache and migraine and during histamine precipitated attack of cluster 
headache. Taken together these data suggest that substance P and endogenous opioids 
could be implicated in the pathophysiology of cluster headache and migraine.” 
[PMID2452018] 
Title 
“Substance P in the human iris: possible involvement in echothiophate-induced miosis 
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in cluster headache.” 
[C0038585|Substance P – CAUSES – C0009088|Cluster Headache] 
[PMID2981405] 
Abstract – Taken from publisher’s site. 
“Verapamil is a calcium-channel blocking agent that has been used extensively in the 
treatment of coronary vasospasm and supraventricular arrhythmias.” 
[C0042523|Verapamil – ISA – C0006684|Calcium Channel Blockers] 
[PMID3458981] 
Title 
“Vasomotor effects of magnesium: a comparison with nifedipine and verapamil of in 
vitro reactivity in feline cerebral and peripheral arteries.” 
[C0024467|Magnesium – compared_with – C0028066|Nifedipine] 
Abstract 
“The order of potency for eliciting relaxation was: nifedipine greater than verapamil 
greater than magnesium.” 
[C0042523|Verapamil – compared_with – C0024467|Magnesium] 
[PMID3521194] 
Title 
“Migraine treatment with calcium channel blockers.” 
[C0006684|Calcium Channel Blockers – TREATS – C0149931|Migraine Disorders] 
[PMID3585352] 
Title 
Laterality of pain in migraine distinguished by interictal rates of habituation of 
electrodermal responses to visual and auditory stimuli. 
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[C0030193|Pain – ASSOCIATED_WITH – C0149931|Migraine Disorders] 
[PMID361756] 
Abstract 
Prostacyclin (PGI(2)) is an unstable prostaglandin which inhibits platelet aggregation 
and serotonin release and causes vasodilation. 
[C0033554|Prostaglandins – DISRUPTS – C0032176|Platelet aggregation] 
[PMID3629724] 
Abstract 
“A stimulating effect of serotonin, guanine nucleotides and sodium fluoride is found as 
well as a dependence of the catalytic activity of adenylate cyclase on magnesium and 
manganese ions.” 
[C0001492|Adenylate Cyclase – INTERACTS_WITH – C0024467|Magnesium] 
[PMID372242] 
Abstract 
Endothelial cells synthesize prostacyclin (PGI(2)), an unstable prostaglandin that 
inhibits platelet aggregation and serotonin release. 
[C0033554|Prostaglandins – DISRUPTS – C0032176|Platelet aggregation] 
[PMID379918] 
Abstract 
“However, in 1 X 10(-5)M concentrations PGI2 contracted the arterial muscle and did 
not antagonize contractions induced by serotonin or PGF2 alpha.” 
[C0012471|Dinoprost – CAUSES – C1140999|Contraction] 
[C0036751|Serotonin – CAUSES – C1140999|Contraction] 
[PMID386807] 
Abstract – Taken from publisher’s site. 
“Substantial species variability has been described for the effects of extracellular 
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magnesium upon tension development, which arises out of striking calcium-magnesium 
antagonism at an extracellular site in the rat and guinea pig.” 
[C0024467|Magnesium – AFFECTS – C0233494|Tension] 
[PMID3898850] 
Abstract – Introductory paragraph obtained from publisher’s site and used. 
“Prostacyclin is the most potent naturally occurring vasodilator and inhibitor of platelet 
aggregation.” 
[C0033567|Epoprostenol – DISRUPTS – C0032176|Platelet aggregation] 
Abstract – Introductory paragraph obtained from publisher’s site and used. 
“Magnesium is known to exert an inhibitory effect on coagulation and platelet function, 
but, so far, little is known about its influence on prostacyclin metabolism. Therefore the 
effect of magnesium sulfate on vascular prostacyclin synthesis and platelet prostacyclin 
interaction was investigated.” 
[C0024467|Magnesium – INTERACTS_WITH – C0033567|Epoprostenol] 
[PMID390330] 
Abstract 
“Other direct studies, from our laboratory, indicate that [Mg2+]o regulates calcium 
exchange and content of vascular smooth muscle.” 
SemRep did not derive a predicate from this statement, but it is worth noting. 
Abstract 
“In summary, the concept to be presented suggests that a deficiency in dietary Mg2+ is 
a key factor in the high incidence of mortality noted in SDIHD in nations of the 
Western world.” 
SemRep did not derive a predicate from this statement, but it is worth noting. 
Abstract 
”The hypomagnesemia produces progressive vasoconstriction, vasospasm and 
ischemia, which, given time, will lead to SDIHD.” 
[C0022116|Ischemia – CAUSES – C0151744|Myocardial Ischemia] 
[C0085616|Vasospasm – CAUSES – C0151744|Myocardial Ischemia] 
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[PMID4016946] 
Title 
“Relevance of prostaglandins in migraine.” 
[C0033554|Prostaglandins – ASSOCIATED_WITH – C0149931|Migraine Disorders] 
Abstract 
“Prostaglandins (PG), particularly PGE, may be linked to the pathophysiology of 
migraine in several important ways. PGE1 may “simulate” a migraine attack in healthy 
volunteers. In animal experiments and in human infusions, PGEs cause vasodilation 
and hyperalgesia, both typical reactions of inflammation.” 
[C0033559|Prostaglandins E – ISA – C0033554|Prostaglandins] 
Abstract 
“The view that vascular headache is an “inflammatory reaction” allows the best 
concept concerning the local role of PGs and the effectiveness of PG-inhibitors in the 
treatment of migraine. 
[C0033529|Prostaglandin Antagonists – TREATS – C0149931|Migraine Disorders] 
[PMID4260015] 
Title 
“Magnesium metabolism from the viewpoint of cardioangiology. II. Findings in 
magnesium metabolism in vascular diseases” 
[C0024467|Magnesium – ASSOCIATED_WITH – C0042373|Vascular Diseases] 
[PMID450213] 
Abstract 
“We performed in vitro experiments with a small volume chamber to determine the 
inhibitory effect of nifedipine on serotonin-, phenylephrine-, and potassium-induced 
contractions of canine basilar and femoral arteries.” 
[C0028066|Nifedipine – INHIBITS – C0036751|Serotonin] 
Abstract 
“In contrast, nifedipine did not significantly inhibit the serotonin- and phenylephrine-
 
 
 
231 
 
 
 
induced contractions of the femoral artery but did inhibit potassium-induced 
contractions of the femoral artery. Calcium-induced contractions of the basilar artery 
were also inhibited by nifedipine.” 
SemRep did not derive a predicate from this statement, but it is worth noting. 
[PMID4760464] 
Abstract – Taken from publisher’s site. 
“Reserpine pretreatment did not alter the effect of magnesium on contractility to those 
agents both in polarizing and calcium-free depolarizing solutions.” 
[C0024467|Magnesium – NEG_AFFECTS – C1140999|Contraction] 
Abstract – Taken from publisher’s site. 
“However, such pretreatment modified the effect of magnesium on sensitivity of aortas 
to acetylcholine and norepinephrine.” 
[C0024467|Magnesium – INTERACTS_WITH – C0001041|Acetylcholine] 
[C0024467|Magnesium – INTERACTS_WITH – C0028351|Norepinephrine] 
Abstract – Taken from publisher’s site. 
“These results suggest that magnesium and reserpine act to alter calcium binding, and 
its availability to the contractile apparatus, by different mechanisms.” 
[C0024467|Magnesium – AFFECTS – C1516144|Calcium Binding] 
[PMID4814375] 
Abstract 
“Methylsergide reversibly blocked the artery’s response to serotonin and caused a 
contraction of the basilar artery.” 
[C0025842|Methysergide – AFFECTS – C0871261|response] 
[C0036751|Serotonin – CAUSES – C1140999|Contraction] 
[PMID4978139] 
Introduction – Taken from paper itself. 
“It is the purpose of this paper to examine the question of the relation of migraine and 
epilepsy by an analysis of 1,800 cases of migraine seen at the Northcott Neurological 
Centre since 1951 with particular reference to those cases in which migraine and 
epilepsy were manifested in the same individual.” 
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[C0014544|Epilepsy – COEXISTS_WITH – C0149931|Migraine Disorders] 
[PMID527222] 
Title 
“Hypomagnesaemia in diabetes.” 
[C0151723|Hypomagnesemia – COEXISTS_WITH – C0011847|Diabetes] 
Abstract 
“Although its significance is unclear, hypomagnesaemia could conceivably predispose 
to ischaemic heart disease in diabetes.” 
[C0151723|Hypomagnesemia – PREDISPOSES – C0151744|Myocardial Ischemia] 
[PMID5297855] 
Title 
“Plasma serotonin in migraine and stress.” 
[C0036751|Serotonin – ASSOCIATED_WITH – C0149931|Migraine Disorders] 
Abstract – Taken from publisher’s site/paper 
“Interest in the possible relationship of serotonin to the migraine syndrome had 
quickened following Sicuteri’s preliminary trial of methysergide, a serotonin 
“antagonist,” in the treatment of migraine.” 
[C0025842|Methysergide – TREATS(SPEC) – C0149931|Migraine Disorders] 
[C0036753|Serotonin Antagonists – TREATS – C0149931|Migraine Disorders] 
Abstract – Taken from publisher’s site/paper 
“Finally, total plasma serotonin was investigated after the intramuscular injection of 
reserpine 2.5 mg, which has been reported to induce migraine headache in susceptible 
patients.” 
[C0036751|Serotonin – CAUSES – C0149931|Migraine Disorders] 
Abstract – Taken from publisher’s site/paper 
“The effect of injected serotonin on spontaneous and reserpine-induced headaches was 
noted and correlated with serotonin levels.” 
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[C0036751|Serotonin – ASSOCIATED_WITH – C0018681|Headache] 
[PMID5483751] 
Title 
“Influence of magnesium and cysteine on vasopressin-induced contractions in various 
canine blood vessels.” 
[C0024467|Magnesium – AUGMENTS – C0005847|Blood Vessels] 
[PMID5658323] 
Title 
“Plasma serotonin levels in migraine.” 
[C0036751|Serotonin – ASSOCIATED_WITH – C0149931|Migraine Disorders] 
[PMID5674982] 
Title 
“Magnesium-calcium antagonism in the contraction of arterioles”  
[C0006684|Calcium Channel Blockers – TREATS – C1140999|Contraction] 
Abstract – Taken from publisher’s site. 
“Increasing the level of Mg in the blood inhibits the tone and contractility of the 
resistance vessels in the muscle.” 
SemRep did not derive a predicate from this statement, but it is worth noting. 
[PMID5682248] 
Abstract – Taken from publisher’s site 
“Diabetes mellitus was the most common condition associated with hypomagnesemia.” 
[C0151723|Hypomagnesemia – COEXISTS_WITH – C0011849|Diabetes Mellitus] 
[PMID572225] 
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Abstract 
“FFA fell by a maximum of 65% or 0.44 meq/liter and Mg fell by a maximum of 0.31 
meq/liter during the glucose-insulin infusions.” 
[C0015688|Fatty Acids, Nonesterified – COEXISTS_WITH – C0021641|Insulin] 
[C0024467|Magnesium – COEXISTS_WITH – C0021641|Insulin] 
Abstract 
“The sharp divergent changes in FFA and Mg after cessation of nicotinic acid infusion 
support the prime role of FFA-effecting movements of Mg and the thesis that FFA bind 
Mg.” 
[C0015688|Fatty Acids, Nonesterified – INTERACTS_WITH – 
C0024467|Magnesium] 
[PMID5803690] 
Introduction – Taken from paper itself. 
“According to the classical theory the first (prodromal) phase in migraine is caused by 
ischemia within the internal carotid system and the second phase (headache) by a 
vasodilation, especially within the external carotid system.” 
[C0022116|Ischemia – CAUSES – C0149931|Migraine Disorders] 
[PMID597797] 
Abstract 
“These findings do not exclude the possibility of distension of the larger intracranial 
arteries during migraine headache, but the angiographic evidence, however limited, 
does not support this speculation.” 
[C0012359|Pathological Dilatation – COEXISTS_WITH – C0149931|Migraine 
Disorders] 
[PMID6022537] 
Title 
“Serotonin, the carotid body, and cranial vessels in migraine.” 
[C0036751|Serotonin – ASSOCIATED_WITH – C0149931|Migraine Disorders] 
[PMID6116625] 
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Abstract – Taken from article on www.researchgate.net 
“Lowering (or removal) of magnesium ions enhances reactivity of a number of arterial, 
arteriolar, and venous vessels to several neurohumoral agents (e.g., catecholamines, 
angiotensin, acetylcholine, serotonin) and K+; relaxations induced by prostaglandins 
and beta-adrenergic stimulation are often attenuated in the absence of magnesium 
ions.” 
[C0033554|Prostaglandins – STIMULATES – C0596876|Magnesium Ions] 
[PMID6117893] 
Abstract 
“Prostacyclin is a potent vasodilator and the most potent inhibitor of platelet 
aggregation so far described.”  
[C0033567|Epoprostenol – DISRUPTS – C0032176|Platelet aggregation] 
Abstract 
“Additionally, since prostacyclin powerfully inhibits platelet aggregation and promotes 
their disaggregation, this agent could have an important use in the therapy of conditions 
in which increased platelet aggregation takes place and in which, perhaps, a 
prostacyclin deficiency exists.” 
[C0033567|Epoprostenol – DISRUPTS – C0032176|Platelet aggregation] 
[C0033567|Epoprostenol – AUGMENTS – C0032176|Platelet aggregation] 
[PMID6141690] 
Title 
“Magnesium requirement for somatostatin inhibition of insulin secretion.” 
[C0024467|Magnesium – INHIBITS – C0037659|Somatostatin] 
Abstract 
“We observed that in the absence of magnesium, somatostatin concentrations of 0.5 
and 2.0 ng/ml were without effect on first phase insulin secretion. However, these same 
somatostatin levels produced 50% or more inhibition of insulin secretion in the 
presence of magnesium at 0.3 or 0.6 mEq/l.” 
[C0024467|Magnesium – DISRUPTS – C1256369|insulin secretion] 
Abstract 
“Therefore, magnesium ion is necessary for the full inhibitory effect of somatostatin to 
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occur.” 
[C0596876|Magnesium Ions – INHIBITS – C0037659|Somatostatin] 
[PMID6149922] 
Abstract 
“A number of CHD and myocardial ischaemic syndromes such as unstable angina 
pectoris, sudden death ischaemic heart disease, acute myocardial infarction and 
ventricular arrhythmias have been associated with losses of myocardial magnesium and 
potassium.” 
[C0024467|Magnesium – ASSOCIATED_WITH – C0151744|Myocardial Ischemia] 
Abstract  
“Mg++ ions are essential for regulation of Na+ and K+ transport across cell 
membranes, including those found in cardiac and vascular smooth muscle cells. Loss of 
cellular Mg++ results in loss of critically important phosphagens: MgATP and creatine 
phosphate. Thus, under conditions where cellular Mg++ is depleted (e.g. hypoxia, 
ischaemia, anoxia), the Na+-K+ pump and phosphagen stores will be compromised, 
leading to alterations in resting membrane potentials.” 
N/A 
Abstract  
“Considerable evidence has accumulated to indicate that the extracellular concentration 
of Mg++ is important in control of arterial tone and blood pressure via pressure via 
regulation of vascular membrane Mg++-Ca++ exchange sites. A reduction in the 
extracellular Mg++ concentration can produce hypertension, coronary vasospasm and 
potentiation of vasoconstrictor agents by allowing excess entry of Ca++; 
concomitantly, the potency of vasodilator agents is reduced.” 
N/A 
[PMID6171999] 
Abstract 
“Indirect evidence has abundantly been presented to support the view that substance P 
(SP) is involved in the vasodilatation following activation of fine calibre pain fibres 
(Lembeck & Holzer 1979).” 
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[C0038585|Substance P – ASSOCIATED_WITH – C0595862|Vasodilation disorder] 
Abstract 
“We have also determined whether (D-Pro2, D-Phe7, D-Trp9)-SP specifically blocks 
the vascular effects of SP.” 
[C0038585|Substance P – AFFECTS – C0005847|Blood Vessels] 
[PMID6184468] 
Title 
“The effects of substance P on histamine and 5-hydroxytryptamine release in the rat.” 
[C0038585|Substance P – INTERACTS_WITH – C0019588|Histamine] 
Abstract 
“Substance P (SP) induces histamine release from isolated rat peritoneal mast cells at 
concentrations of 0.1-10 muM. 
[C0038585|Substance P – CAUSES – C0019595|Histamine Release] 
Abstract 
“Extracellular calcium (0.1-1 mM), magnesium (1-10 mM) and cobalt (0.01-0.1 mM) 
all inhibit SP-induced histamine release when added before the peptide.” 
[C0024467|Magnesium – DISRUPTS – C0019595|Histamine Release] 
[PMID6193886] 
Title 
“Substance P and endogenous opioids: how and where they could play a role in cluster 
headache.” 
[C0038585|Substance P – AFFECTS – C0009088|Cluster Headache] 
Abstract 
“Substance P appears to be involved in the transmission of pain signals from the 
periphery to the spinal cord and brain stem. Substance P containing neurons are 
responsible for the neurogenic vasodilation identical to that obtained by substance P 
release evoked by antidromic stimulation of these fibres.” 
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N/A 
[PMID6202853] 
Abstract 
“In NCB -20 cells, this voltage-sensitive 45Ca2+ uptake was inhibited selectively by 
organic calcium antagonists such as nitrendipine, cinnarizine, verapamil, and diltiazem 
(IC50 values = 6.4, 750, 1800, and 4500 nM, respectively).” 
[C0008803|Cinnarizine – ISA – C0006684|Calcium Channel Blockers] 
[C0012373|Diltiazem – ISA – C0006684|Calcium Channel Blockers] 
[C0028127|Nitrendipine – ISA – C0006684|Calcium Channel Blockers] 
[C0042523|Verapamil – ISA – C0006684|Calcium Channel Blockers] 
[PMID6275679] 
Title 
“Serotonin and cyclic nucleotides in migraine.” 
[C0036751|Serotonin – ASSOCIATED_WITH – C0149931|Migraine Disorders] 
[PMID6279807] 
Abstract 
“The relation of circulating insulin and glucagon concentrations to effects of 
magnesium deficiency was explored in experiment 3. The results of these experiments 
suggest that magnesium deficiency alters PEPCK activity by affecting secretion of 
pancreatic hormones.” 
[C0021641|Insulin – AFFECTS – C0024473|Magnesium Deficiency] 
[PMID6339937] 
Title 
“Nifedipine in the treatment of migraine in patients with Raynaud’s phenomenon.” 
[C0028066|Nifedipine – TREATS – C0149931|Migraine Disorders] 
[PMID6358126] 
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Abstract – Taken from publisher’s site. 
“Since Wolff’s original proposal regarding the vascular etiology of cyclic head pain, 
evidence has accumulated that the prodromes of migraine are due to cerebral 
vasoconstriction and headaches of both cluster and migraine are due to painful 
dilatation.” 
[C0018681|Headache – CAUSES – C0149931|Migraine Disorders] 
[C0149931|Migraine Disorders – ISA – C0018681|Headache] 
[C1167661|Cerebral vasoconstriction – CAUSES – C0149931|Migraine Disorders] 
Abstract – Taken from publisher’s site. 
“Nifedipine and verapamil provided equivalent relief for cluster but produced more 
side effects, and were less effective, than nimodipine in control of migraine.” 
[C0028066|Nifedipine – TREATS – C0149931|Migraine Disorders] 
[C0042523|Verapamil – TREATS – C0149931|Migraine Disorders] 
Abstract – Taken from publisher’s site. 
“Theories regarding their pathogenesis include cyclic release of vasoactive substances 
from platelets and/or other sources (such as serotonin, catecholamines, histamine, 
acetyl choline, prostaglandins, substance P, endogenous opiates). Drugs which modify 
receptors (such as methysergide, alpha and beta blockers, antihistaminics, 
anticholinergics, steroids and non-steriodal anti-inflammatory agents) have had some 
therapeutic success in migraine but provide little benefit for cluster patients. Ca2+ entry 
blockers (including nimodipine, nifedipine, verapamil) theoretically should diminish 
cephalic vasoconstriction and –dilatation no matter what their cause.” 
SemRep did not derive a predicate from this statement, but it is worth noting. 
Abstract – Taken from publisher’s site. 
“Within 10 days migraine prodromes became infrequent and after 2-4 weeks headache 
frequency was significantly reduced for migraine and within 4-6 weeks for cluster.” 
[C0149931|Migraine Disorders – ISA – C0018681|Headache] 
[PMID6358127] 
Abstract – Taken from publisher’s site. 
“The calcium channel antagonists are a recently developed class of vasodilators that 
prevent the influx of calcium into vascular smooth muscle. The unique pharmacologic 
effects of these agents provide a theoretical basis for their use in the treatment of 
migraine.” 
[C0450442|Agent – TREATS – C0149931|Migraine Disorders] 
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Abstract – Taken from publisher’s site. 
“Clinically, two specific calcium antagonists (flunarizine, cinnarizine) and two non-
specific antagonists (cyproheptadine, amitriptyline) are effective in the treatment of 
migraine.” 
[C0006684|Calcium Channel Blockers – TREATS – C0149931|Migraine Disorders] 
[PMID6375330] 
Introductory Paragraph – Taken from article. 
“In a sense, magnesium may be considered nature’s physiologic calcium blocker.”  
[C0024467|Magnesium – INHIBITS – C0006675|Calcium] 
[PMID6392763] 
Title 
“Reversible retinal vasospasm in magnesium-treated hypertension despite no 
significant change in blood pressure.” 
[C0085616|Vasospasm – COEXISTS_WITH – C0020538|Hypertensive disease] 
[PMID6399344] 
Abstract 
“Experimental magnesium deficiency induces arterial damage, a loss of magnesium 
and potassium and an increase in the calcium and sodium content of the cell.” 
[C0024467|Magnesium – COEXISTS_WITH – C0006675|Calcium] 
Abstract 
“Magnesium and potassium depletion have also been reported in diabetes and the 
vascular implications of this should be considered.” 
[C0024467|Magnesium – ASSOCIATED_WITH – C0011847|Diabetes] 
[PMID6407598] 
Abstract 
“The effect of magnesium on blood pressure may be direct or through influences on the 
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internal balance of potassium, sodium, and calcium.” 
[C0006675|Calcium – INTERACTS_WITH|C0024467|Magnesium|bacs,elii|bacs|| 
[PMID6503357] 
Title  
“Inhibition of calcium by magnesium in the contraction of rat aortic smooth muscle.” 
[C0024467|Magnesium – ASSOCIATED_WITH – C1140999|Contraction] 
[C0024467|Magnesium – INHIBITS – C0006675|Calcium] 
[PMID6538269] 
Abstract 
“Cyproheptadine is equipotent (IC50 = 41 to 45 nM) in blocking contractions of canine 
basilar artery segments induced by serotonin, norepinephrine, potassium, or calcium.” 
[C0006675|Calcium – CAUSES – C1140999|Contraction] 
[C0028351|Norepinephrine – CAUSES – C1140999|Contraction] 
[C0036751|Serotonin – CAUSES – C1140999|Contraction] 
Abstract  
“Propranolol, at concentrations to 10 micromolar, had minimal effect on vessel 
contractions.” 
[C0033497|Propranolol – AFFECTS – C1140999|Contraction] 
Abstract  
“We conclude that the primary action of cyproheptadine in preventing induced 
contractions of the canine basilar artery is antagonism of calcium channels.This action 
is unique among drugs used for migraine prophylaxis and may have important 
implications for the treatment of headache and other neurologic disorders.” 
SemRep did not derive a predicate from this statement, but it is worth noting. 
[PMID6539877] 
Title 
“Verapamil in prophylactic therapy of migraine.” 
[C0042523|Verapamil – TREATS – C0149931|Migraine Disorders] 
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Abstract  
“Verapamil significantly reduced both headache frequency and duration with few side 
effects.” 
[C0042523|Verapamil – PREVENTS – C0018681|Headache] 
[PMID65562] 
Abstract 
“No differences were found in plasma tryptophan, glucose, insulin, and free fatty acid 
levels in the migraine/no-migraine categories.” 
[C0017725|Glucose – ASSOCIATED_WITH – C0149931|Migraine Disorders] 
[C0021641|Insulin – ASSOCIATED_WITH – C0149931|Migraine Disorders] 
[PMID6680619] 
Title 
“Pharmacologic inhibition of cerebral vasospasm in ischemia, hallucinogen ingestion, 
and hypomagnesemia: barbiturates, calcium antagonists, and magnesium.” 
[C0006684|Calcium Channel Blockers – DISRUPTS – C0265110|Cerebral Vasospasm] 
[C0024467|Magnesium – DISRUPTS – C0265110|Cerebral Vasospasm] 
[C0265110|Cerebral Vasospasm – COEXISTS_WITH – C0022116|Ischemia] 
[C0265110|Cerebral Vasospasm – COEXISTS_WITH – C0151723|Hypomagnesemia] 
Abstract 
“Experiments indicate that several different calcium antagonists have vasodilatory 
properties which may be expressed selectively on different organ vascular beds. 
Magnesium is a competitive calcium antagonist, and alterations in the extracellular 
content of this ion have profound effects on cerebral vascular resistance.” 
[C0006684|Calcium Channel Blockers – AFFECTS – C0042380|Vascular resistance] 
[PMID6708731] 
Abstract 
“Flunarizine is a calcium entry blocking drug possessing antihypoxic activity in animal 
models of cerebral and peripheral ischemia-anoxia and has clinical usefulness in 
circulatory disorders of both central and peripheral origin.” 
[C0016295|Flunarizine – ISA – C0006684|Calcium Channel Blockers] 
Abstract 
“This report compares the activity of flunarizine and verapamil, another calcium entry 
blocking drug, on the central nervous system (CNS) and peripheral consequences of 
cytotoxic hypoxia induced by high and low doses of KCN.” 
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[C0042523|Verapamil – ISA – C0006684|Calcium Channel Blockers] 
Abstract 
“Since low doses of the cyanide ion render respiration quicker and deeper by an action 
on chemoreceptive cells in peripheral arteries, the effect of verapamil against the 
hypoxic effect of KCN is mediated by an action in the periphery.” 
[C0042523|Verapamil – AFFECTS – C0242184|Hypoxia] 
Abstract 
“In summary, we have shown that the physiological consequences of cytotoxic hypoxia 
can be affected by calcium entry blocking drugs having site-specific activities.” 
[C0006684|Calcium Channel Blockers – AFFECTS – C0242184|Hypoxia] 
[PMID6715160] 
Title 
 “Relative potency and selectivity of calcium antagonists used in the treatment of 
migraine.” 
[C0006684|Calcium Channel Blockers – TREATS – C0149931|Migraine Disorders] 
Abstract – Taken from publisher’s site. 
“Calcium channel antagonists selectively block intracerebral vasoconstriction and 
appear clinically effective in the treatment of migraine.” 
[C0243076|antagonists – TREATS – C0149931|Migraine Disorders] 
[PMID6802656] 
Title 
“Renal hypomagnesaemia in human diabetes mellitus: its relation to glucose 
homeostasis.” 
[C0151723|Hypomagnesemia – COEXISTS_WITH – C0011849|Diabetes Mellitus] 
Abstract 
“These data indicate that the net tubular reabsorption of magnesium is decreased in 
diabetic patients in presence of hyperglycaemia, leading to hypermagnesiuria and 
hypomagnesaemia.” 
SemRep did not derive a predicate from this statement, but it is worth noting. 
[PMID6830162] 
Title 
“Extracranial vascular changes and the source of pain in migraine headache.” 
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[C0030193|Pain – ASSOCIATED_WITH – C0149931|Migraine Disorders] 
[PMID6847018] 
Title 
“Calcium and magnesium nutrition in human hypertension.” 
[C0006675|Calcium – ASSOCIATED_WITH – C0020538|Hypertensive disease] 
Abstract 
“Many studies suggest that reduced consumption of calcium or magnesium is 
associated with an increased risk of developing hypertension and cardiovascular 
disease.” 
[C0024467|Magnesium – PREDISPOSES – C0020538|Hypertensive disease] 
[C0006675|Calcium – PREDISPOSES – C0020538|Hypertensive disease] 
[PMID6864566] 
Abstract 
“These results show that monoamines can modulate long-term changes in synaptic 
function in the dentate gyrus, and suggest that 5-HT is more potent in this respect than 
NA.” 
[C0036751|Serotonin – compared_with – C0028351|Norepinephrine] 
[C0036751|Serotonin – higher_than – C0028351|Norepinephrine] 
[PMID6869560] 
Abstract  
“The vasodilator effect of Mg2+ on pial arterioles was enhanced in the presence of the 
calcium antagonist verapamil (0.5 micrograms/ml), despite the fact that verapamil by 
itself caused a 12-13% arteriolar dilation”. 
[C0042523|Verapamil – CAUSES – C0012359|Pathological Dilatation] 
[C0042523|Verapamil – ISA – C0006684|Calcium Channel Blockers] 
[PMID6948814] 
Abstract 
“In isolated human pial arteries (diameter 0.4-0.5 mm), contractions were produced by 
potassium, noradrenaline, serotonin, and prostaglandin F2 alpha.” 
[C0028351|Norepinephrine – CAUSES – C1140999|Contraction] 
[C0036751|Serotonin – CAUSES – C1140999|Contraction] 
Abstract  
“Both nifedipine and nimodipine effectively inhibited contraction elicited by 
noradrenaline and serotonin in pial arteries.” 
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[C0028066|Nifedipine – DISRUPTS – C1140999|Contraction] 
[C0028094|Nimodipine – DISRUPTS – C1140999|Contraction] 
[C0028351|Norepinephrine – AUGMENTS – C1140999|Contraction] 
[C0036751|Serotonin – AUGMENTS – C1140999|Contraction] 
Abstract  
“Both nifedipine and nimodipine effectively inhibited contractions induced by calcium 
in pial arteries pretreated in a calcium-free medium and depolarised by potassium.” 
[C0006675|Calcium – CAUSES – C1140999|Contraction] 
[C0028066|Nifedipine – DISRUPTS – C1140999|Contraction] 
[PMID6992233] 
Abstract 
“Graft failure, as determined by reduction and ultimate cessation of renal blood flow 
and urine production, can be abrogated in the short term by prostacyclin which is the 
most potent inhibitor of platelet aggregation yet discovered.” 
[C0033567|Epoprostenol – DISRUPTS – C0032176|Platelet aggregation] 
[PMID7014260] 
Abstract 
“Further, authentic 6-keto-PGE1, like PGI2, escapes pulmonary degradation and is a 
potent inhibitor of platelet aggregation.” 
[C0033567|Epoprostenol – DISRUPTS – C0032176|Platelet aggregation] 
[PMID7026501] 
Title 
“The effect of infused prostacyclin in migraine and cluster headache.” 
[C0033567|Epoprostenol – AFFECTS – C0009088|Cluster Headache] 
[C0033567|Epoprostenol – AFFECTS – C0149931|Migraine Disorders] 
Abstract – Taken from publisher’s site. 
Prostacyclin appears to be the most active of the vasodilating prostaglandins with 
inflammatory and hyperalgesic properties. 
[C0033567|Epoprostenol – ISA – C0033554|Prostaglandins] 
Abstract – Taken from publisher’s site. 
Its actions are very similar to those of prostaglandin E1, which has long been known to 
cause “vascular-type” headaches. 
[C0002335|Alprostadil – CAUSES – C0042376|Vascular Headaches] 
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[PMID7048862] 
Abstract 
“Prostacyclin (PGI2), a strong vasodilator of cerebral vessels and potent inhibitor of 
platelet aggregation, was infused intravenously into seven cats after induction of 
prolonged vasospasm by hourly application of oxyhaemoglobin solution into the 
subarachnoid space round the basilar artery.”  
[C0033567|Epoprostenol – DISRUPTS – C0032176|Platelet aggregation] 
[PMID7060640] 
Abstract 
“5-Hydroxytryptamine amplified the contractions evoked by threshold concentrations 
of histamine, angiotensin II and prostaglandin F2 alpha; in all three cases, the 
amplification was antagonized by comparable concentrations of ketanserin.” 
[C0036751|Serotonin – AUGMENTS – C1140999|Contraction] 
Abstract 
“The inhibition by ketanserin of the amplifying effect of 5-hydroxytryptamine on 
vascular responses may help explain the antihypertensive properties of the compound.” 
[C0022616|Ketanserin – INHIBITS – C0036751|Serotonin] 
[PMID7068108] 
Abstract – taken from paper itself  
“Hypomagnesemia has been reported to occur in diabetes mellitus in the course of 
recovery from ketoacidoses, as well as during insulin maintenance therapy.”  
[C0151723|Hypomagnesemia – COEXISTS_WITH – C0011849|Diabetes Mellitus] 
[PMID7150872] 
Title 
“Withdrawal of magnesium enhances coronary arterial spasms produced by vasoactive 
agents.” 
[C0024467|Magnesium – AUGMENTS – C0010073|Coronary Artery Vasospasm] 
Abstract 
“The calcium channel blocking agent, verapamil (10(-6)M), inhibited completely 
contractile responses to KCl; contractile responses elicited by angiotensin II and 5-HT 
were attenuated by verapamil” 
[C0036751|Serotonin – STIMULATES – C0042523|Verapamil] 
[PMID7174304] 
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Title  
“Long-term study of propranolol in the treatment of migraine.” 
[C0033497|Propranolol – TREATS – C0149931|Migraine Disorders] 
[PMID7195070] 
Abstract 
“A specific calcium antagonist, verapamil, readily prevented (and reversed) PCP-
induced vasospasm.” 
[C0042523|Verapamil – ISA – C0006684|Calcium Channel Blockers] 
[C0042523|Verapamil – PREVENTS – C0085616|Vasospasm] 
[PMID7297597] 
Abstract 
“Previous studies on isolated blood vessels indicate that (1) withdrawal of magnesium 
([Mg2+]0) induces calcium-dependent contractile responses, and (2) Mg2+]0 and 
verapamil (VE) inhibit calcium influx across the cell membrane.” 
[C0024467|Magnesium – STIMULATES – C0042523|Verapamil] 
Abstract 
“The present study, using isolated rat aortic strips and portal veins, was designed to 
assess the interactions of [Mg2+]0 and VE on increases in active tension and 
contractility induced by withdrawal of [Mg2+]0.[Mg2+]0 was found to: (1) enhance 
VE-induced inhibition of portal vein amplitude, and (2) antagonize VE-induced 
enhanced frequency of spontaneous phasic contractions in portal veins.” 
[C0042523|Verapamil – AUGMENTS – C1140999|Contraction] 
[C0042523|Verapamil – CAUSES – C1140999|Contraction] 
Abstract 
“Both [Mg2+]0 and VE could prevent and reverse the increases in active tension 
developed in aortic smooth muscle upon removal of [Mg2+]0.[Mg2+]0 markedly 
potentiated the inhibitory effect of verapamil on calcium-induced contractions of K+-
depolarized aorta but not in K+-depolarized portal vein.” 
[C0042523|Verapamil – DISRUPTS – C1140999|Contraction] 
[C0042523|Verapamil – TREATS – C0233494|Tension] 
[PMID7305671] 
Title 
”Hypomagnesemia and vasoconstriction: possible relationship to etiology of sudden 
death ischemic heart disease and hypertensive vascular diseases.” 
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[C0085616|Vasospasm – CAUSES – C0020538|Hypertensive disease] 
[C0085616|Vasospasm – CAUSES – C0151744|Myocardial Ischemia] 
Abstract 
”Hypomagnesemia and vasoconstriction: possible relationship to etiology of sudden 
death ischemic heart disease and hypertensive vascular diseases.” 
[C0085616|Vasospasm – CAUSES – C0020538|Hypertensive disease] 
Abstract 
“In-vitro experiments are presented which indicate that the concentration of 
extracellular magnesium ions ([Mg2+]o) can exert profound influences on the 
contractility and reactivity of arteries, arterioles and veins from a number of regional 
vasculatures in several mammalian species, including man.” 
SemRep did not derive a predicate from this statement, but it is worth noting. 
Abstract 
“Hypomagnesemia can potentiate the contractile activity of a variety of neurohumoral 
substances and induce vasospasm. Hypermagnesemia can do the reverse, i.e., induce 
hyporeactivity, relaxation and vasodilatation.” 
SemRep did not derive a predicate from this statement, but it is worth noting. 
Abstract 
“Data are reviewed which suggest that certain vascular diseases (e.g., sudden-death 
ischemic heart disease, hypertension, eclampsia, diabetes mellitus) are associated with 
a Mg-deficiency.” 
SemRep did not derive a predicate from this statement, but it is worth noting. 
[PMID7310427] 
Title 
“Asymmetry of the aura and pain in migraine” 
[C0030193|Pain – ASSOCIATED_WITH – C0149931|Migraine Disorders] 
[PMID7437647] 
Title 
“Differential effects of the calcium antagonist, verapamil, on lumen sizes of terminal 
arterioles and muscular venules in the rat mesenteric, pial and skeletal muscle 
microvasculatures.” 
[C0042523|Verapamil – INTERACTS_WITH – C0006684|Calcium Channel Blockers] 
[C0042523|Verapamil – ISA – C0006684|Calcium Channel Blockers] 
Abstract 
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“Local application of verapamil (1 to 100 micrograms) to cremaster muscle arterioles 
and venules of the rat induces dose-dependent vasodilatation and increased perfusion of 
capillaries.” 
[C0042523|Verapamil – CAUSES – C0042401|Vasodilation] 
Abstract 
“Although these direct in situ microvascular findings do indicate that verapamil can 
induced dilatation of microscopic resistance and capacitance vessels in skeletal muscle, 
our data do not support the concept that verapamil induces non-specific peripheral 
vasodilatation.” 
[C0042523|Verapamil – CAUSES – C1328540|Peripheral vasodilatation] 
[PMID7443079] 
Abstract – Taken from publisher’s site. 
“Withdrawal of magnesium causes vasospasm while elevated magnesium produces 
relaxation of tone in cerebral arteries.” 
[C0024467|Magnesium – CAUSES – C0085616|Vasospasm] 
[PMID773081] 
Title  
“Short-term clinical trial of phopranolol in racemic form (Inderal), D-propranolol and 
placebo in migraine.” 
[C0033497|Propranolol – TREATS – C0149931|Migraine Disorders] 
Abstract  
“The results indicate that beta-receptor blocking properties, but possibly also properties 
other than the beta-blocking ones, may be of importance for the anti-migraine effect of 
propranolol.” 
SemRep did not derive a predicate from this statement, but it is worth noting. 
[PMID89390] 
Abstract 
“The effectiveness of tolfenamic acid in acute migraine attacks accords with the 
postulated role of prostaglandins in migraine.”  
[C0033554|Prostaglandins – ASSOCIATED_WITH – C0149931|Migraine Disorders] 
[PMID939020] 
Abstract 
“The aim of the studies was to develop a solution which, if infused into the coronary 
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vessels just prior to the onset of ischemia, would rapidly induce arrest and would also 
counteract several of the deleterious cellular changes known to occur during 
myocardial ischemia.” 
[C0022116|Ischemia – COEXISTS_WITH – C0151744|Myocardial Ischemia] 
[PMID953864] 
Abstract  
“When taken in conjunction with other evidence these results suggest that the diuretics 
exert their vascular effects by inhibiting prostaglandin synthesis whereas prolactin acts 
by stimulating such synthesis.” 
[C0033554|Prostaglandins – AFFECTS – C0005847|Blood Vessels] 
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Table B-3. Precision and recall using citations for Magnesium study 
Result New Intermediate Terms Relevancy (Topic) Precision Recall 
d0 Epilepsy Epilepsy 1.0 0.083 
d1 Potassium 
Verapamil 
Dilitazam 
Nifedipine 
Calcium Channel Blockers 
Serotonin 
Calcium Channel Blockers 
Calcium Channel Blockers 
Calcium Channel Blockers 
Calcium Channel Blockers 
Calcium Channel Blockers 
Serotonin 
1.0 0.25 
d2 Glucose 
Insulin Secretion 
Diabetes 
Diabetes 
1 0.333 
d3 Pathological Dilatation Vascular Mechanisms 1 0.417 
d4 Insulin 
Fatty Acids 
Diabetes 
Not Relevant 
0.833 0.417 
d5 Epoprostenol 
Prostaglandins 
Aspirin 
Platelet Aggregation 
Prostaglandins 
Platelet Aggregation 
0.875 0.583 
d6 Sodium 
Hypertensive Disease 
Calcium Channel Blockers 
Stress / Type A 
0.889 0.667 
d7 Pain 
Somatostatin 
Inflammation 
Inflammation 
0.9 0.75 
d8 N/A  0.9 0.75 
d9 Calcium Calcium Channel Blockers 0.9 0.75 
d10 Isoproterenol 
Propranolol 
Vascular Mechanisms 
Vascular Mechanisms 
0.9 0.75 
d11 Norepinephrine 
Clonidine 
Serotonin 
Vascular Mechanisms 
0.9 0.75 
d12 Homeostasis Not Relevant 0.818 0.75 
d13 N/A  0.818 0.75 
d14 N/A  0.818 0.75 
d15 Onset of illness Not Relevant 0.75 0.75 
d16 N/A  0.75 0.75 
d17 Myocardial Ischemia 
Ischemia 
Hypoxia 
Hypoxia 
0.769 0.833 
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Table B-4. Precision and recall not using citations for Magnesium study 
Result New Intermediate Terms Relevancy (Topic) Precision Recall 
d0 Excretory Function Not Relevant 0.0 0.0 
d1 Epilepsy Epilepsy 0.5 0.083 
d2 Potassium 
Verapamil 
Nifedipine 
Calcium Channel Blockers 
Calcium Channel Blockers 
Calcium Channel Blockers 
Calcium Channel Blockers 
Calcium Channel Blockers 
0.667 0.167 
d3 Glucose 
Insulin Secretion 
Diabetes 
Diabetes 
0.75 0.25 
d4 Serotonin 
Pathological Dilatation 
Serotonin 
Vascular Mechanisms 
0.833 0.417 
d5 Insulin 
Fatty Acids 
Diabetes 
Not Relevant 
0.714 0.417 
d6 Epoprostenol 
Prostaglandins 
Platelet Aggregation 
Prostaglandins 
0.778 0.583 
d7 Hypertensive Disease Stress / Type A 0.8 0.667 
d8 Pain 
Somatostatin 
Inflammation 
Inflammation 
0.818 0.75 
d9 N/A  0.818 0.75 
d10 Dilitazam 
Calcium 
Calcium Channel Blockers 
Calcium Channel Blockers 
0.818 0.75 
d11 ATP Not Relevant 0.75 0.75 
d12 N/A  0.75 0.75 
d13 Falls Not Relevant 0.692 0.75 
d14 Vasospasm Vascular Mechanisms 0.692 0.75 
d15 Myocardial Ischemia 
Ischemia 
Hypoxia 
Hypoxia 
0.714 0.833 
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 Appendix C
Somatomedins – Arginine Study 
 
Table C-1. Somatomedins – Arginine Core Corpus Medline IDs 
412936 3075738 3690631 5459997 6754563 
425782 3080468 3700933 5786514 6790230 
430225 3080558 3731567 5841101 6846217 
448444 3096900 3758932 5859253 6890417 
492275 3099250 3782436 5877589 6989150 
515169 3109352 3803997 5917038 6998997 
606683 3127426 3833530 5929465 7007997 
617386 3140744 3865530 5944094 7020137 
632300 3259505 3884753 6176592 7038514 
684614 3262126 3902942 6190641 7042736 
686863 3288047 3918429 6202444 7045779 
722344 3310600 3918442 6243390 7058674 
744062 3315866 3923266 6262917 7079756 
794768 3322823 4038409 6299718 7189195 
839329 3380847 4056323 6324479 7193684 
870020 3434631 4058978 6343062 7194884 
893668 3499612 4158217 6363657 7194952 
908965 3514981 4164428 6370513 7195462 
939198 3525601 4205831 6373069 7197311 
1110767 3533330 4430939 6414318 7197688 
1120749 3546937 4538721 6416888 7198145 
1254283 3558728 4550398 6427525 7198682 
2536517 3558729 4568402 6428892 7213491 
2648317 3569122 4624624 6540317 7264776 
2840748 3652525 4631334 6583688 7327721 
2897974 3653346 4696902 6609081 7350218 
2899993 3654912 4919910 6639868 7391725 
2938688 3665113 5059775 6681614 13429201 
2959373 3668688 5165405 6684729 13491695 
2972888 3683183 5347431 6749885 14328387 
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Figure C-1. Somatomedins – Arginine search parameters 
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Figure C-2. Somatomedins – Arginine result 1 (with citations) 
 
 
Figure C-3. Somatomedins – Arginine result 2 (with citations) 
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Figure C-4. Somatomedins – Arginine result 3 (with citations) 
 
 
Figure C-5. Somatomedins – Arginine result 4 (with citations) 
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Figure C-6. Somatomedins – Arginine result 5 (with citations) 
 
 
Figure C-7. Somatomedins – Arginine result 6 (with citations) 
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Figure C-8. Somatomedins – Arginine result 7 (with citations) 
 
 
Figure C-9. Somatomedins – Arginine result 8 (with citations) 
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Figure C-10. Somatomedins – Arginine result 9 (with citations) 
 
 
Figure C-11. Somatomedins – Arginine result 10 (with citations) 
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Figure C-12. Somatomedins – Arginine result 11 (with citations) 
 
 
Figure C-13. Somatomedins – Arginine result 12 (with citations) 
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Figure C-14. Somatomedins – Arginine result 13 (with citations) 
 
 
Figure C-15. Somatomedins – Arginine result 14 (with citations) 
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Figure C-16. Somatomedins – Arginine result 15 (with citations) 
 
 
Figure C-17. Somatomedins – Arginine result 16 (with citations) 
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Figure C-18. Somatomedins – Arginine result 1 (no citations) 
 
 
 
Figure C-19. Somatomedins – Arginine result 2 (no citations) 
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Figure C-20. Somatomedins – Arginine result 3 (no citations) 
 
 
Figure C-21. Somatomedins – Arginine result 4 (no citations) 
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Figure C-22. Somatomedins – Arginine result 5 (no citations) 
 
 
Figure C-23. Somatomedins – Arginine result 6 (no citations) 
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Figure C-24. Somatomedins – Arginine result 7 (no citations) 
 
 
 
Figure C-25. Somatomedins – Arginine result 8 (no citations) 
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Figure C-26. Somatomedins – Arginine result 9 (no citations) 
 
 
Figure C-27. Somatomedins – Arginine result 10 (no citations) 
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Figure C-28. Somatomedins – Arginine result 11 (no citations) 
 
 
Figure C-29. Somatomedins – Arginine result 12 (no citations) 
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Figure C-30. Somatomedins – Arginine result 13 (no citations) 
 
 
 
Figure C-31. Somatomedins – Arginine result 14 (no citations) 
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Figure C-32. Somatomedins – Arginine result 15 (no citations) 
 
 
Figure C-33. Somatomedins – Arginine result 16 (no citations) 
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Figure C-34. Somatomedins – Arginine result 17 (no citations) 
 
 
Figure C-35. Somatomedins – Arginine result 18 (no citations) 
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Table C-2. Somatomedins – Arginine generated predicates 
[PMID105670] 
Title 
“Plasma somatomedin activity in protein calorie malnutrition.” 
[C0037657|Somatomedins – ASSOCIATED_WITH – C0033677|Protein-Energy 
Malnutrition] 
[PMID107298] 
Abstract – Taken from publisher’s site. 
“These data suggest that dietary composition has a direct effect on plasma SM activity 
and that the severe growth retardation associated with protein malnutrition may be 
related to its additional effect on serum SM.” 
[C0037657|Somatomedins – ASSOCIATED_WITH – C0022806|Kwashiorkor] 
[PMID1128255] 
Abstract – Taken from publisher’s site. 
“Somatomedin (SM) is a growth hormone (GH)-dependent peptide, circulating in 
normal serum, which directly causes skeletal growth.” 
[C0037657|Somatomedins – AUGMENTS – C0018270|Growth] 
Abstract – Taken from publisher’s site. 
“It is hypothesized that GH produces skeletal growth indirectly by causing the 
generation of a “sulfation factor,” now called “SM,” which acts directly to cause 
proliferation of cartilage.” 
[C0037663|Somatotropin – CAUSES – C0018270|Growth] 
[PMID1128683] 
Abstract – Taken from publisher’s site. 
“In the whole animal a major function of GH is to stimulate the longitudinal growth of 
the skeleton, and GH acts by controlling the production of a second series of hormones, 
the somatomedins.” 
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[C0037663|Somatotropin – AUGMENTS – C0018270|Growth] 
[PMID1261514] 
Abstract 
“When compared with the results without hormone, the addition of 1000 muU/ml of 
insulin per ml of medium during the 2nd to 6th period led to a significant increase in 
perfusate somatomedin activity at all periods.” 
[C0021641|Insulin – STIMULATES – C0037657|Somatomedins] 
Abstract 
“Differences in insulin concentration may explain some clinical situations in which 
somatomedin concentrations cannot be correlated with GH levels.” 
[C0021641|Insulin – COEXISTS_WITH – C0037657|Somatomedins] 
[PMID132381] 
Abstract 
“Since diabetes mellitus is a condition in which poor growth occurs despite elevation of 
plasma GH, we have attempted to determine if poor growth in diabetes, as in 
malnutrition, could be associated with a decrease in somatomedin activity.” 
[C0018270|Growth – ASSOCIATED_WITH – C0011847|Diabetes] 
[C0018270|Growth – ASSOCIATED_WITH – C0162429|Malnutrition] 
Abstract 
“Administration of insulin to diabetic rats 48 hours after STZ led to significant 
increases in SM and cartilage growth activity, and insulin therapy 24 hours after STZ 
prevented the decreases in SM and cartilage growth activity which occurred without 
insulin.” 
[C0021641|Insulin – INHIBITS – C0037657|Somatomedins] 
[PMID13251208] 
Abstract – Taken from publisher’s site. 
“In view of the notable influence of the growth hormone of the pituitary body on the 
growth of cartilage knowledge of the effects of this principle on the metabolism of 
cartilage becomes essential.” 
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[C0037663|Somatotropin – AFFECTS – C0018270|Growth] 
[PMID142677] 
Abstract – Taken from publisher’s site. 
“Observations of a growth hormone-resistant decrease in somatomedin activity 
associated with conditions of insulinopenia suggest that somatomedin and growth 
might be related to metabolic control in diabetes mellitus.” 
[C0037657|Somatomedins – AFFECTS – C1513158|Metabolic Control] 
[C0037657|Somatomedins – ASSOCIATED_WITH – C0011849|Diabetes Mellitus] 
Abstract – Taken from publisher’s site. 
“We examined this relationship by comparing measures of insulin effect with serum 
somatomedin activity (porcine cartilage bioassay), cartilage growth activity (SO4 
uptake in vitro), and change in body weight in streptozotocin-diabetic rats.” 
[C0037657|Somatomedins – INTERACTS_WITH – C0021641|Insulin] 
Abstract – Taken from publisher’s site. 
“These studies demonstrate a close relationship between insulin efficacy, serum 
somatomedin activity, cartilage growth activity, and weight gain and support the 
hypothesis that through somatomedin, insulin may contribute to growth.” 
[C0021641|Insulin – AFFECTS – C0018270|Growth] 
[PMID20276173] 
Title 
“The rôle of arginine in growth with some observations on the effects of argininic 
acid.” 
[C0003765|Arginine – AFFECTS – C0018270|Growth] 
[PMID2408950] 
Abstract 
“Islet cell IGF was identified as predominantly IGF-I or a closely related species and 
not IGF-II” 
[C0021665|Insulin-Like Growth Factor I – ISA – C0037657|Somatomedins] 
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Abstract 
“Growth hormone did not consistently increase IGF-I synthesis, suggesting that the 
previously described effects of growth hormone on islet cell replication do not result 
from stimulation of IGF-I synthesis by islet cells.” 
[C0037663|Somatotropin – AFFECTS – C0007590|Cell division] 
[C0037663|Somatotropin – STIMULATES – C0021665|Insulin-Like Growth Factor I] 
Abstract 
“Thus, although the IGF-I synthesized by islet cells may be a physiologically relevant 
growth factor for these cells, the mitogenic effects of growth hormone in islet cells 
appear to be independent and not mediated by IGF-I.” 
[C0018284|Growth Factor – INTERACTS_WITH – C0037663|Somatotropin] 
[C0021665|Insulin-Like Growth Factor I – INTERACTS_WITH – 
C0037663|Somatotropin] 
[C0021665|Insulin-Like Growth Factor I – ISA – C0018284|Growth Factor] 
[PMID2413420] 
Abstract 
“Insulin promotes the growth of these cells by binding, with low affinity, to the type I 
insulin-like growth factor (IGF) receptor, not through the high affinity insulin 
receptor.” 
[C0021641|Insulin – AUGMENTS – C0018270|Growth] 
Abstract 
“In other cell types, such as hepatocytes, embryonal carcinoma cells, or mammary 
tumor cells, the type I IGF receptor is virtually absent, and insulin stimulates the 
growth of these cells at physiological concentrations by binding to the high affinity 
insulin receptor.” 
[C0021641|Insulin – AUGMENTS – C0018270|Growth] 
[C0140079|Insulin-Like Growth Factor Receptor – AUGMENTS – C0018270|Growth] 
Abstract 
“Poor growth follows impaired insulin secretion in diabetes mellitus.” 
[C0018270|Growth – ASSOCIATED_WITH – C0011849|Diabetes Mellitus] 
Abstract 
“This is associated with reduced circulating levels of IGF’s which may be partly 
responsible for the growth failure.” 
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[C0037657|Somatomedins – CAUSES – C0878787|Growth failure] 
Abstract 
“Diabetic children, treated conventionally, have normal circulating IGF levels, but both 
growth rate and serum IGF concentration may increase dramatically when diabetic 
control is optimized” 
[C0037657|Somatomedins – AFFECTS – C0241863|Diabetic] 
[PMID2899993] 
Abstract 
“Growth hormone stimulates protein synthesis during hypocaloric parenteral nutrition.” 
[C0037663|Somatotropin – AUGMENTS – C0597295|Protein Biosynthesis] 
Abstract 
“The influence of growth hormone (GH) on protein metabolism and fuel utilization was 
investigated in eight paired studies of normal volunteers.” 
[C0037663|Somatotropin – AFFECTS – C0597299|Protein Metabolism] 
Abstract 
“GH was associated with an increase in insulin and insulin-like growth factor-I 
concentrations (IGF-I, 9.1 +/- 0.6 IU/ml vs. 3.3 +/- 0.5, p less than 0.001).” 
[C0037663|Somatotropin – STIMULATES – C0021641|Insulin] 
[C0037663|Somatotropin – STIMULATES – C0021665|Insulin-Like Growth Factor I] 
[PMID3099250] 
Title 
“Serum insulin-like growth factors I and II concentrations and growth hormone and 
insulin responses to arginine infusion in children with protein-energy malnutrition 
before and after nutritional rehabilitation.” 
[C0003765|Arginine – TREATS(INFER) – C0033677|Protein-Energy Malnutrition] 
Abstract 
“GH responses to arginine were depressed in the three malnourished groups and 
improved significantly in marasmic-kwashiorkor and marasmic children after 
nutritional rehabilitation.” 
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[C0003765|Arginine – TREATS – C0342914|Marasmic kwashiorkor] 
Abstract 
“Insulin responses to arginine were impaired in kwashiorkor, and marasmic-
kwashiorkor children and improved significantly after refeeding.” 
[C0003765|Arginine – DISRUPTS – C0022806|Kwashiorkor] 
[C0003765|Arginine – DISRUPTS – C0342914|Marasmic kwashiorkor] 
[PMID3259505] 
Abstract 
“It was found that GH does not show any effect on the recovery of SRBC receptor, but 
it may act through the increase of SM level.” 
[C0037663|Somatotropin – STIMULATES – C0037657|Somatomedins] 
[PMID3322823] 
Abstract 
“Levels of circulating IGF I and IGF II are affected by growth hormone, but the former 
peptide is the more sensitive to growth hormone.” 
[C0037663|Somatotropin – INTERACTS_WITH – C0021665|Insulin-Like Growth 
Factor I] 
Abstract 
“There is good evidence that the reduction in levels of circulating IGF I is related to 
decreased secretion of growth hormone that accompanies aging.” 
[C0021665|Insulin-Like Growth Factor  - INHIBITS- C0037663|Somatotropin] 
[PMID3380847] 
Title 
“Somatomedins: do they play a pivotal role in wound healing?” 
[C0037657|Somatomedins – AFFECTS – C0043240|Wound Healing] 
Abstract 
“An understanding of the role of somatomedins in normal wound healing might be able 
to help us understand abnormalities of the repair process such as keloid formation.” 
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[C0037657|Somatomedins – AFFECTS – C0043240|Wound Healing] 
[PMID3690631] 
Abstract 
“It is concluded that IGF-I is likely to be involved in the repair of the intima in injured 
arteries.” 
[C0021665|Insulin-Like Growth Factor I – AFFECTS – C0043240|Wound Healing] 
[PMID3803997] 
Abstract 
“These results show that old rats respond to GH in a mechanism involving 
somatomedin and that significant increases in somatic growth can be obtained, even at 
advanced age.” 
[C0037663|Somatotropin – INTERACTS_WITH – C0037657|Somatomedins] 
[PMID3898005] 
Abstract 
“Recent reports indicate that children with normal growth hormone responses who 
have very low integrated concentration of growth hormone may have the potential to 
improve their growth with growth hormone therapy.” 
[C0037663|Somatotropin – AFFECTS – C0018270|Growth] 
[PMID3923266] 
Abstract 
“The experiments indicate that high arginine levels in IVH solutions improve wound 
healing and thymic immune function following injury.” 
[C0003765|Arginine – AFFECTS – C0043240|Wound Healing] 
[PMID412936] 
Abstract 
“This study was undertaken to define the interrelationships of somatomedin, growth 
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hormone, and an inhibitor of SM in protein-calorie malnutrition.” 
[C0037657|Somatomedins – ASSOCIATED_WITH – C0033677|Protein-Energy 
Malnutrition] 
[C0037663|Somatotropin – ASSOCIATED_WITH – C0033677|Protein-Energy 
Malnutrition] 
[PMID4201417] 
Abstract – Taken from publisher’s site. 
“Arginine infusion elicited an associated release in PRL and GH with a dissociated 
time course of approximately 15 min earlier for PRL than for GH.” 
[C0003765|Arginine – COEXISTS_WITH – C0037663|Somatotropin] 
[PMID430225] 
Abstract – Taken from publisher’s site. 
“The diet supplemented with arginine and glycine improved growth before and after 
trauma, and nitrogen retention after trauma.” 
[C0003765|Arginine – AFFECTS – C0018270|Growth] 
[PMID430251] 
Title 
“Inhibitory effect of dietary arginine on growth of Ehrlich ascites tumor cells in mice.” 
[C0003765|Arginine – DISRUPTS – C0018270|Growth] 
Abstract 
“The effect of dietary L-arginine on the growth and development of transplantable 
Ehrlich Ascites tumor cells was examined.” 
[C0003765|Arginine – AFFECTS – C0018270|Growth] 
Abstract 
“Supplemental dietary arginine at 3 or 5% did not significantly affect the growth of 
non-tumor bearing mice.” 
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[C0003765|Arginine – AFFECTS – C0018270|Growth] 
Abstract 
“Dietary arginine may play a critical role in growth of normal as well as neoplastic 
tissue.” 
[C0003765|Arginine – AFFECTS – C0018270|Growth] 
[PMID4430939] 
Title 
“Effect of arginine deficiency on growth and intermediary metabolism in rats.” 
[C0003765|Arginine – AFFECTS – C0018270|Growth] 
[PMID4506104] 
Abstract 
“The action of growth hormone on skeletal tissue is mediated through somatomedin, a 
low molecular weight peptide found in serum.” 
[C0037663|Somatotropin – INTERACTS_WITH – C0037657|Somatomedins] 
Abstract 
“Since at least some of the metabolic effects of insulin on target cells are initiated by a 
highly specific interaction with receptors on cell membranes, this study was undertaken 
to determine whether somatomedin might interact with the same binding sites.” 
[C0037657|Somatomedins – INTERACTS_WITH – C0021641|Insulin] 
[PMID4538721] 
Abstract – Taken from publisher’s site. 
“The significance of pituitary growth hormone (GH) for the regulation of skeletal 
growth is uniformly recognized.” 
[C0037663|Somatotropin – AFFECTS – C0018270|Growth] 
[PMID4903729] 
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Abstract – Taken from publisher’s site. 
“All individuals responded to arginine infusion with an increase in the IRI 
concentrations.” 
[C0003765|Arginine – STIMULATES – C0021641|Insulin] 
Abstract – Taken from publisher’s site. 
“Four of the five females and two of the five males responded to the initial infusion of 
arginine with a significant increase in plasma GH concentration.” 
[C0003765|Arginine – STIMULATES – C0037663|Somatotropin] 
Abstract – Taken from publisher’s site. 
“It is concluded (1) that saline is not a stimulus to GH release, (2) that arginine 
consistently increases IRI concentration, (3) that plasma glucose levels usually, but not 
invariably, increase with arginine infusion and (4) that some males have a variable GH 
response to arginine, which is independent of estrogen replacement.” 
[C0003765|Arginine – STIMULATES – C0021641|Insulin] 
[PMID521015] 
Title 
“Prolactin nonresponsiveness to arginine in diabetes mellitus.” 
[C0003765|Arginine – ASSOCIATED_WITH – C0011849|Diabetes Mellitus] 
[PMID5361695] 
Abstract – Taken from publisher’s site. 
“The apparently normal production of growth hormone and the impaired insulin, which 
was persistently demonstrated by these infants, along with the poor growth in cell mass 
of those under 11 months of age, suggest that gains in cell mass in the younger infant 
may be primarily dependent on insulin and not on growth hormone.” 
[C0018270|Growth – PRODUCES – C0021641|Insulin] 
[C0018270|Growth – PRODUCES – C0037663|Somatotropin] 
[PMID5917038] 
Abstract – Taken from publisher’s site. 
“During the course of experience with subjects who were given infusions of arginine, 
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we observed that female subjects showed a greater rise in serum insulin and in serum 
HGH than did males of a comparable age.” 
[C0003765|Arginine – COEXISTS_WITH – C0021641|Insulin] 
[C0003765|Arginine – COEXISTS_WITH – C0169964|Somatropin] 
[PMID6027286] 
Title 
“Effect of arginine on serum levels of insulin and growth hormone in obese subjects.” 
[C0037663|Somatotropin – INTERACTS_WITH – C0003765|Arginine] 
[C0021641|Insulin – INTERACTS_WITH – C0003765|Arginine] 
[PMID6153391] 
Abstract 
“This peptide has been classified as a somatomedin on the basis of its biological actions 
and growth hormone dependence.” 
[C0037657|Somatomedins – INTERACTS_WITH – C0037663|Somatotropin] 
[C0037663|Somatotropin – INTERACTS_WITH – C0037657|Somatomedins] 
Abstract 
“We have generated an antibody to the synthetic 12 amino acid C-peptide region of 
insulin-like growth factor-I and used it to compare three somatomedin preparations to 
insulin-like growth factor-I.” 
[C0037657|Somatomedins – compared_with – C0021665|Insulin-Like Growth Factor 
I] 
Abstract 
“We also compared these somatomedin preparations to insulin-like growth factor-I 
using the standard SM-C RIA.” 
[C0037657|Somatomedins – compared_with – C0021665|Insulin-Like Growth Factor 
I] 
[PMID6181237] 
Abstract 
“The possible mechanism(s) by which arginine can modify mammary growth are 
discussed.” 
[C0003765|Arginine – AFFECTS – C0018270|Growth] 
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[PMID6243390] 
Abstract – Taken from publisher’s site. 
“It is now over 20 years since Salmon and Daughaday hypothesized that stimulation of 
growth by growth hormone (somatotropin) was mediated by a circulating ‘sulfation 
factor’.” 
[C0037663|Somatotropin – AUGMENTS – C0018270|Growth] 
[PMID6338399] 
Abstract – Taken from publisher’s site. 
“Plasma IGF-I levels reflect circulating concentrations of pituitary growth hormone 
(GH), and exogenous IGF-I substitutes for GH in inducing somatic and skeletal growth 
in GH-deficient rats2.” 
[C0021665|Insulin-Like Growth Factor I – COEXISTS_WITH – 
C0037663|Somatotropin] 
Abstract – Taken from publisher’s site. 
“By contrast, both GH and PL stimulate IGF-I synthesis in fibroblasts from older rats 
with no effect on IGF-II synthesis.” 
[C0037663|Somatotropin – STIMULATES – C0021665|Insulin-Like Growth Factor I] 
[PMID6368579] 
Abstract 
“During simultaneous incubation with PDGF and SM-C-deficient PPP, however, 
hydrocortisone, T4, EGF, and insulin produced concentration-dependent increases in 
IR-SM production.” 
[C0021641|Insulin – STIMULATES – C0037657|Somatomedins] 
[PMID6385593] 
Abstract 
“There was also a significantly enhanced increase of SM-C/IGF I in the presence of 
GH during culture in comparison to the controls.” 
[C0037663|Somatotropin – STIMULATES – C0021665|Insulin-Like Growth Factor I] 
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Abstract 
“Evidently IGF I is produced locally in bone and mediates the effect of GH on bone 
formation.” 
[C0021665|Insulin-Like Growth Factor I – INTERACTS_WITH – 
C0037663|Somatotropin] 
[PMID6639868] 
Abstract 
“The acceleration resulting from growth hormone and thyroxine administration may be 
due to an increased production of somatomedins locally or systemically or by direct 
action on connective tissue.” 
[C0037663|Somatotropin – PRODUCES – C0037657|Somatomedins] 
[PMID6751804] 
Abstract 
“The addition of human growth hormone (25 micrograms/ml) and/or insulin (1 mU/ml) 
to the perfusates caused a significant increase in somatomedin after 120 minutes of 
recirculation.” 
[C0021641|Insulin – COEXISTS_WITH – C0037657|Somatomedins] 
Abstract 
“The effect of insulin on the release of somatomedin was greater in hypox rats than that 
observed in normal rats.” 
[C0037657|Somatomedins – INTERACTS_WITH- C0021641|Insulin] 
[PMID6754563] 
Abstract 
“These data suggest that glucose intolerance during arginine deficiency is related to 
decreased insulin release immediately following glucose administration and possibly a 
mild insulin resistance.” 
[C0003765|Arginine – COEXISTS_WITH – C0021641|Insulin] 
[PMID6986740] 
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Abstract – Taken from publisher’s site. 
“The addition of GH (1 mU/ml) or insulin (0.25-1 mU/ml) to the culture dishes 
significantly increased the SM activity of the medium and a dose-dependent effect was 
observed with insulin.” 
[C0021641|Insulin – STIMULATES – C0037657|Somatomedins] 
“These findings suggest that: 1) SM is synthesized by rat liver in organ culture; 2) 
insulin plays an important role in SM generation, as it itself is capable of both 
stimulating the release of SM and amplifying the stimulatory effect of GH.” 
[C0021641|Insulin – INTERACTS_WITH – C0037657|Somatomedins] 
[PMID702022] 
Title 
“Production of somatomedin activity in vitro in the presence of growth hormone and 
cycloheximide.” 
[C0037663|Somatotropin – PRODUCES – C0037657|Somatomedins] 
[PMID7424474] 
Abstract 
“The effect of growth hormone on somatomedin generation was abolished in 
hypophysectomized rats fed with low-protein diet.” 
[C0037663|Somatotropin – INTERACTS_WITH – C0037657|Somatomedins] 
[PMID807324] 
Title 
“Inhibitory effect of L-arginine on growth of rat mammary tumors induced by 7,12-
dimethylbenz(a)anthracene.” 
[C0003765|Arginine – DISRUPTS – C0018270|Growth] 
[PMID862560] 
Abstract 
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“The roles of growth hormone and somatomedin in stimulating muscle cell 
proliferation were investigated in a series of experiments on myoblast growth in 
culture.” 
[C0037657|Somatomedins – AUGMENTS – C0018270|Growth] 
[C0037663|Somatotropin – AUGMENTS – C0018270|Growth] 
[PMID895522] 
Abstract – Taken from publisher’s site. 
“Although pituitary hormones, particularly growth hormone (GH), are known to 
influence skeletal growth, there is no evidence for a direct effect of GH or GH-
dependent factors (somatomedins) on bone as opposed to cartilage.” 
[C0037663|Somatotropin – AFFECTS – C0018270|Growth] 
[PMID96201] 
Title 
“Sulphation factor (somatomedin activity) in experimental protein malnutrition in the 
rat.” 
[C0037657|Somatomedins – ASSOCIATED_WITH – C0022806|Kwashiorkor] 
Abstract 
“In a rat model of protein malnutrition in which the failure of growth is a major feature, 
a low level of bioassayable sulphation factor activity was present in the serum, 
associated with normal levels of growth hormone and low insulin in the plasma.” 
[C0021641|Insulin – ASSOCIATED_WITH – C0022806|Kwashiorkor] 
[C0037663|Somatotropin – ASSOCIATED_WITH – C0022806|Kwashiorkor] 
Abstract 
“The administration of pharmacological doses of human or bovine growth hormone did 
not increase the amount of sulphation factor activity in the serum or the width of the 
tibial epiphyses in the protein-malnourished animals.” 
[C0520986|growth hormone, bovine – NEG_STIMULATES – C0037657|Somatomedins] 
[PMID967246] 
Abstract – Taken from publisher’s site. 
“SOMATOMEDINS are growth hormone-dependent polypeptides that have been 
 
 
 
287 
 
 
 
proposed as the mediators of the peripheral actions of growth hormone on skeletal 
tissue.” 
[C0037657|Somatomedins – STIMULATES – C0037663|Somatotropin] 
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Table C-3. Precision and recall using citations for Somatomedins study 
Result New Intermediate Terms Relevancy (Topic) Precision Recall 
d0 Growth Body Weight 1.0 0.2 
d1 Somatotropin Growth Hormone 1.0 0.4 
d2 Insulin Diabetes 1.0 0.6 
d3 Glucose Diabetes 1.0 0.6 
d4 Wound Healing Wound Healing 1.0 0.8 
d5 Ornithine Not Relevant 0.8 0.8 
d6 Testosterone Not Relevant 0.667 0.8 
d7 Protein Biosynthesis Growth Hormone 0.667 0.8 
d8 Diabetes Mellitus Diabetes 0.667 0.8 
d9 Somatropin Growth Hormone 0.667 0.8 
d10 Somatostatin Growth Hormone 0.667 0.8 
d11 Exocytosis Not Relevant 0.571 0.8 
d12 Leucine Not Relevant 0.5 0.8 
d13 Androgens Not Relevant 0.444 0.8 
d14 Kwashiorkor Malnutrition 0.5 1.0 
d15 Protein-Energy 
Malnutrition 
Malnutrition 0.5 1.0 
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Table C-4. Precision and recall not using citations for Somatomedins study 
Result New Intermediate Terms Relevancy (Topic) Precision Recall 
d0 Growth Body Weight 1.0 0.2 
d1 Somatotropin Growth Hormone 1.0 0.4 
d2 Insulin Diabetes 1.0 0.6 
d3 Glucose Diabetes 1.0 0.6 
d4 Wound Healing Wound Healing 1.0 0.8 
d5 Infant Not Relevant 0.8 0.8 
d6 Ornithine Not Relevant 0.667 0.8 
d7 Testosterone Not Relevant 0.571 0.8 
d8 Protein Biosynthesis Growth Hormone 0.571 0.8 
d9 Diabetes Mellitus Diabetes 0.571 0.8 
d10 Somatropin Growth Hormone 0.571 0.8 
d11 Somatostatin Growth Hormone 0.571 0.8 
d12 Exocytosis Not Relevant 0.5 0.8 
d13 Leucine Not Relevant 0.444 0.8 
d14 Glycine Not Relevant 0.4 0.8 
d15 Androgens Not Relevant 0.364 0.8 
d16 Kwashiorkor Malnutrition 0.417 1.0 
d17 Protein-Energy 
Malnutrition 
Malnutrition 0.417 1.0 
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 Appendix D
Testosterone – Sleep Study 
 
Table D-1. Testosterone – Sleep Core Corpus Medline IDs 
1740593 10484567 14687700 17201728 19647784 
4321505 10566905 15714228 17253619 19684340 
4326799 10628505 15724043 17520786 19738366 
6348068 10774867 15728214 18035227 19769952 
6405703 10785345 15743338 18248637 20026350 
6781027 10938176 15841103 18413429 20171018 
6822642 11238497 15914523 18519168 20497841 
7089154 11297573 16453977 18710368 20675620 
7440701 12055986 16453985 19075717  
9329339 12843160 16890403 19212126  
10344587 12915643 17032928 19602101  
 
 
 
Figure D-1. Testosterone – Sleep search parameters 
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Figure D-2. Testosterone – Sleep result 1 
 
 
 
Figure D-3. Testosterone – Sleep result 2 
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Figure D-4. Testosterone – Sleep result 3 
 
 
 
Figure D-5. Testosterone – Sleep result 4 
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Figure D-6. Testosterone – Sleep result 5 
 
 
 
Figure D-7. Testosterone – Sleep result 6 
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Figure D-8. Testosterone – Sleep result 7 
 
 
Figure D-9. Testosterone – Sleep result 8 
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Figure D-10. Testosterone – Sleep result 9 
 
 
Figure D-11. Testosterone – Sleep result 10 
 
 
 
Figure D-12. Testosterone – Sleep result 11 
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Figure D-13. Testosterone – Sleep result 12 
 
 
Figure D-14. Testosterone – Sleep result 13 
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Table D-2. Testosterone – Sleep generated predicates 
[PMID10841212] 
Abstract 
“The study compared sleep, cortisol, and sleep-cortisol correlations under baseline and 
“stress” conditions in men and women.” 
[C0020268|Hydrocortisone – AFFECTS – C0037313|Sleep] 
[PMID10956236] 
Title 
“IL-1 is a mediator of increases in slow-wave sleep induced by CRH receptor 
blockade.” 
[C0021753|Interleukin-1 beta – AUGMENTS – C0234451|Sleep, Slow-Wave] 
Abstract 
“IL-1 promotes sleep, and glucocorticoids inhibit IL-1 synthesis.” 
[C0017710|Glucocorticoids – AUGMENTS – C0037313|Sleep] 
[C0021753|Interleukin-1 beta – AUGMENTS – C0037313|Sleep] 
[PMID12000022] 
Title 
“The role of cytokines in physiological sleep regulation.” 
[C0079189|cytokine – AFFECTS – C0037313|Sleep] 
Abstract 
“Several growth factors (GFs) are implicated in sleep regulation.” 
[C0018284|Growth Factor – AFFECTS – C0037313|Sleep] 
Abstract 
“Among these substances, the most extensively studied for their role in sleep regulation 
are interleukin-1beta (IL-1) and tumor necrosis factor alpha (TNF).” 
[C0021753|Interleukin-1 beta – AFFECTS – C0037313|Sleep] 
[C1456820|Tumor Necrosis Factor-alpha – AFFECTS – C0037313|Sleep] 
 
 
 
298 
 
 
 
Abstract 
“Inhibition of either IL-1 or TNF inhibits spontaneous sleep and the sleep rebound that 
occurs after sleep deprivation.” 
[C0021753|Interleukin-1 beta – DISRUPTS – C0037313|Sleep] 
[C1456820|Tumor Necrosis Factor-alpha – DISRUPTS – C0037313|Sleep] 
Abstract 
“IL-1 and TNF are part of a complex biochemical cascade regulating sleep.” 
[C0021753|Interleukin-1 beta – AFFECTS – C0037313|Sleep] 
[C1456820|Tumor Necrosis Factor-alpha – AFFECTS – C0037313|Sleep] 
[PMID12531038] 
Title 
“Treatment of sleep disturbance in Alzheimer’s disease” 
[C0037317|Sleep disturbances – COEXISTS_WITH – C0002395|Alzheimer’s Disease] 
Abstract 
“Nevertheless, the study of sleep in AD is relatively new.” 
[C0037313|Sleep – ASSOCIATED_WITH – C0002395|Alzheimer’s Disease] 
[PMID15240608] 
Abstract 
“Testosterone has immune-modulating properties, and current in vitro evidence 
suggests that testosterone may suppress the expression of the proinflammatory 
cytokines TNFalpha, IL-1beta, and IL-6 and potentiate the expression of the 
antiinflammatory cytokine IL-10.” 
[C0039601|Testosterone – INHIBITS – C0021753|Interleukin-1 beta] 
[C0039601|Testosterone – INHIBITS – C0021760|Interleukin-6] 
[C0039601|Testosterone – STIMULATES – C0085295|Interleukin-10] 
[PMID15724043] 
Abstract 
“Unlike the norm in the adult, where testosterone production is often inhibited by 
cortisol, in the fetus there is a positive link between the two.” 
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[C0020268|Hydrocortisone – INHIBITS – C0039601|Testosterone] 
[PMID15841103] 
Title 
“Testosterone suppression of CRH-stimulated cortisol in men.” 
[C0039601|Testosterone – INHIBITS – C0020268|Hydrocortisone] 
Abstract 
“These data demonstrate that testosterone regulates CRH-stimulated HPA axis activity 
in men, with the divergent effects on ACTH and cortisol suggesting a peripheral 
(adrenal) locus for the suppressive effects on cortisol.” 
[C0039601|Testosterone – STIMULATES – C0001655|Corticotropin] 
[C0039601|Testosterone – STIMULATES – C0020268|Hydrocortisone] 
[PMID15886244] 
Abstract 
“Despite the absence of sex differences in estradiol or testosterone at the time of 
testing, men showed increased stimulated ACTH (repeated-measures ANOVA for 
CRH, P &lt; 0.005) and cortisol (repeated-measures ANOVA for exercise, P &lt; 0.05) 
compared with women.” 
[C0014912|Estradiol – STIMULATES – C0010132|Corticotropin-Releasing Hormone] 
[C0014912|Estradiol -  STIMULATES – C0020268|Hydrocortisone] 
[C0039601|Testosterone – STIMULATES – C0010132|Corticotropin-Releasing 
Hormone] 
[C0039601|Testosterone – STIMULATES – C0020268|Hydrocortisone] 
[PMID15914523] 
Abstract 
“In conclusion, testosterone increased during sleep and fell during waking, whereas 
circadian effects seemed marginal.” 
[C0039601|Testosterone – AUGMENTS – C0037313|Sleep] 
[PMID16344336] 
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Title 
“Effects of testosterone on cognition and mood in male patients with mild Alzheimer 
disease and healthy elderly men.” 
[C0039601|Testosterone – TREATS(INFER) – C0002395|Alzheimer’s Disease] 
[PMID18519168] 
Title 
“The effects of testosterone on sleep and sleep-disordered breathing in men: its 
bidirectional interaction with erectile function” 
[C0039601|Testosterone – AFFECTS – C0035203|Respiration] 
[C0039601|Testosterone – AFFECTS – C0037313|Sleep] 
[PMID2541159] 
Title 
“Influences of corticotropin-releasing hormone, adrenocorticotropin, and cortisol on 
sleep in normal man.” 
[C0001655|Corticotropin – AFFECTS – C0037313|Sleep] 
[C0010132|Corticotropin-Releasing Hormone – AFFECTS – C0037313|Sleep] 
[C0020268|Hydrocortisone – AFFECTS – C0037313|Sleep] 
[PMID3661052] 
Title 
“Differential effects of hydrocortisone, fluocortolone, and aldosterone on nocturnal 
sleep in humans.” 
[C0020268|Hydrocortisone – AFFECTS – C0037313|Sleep] 
Abstract 
“The results demonstrate differential effects of synthetic glucocorticoid, cortisol, and 
aldosterone on sleep in humans, which may be attributed to the heterogeneity of 
corticosteroid receptors in the brain.” 
[C0020268|Hydrocortisone – AFFECTS – C0037313|Sleep] 
[PMID3790626] 
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Abstract 
“The pattern of nocturnal cortisol secretion appeared to be synchronized with the 
periodicity of sleep: rapid eye movement (REM) sleep was found to be primarily 
present when cortisol concentrations were decreasing, indicating a diminished or absent 
secretory activity of the adrenals at that time; wakefulness and Stage 1 sleep, by 
contrast, were associated with increasing plasma cortisol concentrations.” 
[C0020268|Hydrocortisone – AFFECTS – C0037313|Sleep] 
[PMID6822642] 
Title 
“Cortisol secretion is inhibited during sleep in normal man.” 
[C0020268|Hydrocortisone – DISRUPTS – C0037313|Sleep] 
Abstract 
“In order to test the hypothesis that cortisol secretion is inhibited during sleep, six 
healthy young men (ages 18-24) were studied in a 4-day protocol.” 
[C0020268|Hydrocortisone – DISRUPTS – C0037313|Sleep] 
[PMID8077308] 
Title 
“Corticotropin-releasing hormone-induced adrenocorticotropin and cortisol secretion 
depends on sleep and wakefulness.” 
[C0001655|Corticotropin – AUGMENTS – C0037313|Sleep] 
[C0001655|Corticotropin – AUGMENTS – C0043012|Wakefulness] 
[C0020268|Hydrocortisone  - AUGMENTS – C0037313|Sleep] 
[C0020268|Hydrocortisone – AUGMENTS – C0043012|Wakefulness] 
[PMID8548511] 
Abstract 
“Cortisol secretion is also related to sleep processes with the 24 hr nadir occurring, like 
the sleep dependent GH secretory surge, during the first half of nocturnal sleep.” 
[C0020268|Hydrocortisone – AUGMENTS – C0037313|Sleep] 
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Abstract 
“Age-related changes in sleep-dependent secretion of GH and cortisol correlated 
significantly (r = .47, r = -.55, respectively; p &lt; .05) with an age-dependent decrease 
in slow wave sleep.” 
[C0020268|Hydrocortisone – AUGMENTS – C0234451|Sleep, Slow-Wave] 
[C0037663|Somatotropin – AUGMENTS – C0234451|Sleep, Slow-Wave] 
Abstract 
“Both changes in GH and cortisol secretion may act together to reduce anabolic 
functions of sleep in the aged.”  
[C0020268|Hydrocortisone – DISRUPTS – C0037313|Sleep]  
[C0037663|Somatotropin – DISRUPTS – C0037313|Sleep] 
[PMID9329339] 
Abstract 
“The possible role of gonadal steroids in regulating sleep and circadian rhythms in 
humans has received relatively little attention despite the importance of the topic to 
several clinical syndromes.” 
[C0036884|Gonadal Steroid Hormones – AFFECTS – C0037313|Sleep] 
Abstract 
“These results indicate that testosterone has relatively specific and discrete effects on 
sleep and hormonal rhythms in men.” 
[C0039601|Testosterone – AFFECTS – C0037313|Sleep] 
[PMID9530230] 
Abstract 
“IL-1 beta dose dependently increased non-rapid eye movement sleep (NREMS) and 
suppressed rapid eye movement sleep (REMS) in the controls.” 
[C0021753|Interleukin-1 beta – AUGMENTS – C0037322|Sleep, REM] 
[C0021753|Interleukin-1 beta – AUGMENTS – C0234451|Sleep, Slow-Wave] 
Abstract 
“These results 1) provide further evidence that IL-1 beta is involved in sleep regulation, 
2) indicate that the effects of IL-1 beta on sleep are mediated by the type I receptor, and 
3) suggest that TNF-alpha is capable of inducing sleep without the involvement of IL-
1” 
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[C0021753|Interleukin-1 beta – AFFECTS – C0037313|Sleep|orgf|orgf|| 
[C0597357|receptor – INTERACTS_WITH – C0021753|Interleukin-1 beta] 
[PMID956348] 
Abstract 
“It was concluded that administration of cortisol leading to plasma levels as seen under 
treatment with ACTH suppresses testosterone by abolishing or flattening the nocturnal 
rise.” 
[C0020268|Hydrocortisone – INHIBITS – C0039601|Testosterone] 
[PMID9781819] 
Abstract 
“Much evidence implicates interleukin-1beta (IL-1beta) in sleep regulation.” 
[C0021753|Interleukin-1 beta – AFFECTS – C0037313|Sleep] 
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Table D-3. Precision and recall using citations for Testosterone study 
Result New Intermediate Terms Relevancy (Topic) Precision Recall 
d0 N/A – Direct Connection    
d1 Gonadal Steroid Hormones Hormones 1.0 0.333 
d2 Obesity  0.5 0.333 
d3 Hormones Hormones 0.5 0.333 
d4 Parkinson Disease  0.333 0.333 
d5 Aging Hormones 0.333 0.333 
d6 Growth Hormone Secretion Hormones 0.333 0.333 
d7 Circadian Rhythms Hormones 0.333 0.333 
d8 Interleukin-1 beta IL-1 Beta 0.5 0.667 
d9 Hydrocortisone Hydrocortisone 0.6 1 
 
Table D-4. Precision and recall not using citations for Testosterone study 
Result New Intermediate Terms Relevancy (Topic) Precision Recall 
d0 N/A – Direct Connection    
d1 Gonadal Steroid Hormones Hormones 1.0 0.333 
d2 Obesity  0.5 0.333 
d3 Hormones Hormones 0.5 0.333 
d4 Parkinson Disease  0.333 0.333 
d5 Aging Hormones 0.333 0.333 
d6 Growth Hormone Secretion Hormones 0.333 0.333 
d7 Circadian Rhythms Hormones 0.333 0.333 
d8 Interleukin-1 beta IL-1 Beta 0.5 0.667 
d9 Hydrocortisone Hydrocortisone 0.6 1 
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 Appendix E
Parkinson’s Disease – Crohn’s Disease Study 
 
Table E-1. PD – CD Core Corpus Medline IDs 
1374941 16773678 18430617 19093628 19416630 
7834804 17062028 18456695 19120480 19470958 
8739179 17268543 18489401 19221313 19481107 
12105943 18034589 18535002 19221317 19524782 
15342082 18242711 18586394 19265190 19568370 
15370396 18274903 18628756 19289138 19723294 
15784530 18308354    
 
 
 
 
Figure E-1. PD – CD, PL2(path length two) search parameters 
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Figure E-2. PD – CD, PL2 result 1  
 
 
 
Figure E-3. PD – CD, PL2 result 2 
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Figure E-4. PD – CD, PL2 result 3 
 
 
 
Figure E-5. PD – CD, PL2 result 4 
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Figure E-6. PD – CD, PL2 result 5 
 
 
 
Figure E-7. PD – CD, PL2 result 6 
 
 
 
Figure E-8. PD – CD, PL2 result 7 
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Figure E-9. PD – CD, PL2 result 8 
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Figure E-10. PD – CD, PL3 Inflammation search parameters 
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Figure E-11. PD – CD, PL3 Inflammation result 1 (with citations) 
 
 
 
Figure E-12. PD – CD, PL3 Inflammation result 1 (without citations) 
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Figure E-13. PD – CD, PL3 Inflammation result 2 (with citations) 
 
 
 
 
 
 
Figure E-14. PD – CD, PL3 Inflammation result 2 (without citations) 
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Figure E-15. PD – CD, PL3 Inflammation result 3 (with citations) 
 
 
 
 
 
 
 
 
 
 
 
 
<Not Present> 
Figure E-16. PD – CD, PL3 Inflammation result 3 (without citations) 
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Figure E-17. PD – CD, PL3 Inflammation result 4 (without citations) 
 
 
 
 
 
Figure E-18. PD – CD, PL3 Inflammation result 4 (without citations) 
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Figure E-19. PD – CD, PL3 Inflammation result 5 (with citations) 
 
 
 
 
 
 
 
 
 
 
<Not Present> 
Figure E-20. PD – CD, PL3 Inflammation result 5 (without citations) 
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Figure E-21. PD – CD, PL3 Inflammation result 6 (with citations) 
 
 
 
Figure E-22. PD – CD, PL3 Inflammation result 6 (without citations) 
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Figure E-23. PD – CD, PL3 SNP search parameters 
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Figure E-24. PD – CD, PL3 SNP result 1 (with citations) 
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Figure E-25. PD – CD, PL3 SNP result 1 (without citations) 
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Table E-2. PD – CD generated predicates 
[PMID10400088] 
Title 
“Increase in level of tumor necrosis factor (TNF)-alpha in 6-hydroxydopamine-
lesioned striatum in rats without influence of systemic L-DOPA on the TNF-alpha 
induction.” 
[C0023570|Levodopa – STIMULATES – C1448177|TNF protein, human] 
Abstract 
“We previously reported that the levels of proinflammatory cytokines such as tumor 
necrosis factor (TNF)-alpha are increased in the striatum and cerebrospinal fluid from 
patients with Parkinson’s disease (PD) and in the striatum from 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP)-treated mice, a murine model of PD.” 
[C1456820|Tumor Necrosis Factor-alpha – ISA – C0079189|cytokine] 
Abstract 
“Presently we examined the changes in cytokine levels in the nigrostriatal 
dopaminergic regions in rats treated with an intrastriatal injection of 6-
hydroxydopamine (6-OHDA) as a model of slowly progressive neurodegeneration 
similar to that seen in PD.” 
[C0079189|cytokine – ASSOCIATED_WITH – C0030567|Parkinson Disease] 
[PMID11052175] 
Title 
“Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel 
disease: biological and clinical significance.” 
[C0023810|Lipopolysaccharides – ASSOCIATED_WITH – C0021390|Inflammatory 
Bowel Diseases] 
[C0079189|cytokine – ASSOCIATED_WITH – C0021390|Inflammatory Bowel 
Diseases] 
Abstract 
“Ulcerative colitis (UC) and Crohn’s disease (CD) [inflammatory bowel disease (IBD)] 
are both characterized by an exaggerated immune response at the gut associated 
lymphoreticular tissue level.” 
[C0301872|Immune response – ASSOCIATED_WITH – C0009324|Ulcerative Colitis] 
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[C0301872|Immune response – ASSOCIATED_WITH – C0010346|Crohn’s disease] 
Abstract 
“Such an abnormal and dysregulated immune response may be directed against luminal 
and/or enteric bacterial antigens, as also supported by murine models of inflammatory 
bowel disease (IBD) caused by organisms such as Citrobacter rodentium and 
Helicobacter hepaticus.” 
[C0029235|Organism – CAUSES – C0021390|Inflammatory Bowel Diseases] 
[C0887836|Citrobacter rodentium – CAUSES(SPEC) – C0021390|Inflammatory 
Bowel Diseases] 
[C0887836|Citrobacter rodentium – ISA – C0029235|Organism] 
[C1003868|Helicobacter hepaticus – CAUSES(SPEC) – C0021390|Inflammatory 
Bowel Diseases] 
[C1003868|Helicobacter hepaticus – ISA – C0029235|Organism] 
Abstract 
“On these grounds, in experimental models and in human IBD, anti-cytokine 
monoclonal antibodies and interleukin receptor antagonists are under investigation for 
their capacity to neutralize the noxious effects of immune mediators.” 
[C0206553|Interleukin Receptor – DISRUPTS – C0021390|Inflammatory Bowel 
Diseases] 
[PMID11743591] 
Title 
“Infliximab for the treatment of Crohn’s disease: efficacy, safety and 
pharmacoeconomics.” 
00000000.tx.1|relation|C0666743|infliximab|aapp,gngm,imft,phsu|aapp|||TREATS|C00
10346|Crohn’s disease|dsyn|dsyn|| 
Abstract 
“Conventional medical treatment of Crohn’s disease includes the use of nonspecific 
anti-inflammatory drugs, immunosuppressives and antibiotics.” 
00000000.tx.4|relation|C0003209|Anti-Inflammatory 
Agents|phsu|phsu|||TREATS|C0010346|Crohn’s disease|dsyn|dsyn|| 
00000000.tx.4|relation|C0003232|Antibiotics|antb|antb|||TREATS|C0010346|Crohn’s 
disease|dsyn|dsyn|| 
Abstract 
“Infliximab, a chimeric monoclonal antibody directed toward tumour necrosis factor 
alpha, is highly effective for the treatment of active Crohn’s disease.” 
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00000000.tx.7|relation|C1456820|Tumor Necrosis Factor-
alpha|aapp,gngm,imft|aapp|||TREATS|C0010346|Crohn’s disease|dsyn|dsyn|| 
Abstract 
“Moreover, infliximab is the only medical therapy that has been shown to be effective 
for the treatment of fistulizing Crohn’s disease.” 
[C0666743|infliximab|aapp,gngm,imft,phsu|aapp|||TREATS(SPEC)|C0010346|Crohn’s 
disease|dsyn|dsyn|| 
Abstract 
“Infliximab is recommended for the treatment of active Crohn’s disease refractory to 
conventional drugs, and is the treatment of choice for fistulizing Crohn’s disease.” 
00000000.tx.14|relation|C0087111|Therapeutic 
procedure|topp|topp|||TREATS|C0010346|Crohn’s disease|dsyn|dsyn|| 
[PMID11922776] 
Abstract 
“Injection with rolipram, an inhibitor of TNF-alpha expression, or use of IL-6 knockout 
mice was ineffective at impairing thymic apoptosis induction by the toxin cotreatment, 
suggesting that these cytokines did not mediate LPS potentiation.” 
[C0079189|cytokine – CAUSES – C0162638|Apoptosis] 
[PMID12205053] 
Title 
“Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: 
implications for Parkinson’s disease.” 
[C0077503|Tumor Necrosis Factor Receptor – AFFECTS – C0030567|Parkinson 
Disease] 
Abstract 
“Recent findings suggest that inflammatory processes are associated with several 
neurodegenerative disorders, including PD.” 
[C0524851|Neurodegenerative Disorders – AFFECTS – C1512753|Inflammation 
Process] 
Abstract 
“Enhanced expression of the proinflammatory cytokine, tumor necrosis factor (TNF)-
alpha, has been found in association with glial cells in the substantia nigra of patients 
with PD.” 
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[C1448177|TNF protein, human – ISA – C0079189|cytokine] 
Abstract 
“To determine the potential role for TNF-alpha in PD, we examined the effects of the 
1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP), a dopaminergic neurotoxin that 
mimics some of the key features associated with PD, using transgenic mice lacking 
TNF receptors.” 
[C1448177|TNF protein, human – ASSOCIATED_WITH – C0030567|Parkinson 
Disease] 
Abstract 
“The data indicate that the proinflammatory cytokine TNF-alpha is an obligatory 
component of dopaminergic neurodegeneration.” 
[C1456820|Tumor Necrosis Factor-alpha – ISA – C0079189|cytokine] 
 
[PMID12474223] 
Title 
“Chemokine expression in IBD.” 
[C0282554|chemokine – ASSOCIATED_WITH – C0021390|Inflammatory Bowel 
Diseases] 
Abstract 
“Mucosal chemokine expression is unselectively increased in both ulcerative colitis and 
Crohn’s disease.” 
[C0282554|chemokine – AUGMENTS – C0009324|Ulcerative Colitis] 
[C0282554|chemokine – AUGMENTS – C0010346|Crohn’s disease] 
Abstract 
“Individual chemokine expression was found to be significantly up-regulated in IBD 
when patients were compared with the non-diseased group in all areas of the mucosal 
sections.” 
[C0282554|chemokine – AUGMENTS – C0021390|Inflammatory Bowel Diseases] 
Abstract 
“It is concluded that human colonic chemokine expression is non-selectively up-
regulated in IBD.” 
[C0282554|chemokine – AUGMENTS – C0021390|Inflammatory Bowel Diseases] 
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Abstract 
“The results supported the hypothesis that the degree of local inflammation and tissue 
damage in UC and CD is dependent on local expression of specific chemokines within 
IBD tissues.” 
[C0010957|Tissue damage – COEXISTS_WITH – C0009324|Ulcerative Colitis] 
[C0010957|Tissue damage – COEXISTS_WITH – C0010346|Crohn’s disease] 
[C0021368|Inflammation – COEXISTS_WITH – C0009324|Ulcerative Colitis] 
[C0021368|Inflammation – COEXISTS_WITH – C0010346|Crohn’s disease] 
[PMID12724617] 
Title 
“Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link 
between environmental and genetic factors in Parkinson’s disease.” 
[C0376622|ABCB1 gene  - ASSOCIATED_WITH – C0030567|Parkinson Disease] 
Abstract 
“Thus, it appears that mutation of the MDR1 gene predisposes to damaging effects of 
pesticides, and possibly other toxic xenobiotics transported by P-glycoprotein, leading 
to Parkinson’s disease.” 
[C0242643|P-Glycoprotein – CAUSES – C0030567|Parkinson Disease] 
[PMID14724828] 
Title 
“A murine model of chronic inflammation-induced intestinal fibrosis down-regulated 
by antisense NF-kappa B.” 
[C0079904|NF-kappa B – DISRUPTS – C0016059|Fibrosis] 
Abstract 
“To elucidate extracellular matrix (ECM) changes underlying intestinal fibrosis, a 
frequent complication of inflammatory bowel disease, we developed a murine model of 
chronic colitis associated with intestinal fibrosis.” 
[C0016059|Fibrosis – COEXISTS_WITH – C0267375|Chronic colitis] 
Abstract 
“Colonic expression of collagens (Col1a2, Col3a2), ECM remodeling genes (matrix 
metalloproteinase [MMP]-1, -3, and tissue inhibitor of matrix metalloproteinase 
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[TIMP]-1), and inflammation-modulating cytokines (tumor necrosis factor alpha [TNF-
alpha], interferon gamma [IFN-gamma], transforming growth factor beta 1 [TGF-beta 
1], and insulin-like growth factor 1 [IGF-1]) were assessed by semiquantitative reverse-
transcription polymerase chain reaction.” 
[C1448177|TNF protein, human – ISA – C0079189|cytokine] 
[PMID14749689] 
Abstract 
“P-glycoprotein, the encoded product of the human MDR1 (ABCB1) gene, is of 
particular clinical relevance in that this transporter has broad substrate specificity, 
including a variety of structurally divergent drugs in clinical use today.” 
[C0376622|ABCB1 gene – PRODUCES - C0242643|P-Glycoprotein] 
Abstract 
“Recently, a number of single-nucleotide polymorphisms (SNPs) in MDR1 have been 
identified.” 
[C0752046|Single Nucleotide Polymorphism - COEXISTS_WITH - 
C0376622|ABCB1 gene] 
Abstract 
“An increasing number of studies have also implicated certain commonly occurring 
SNPs in MDR1 in problems including altered drug levels and host susceptibility to 
diseases such as Parkinson's disease, inflammatory bowel disease, refractory seizures, 
and CD4 cell recovery during human immunodeficiency virus therapy.” 
[C0376622|ABCB1 gene – TREATS - C0001175|Acquired Immunodeficiency 
Syndrome] 
[C0752046|Single Nucleotide Polymorphism - COEXISTS_WITH – 
C0376622|ABCB1 gene] 
[PMID15058528] 
Abstract 
“Intestinal fibrostenosis is a frequent and debilitating complication of Crohn’s disease 
(CD), not only resulting in small bowel obstruction, but eventually in repeated bowel 
resection and short bowel syndrome.” 
[C0010346|Crohn’s disease – CAUSES – C0036992|Short Bowel Syndrome] 
[C0010346|Crohn’s disease – CAUSES – C0235329|Small bowel obstruction NOS] 
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Abstract 
“Intestinal fibrosis is a consequence of chronic transmural inflammation in CD.” 
[C0021376|Chronic inflammation – COEXISTS_WITH – C0010346|Crohn’s disease] 
Abstract 
“Tumor necrosis factor, on the other hand, has antifibrotic bioactivity and 
pharmacologic inhibition of this cytokine carries a theoretical risk of enhanced stricture 
formation.” 
[C1456820|Tumor Necrosis Factor-alpha – INHIBITS – C0079189|cytokine] 
[PMID15109580] 
Title 
“Inflammation and neurodegeneration in Parkinson’s disease.” 
[C0021368|Inflammation – COEXISTS_WITH – C0030567|Parkinson Disease] 
[C0027746|Nerve Degeneration – COEXISTS_WITH – C0030567|Parkinson Disease] 
Abstract 
“Reports in the literature indicate that antiinflammatory agents inhibit dopaminergic 
cell death in animal models of PD, and there is one epidemiological report that their use 
significantly diminishes the risk of PD in humans.” 
[C0003209|Anti-Inflammatory Agents – DISRUPTS – C0007587|Cell Death] 
Abstract 
“These data support the hypothesis that chronic inflammation may play an important 
role, if secondary, in the pathogenesis of PD.” 
[C0021376|Chronic inflammation – CAUSES – C0030567|Parkinson Disease] 
[PMID15256718] 
Abstract 
“In particular, genetic variations of the human ABCB1 (P-glycoprotein/MDR1) gene 
have been most extensively studied. Hitherto more than fifty single nucleotide 
polymorphisms (SNPs) and insertion/deletion polymorphisms in the ABCB1 gene have 
been reported.” 
[C0752046|Single Nucleotide Polymorphism – COEXISTS_WITH – 
C0376622|ABCB1] 
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[PMID15503194] 
Abstract 
“Accumulating evidence has suggested that inflammation in the brain participates in 
the pathogenesis of Parkinson’s disease (PD).” 
[C0021368|Inflammation – CAUSES – C0030567|Parkinson Disease] 
[PMID15580149] 
Title 
“Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: overview 
of randomized clinical studies.” 
[C0243076|antagonists – TREATS – C0010346|Crohn’s disease] 
Abstract 
“The past decade has brought forth a series of novel biologic agents targeting tumor 
necrosis factor (TNF) for the treatment of Crohn’s disease.” 
[C1456820|Tumor Necrosis Factor-alpha – TREATS – C0010346|Crohn’s disease] 
Abstract 
“However, the anti-TNF strategies might not have identical efficacy and safety profiles 
and might differ in dosing compared with therapy for rheumatoid arthritis.” 
[C1456820|Tumor Necrosis Factor-alpha – TREATS – C0003873|Rheumatoid 
Arthritis] 
Abstract 
“Most recently, adalimumab has been approved by the US Food and Drug 
Administration for the treatment of rheumatoid arthritis and is undergoing evaluation in 
Crohn’s disease, with promising initial results.” 
[C1122087|adalimumab – ASSOCIATED_WITH – C0010346|Crohn’s disease] 
Abstract 
“This review discusses the results of controlled clinical trials of anti-TNF agents for 
Crohn’s disease.” 
[C0040616|Anti-Anxiety Agents – TREATS – C0010346|Crohn’s disease] 
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[PMID15685540] 
Abstract 
“The G2677T SNP was not associated with UC or CD.” 
[C0752046|Single Nucleotide Polymorphism – NEG_ASSOCIATED_WITH – 
C0009324|Ulcerative Colitis] 
[C0752046|Single Nucleotide Polymorphism – NEG_ASSOCIATED_WITH – 
C0010346|Crohn’s disease] 
[PMID15778431] 
Abstract 
“Crohn’s disease (CD) is a chronic, relapsing inflammatory bowel disease, 
characterized by transmural inflammation.” 
[C0010346|Crohn’s disease – ISA – C0021390|Inflammatory Bowel Diseases] 
[C0021368|Inflammation – COEXISTS_WITH – C0021390|Inflammatory Bowel 
Diseases] 
[C0021368|Inflammation – COEXISTS_WITH(SPEC) – C0010346|Crohn’s disease] 
Abstract 
“Because transforming growth factor (TGF)-beta1 can mediate both fibrosis and 
mesenchymal cell proliferation; we studied the effects of delivering adenoviral vectors 
encoding spontaneously active TGF-beta1 into the colons of mice.” 
[C0080222|TGFB1 – ASSOCIATED_WITH – C0016059|Fibrosis] 
[PMID15869932] 
Title 
“Oxidative stress and inflammation in Parkinson’s disease: is there a causal link?” 
[C0021368|Inflammation – COEXISTS_WITH – C0030567|Parkinson Disease] 
[C0242606|Oxidative Stress – COEXISTS_WITH – C0030567|Parkinson Disease] 
Abstract 
“Parkinson’s disease (PD) is a neurodegenerative disorder characterized by a dramatic 
loss of dopaminergic neurons in the substantia nigra (SN).” 
[C0030567|Parkinson Disease – ISA – C0524851|Neurodegenerative Disorders] 
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Abstract 
“Perhaps not surprisingly, non-steroidal anti-inflammatory drugs (NSAIDs) have been 
shown to reduce the risk of developing PD.” 
[C0003211|Anti-Inflammatory Agents, Non-Steroidal – PREVENTS – 
C0030567|Parkinson Disease] 
[PMID15879017] 
Abstract 
“The extract was then tested for its ability to alter in vitro production of TH1 cytokines 
(interleukin-2 [IL-2] and gamma interferon) and TH2 cytokines (IL-4 and IL-10) by 
murine splenocytes.” 
[C0021740|Recombinant Interferon-gamma – ISA|C0079189|cytokine] 
[C0021756|Interleukin-2 – ISA – C0079189|cytokine] 
[C0021758|Interleukin-4 – ISA – C0079189|cytokine] 
[C0085295|Interleukin-10 – ISA – C0079189|cytokine] 
[PMID16252231] 
Abstract 
“We identified 11 SNPs that were associated with PD (P&lt;.01) in both tier 1 and tier 
2 samples and had the same direction of effect.” 
[C0752046|Single Nucleotide Polymorphism – ASSOCIATED_WITH- 
C0030567|Parkinson Disease] 
Abstract 
“The protein encoded by this gene plays an important role in neurogenesis and in 
neuronal apoptosis, which is consistent with existing hypotheses regarding PD 
pathogenesis.” 
[C0030567|Parkinson Disease – AFFECTS – C0162638|Apoptosis] 
[C0030567|Parkinson Disease – AFFECTS – C0814002|Neural Development] 
[PMID16374256] 
Abstract 
“The multidrug resistance MDR1 gene codes for a membrane transporter associated 
with inflammatory bowel disease.” 
[C0376622|ABCB1 gene – ISA – C0376623|Multidrug Resistance Gene] 
[C0596902|Membrane Transport Proteins – ASSOCIATED_WITH – 
C0021390|Inflammatory Bowel Diseases] 
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Abstract 
“We studied the association of both polymorphisms in an independent population to 
reveal the impact of the MDR1 gene on predisposition to inflammatory bowel disease.” 
[C0376622|ABCB1 gene – PREDISPOSES – C0021390|Inflammatory Bowel 
Diseases] 
Abstract 
“Therefore, considering our results and those from others, the MDR1 gene behaves as a 
common risk factor for both CD and UC.” 
[C0376622|ABCB1 gene – PREDISPOSES – C0009324|Ulcerative Colitis] 
[C0376622|ABCB1 gene – PREDISPOSES – C0010346|Crohn’s disease] 
Abstract 
“We discovered that the C3435 allele conferring susceptibility to CD is different from 
the described 3435T UC risk allele.” 
[C0010346|Crohn’s disease – PREDISPOSES – C0009324|Ulcerative Colitis] 
[PMID16461743] 
Abstract 
“These data indicate that the NOD2fs mutation results in a loss-of-function phenotype 
in human myeloid DC and imply decreased immune regulation by IL-10 as a possible 
mechanism for this mutation in CD.” 
[C0085295|Interleukin-10 – ASSOCIATED_WITH – C0010346|Crohn’s disease] 
[PMID16493072] 
Abstract 
“We found that AKBA potentiated the apoptosis induced by TNF and 
chemotherapeutic agents, suppressed TNF-induced invasion, and inhibited receptor 
activator of NF-kappaB ligand-induced osteoclastogenesis, all of which are known to 
require NF-kappaB activation.” 
[C0003392|Antineoplastic Agents – CAUSES – C0162638|Apoptosis] 
[C0812246|TNF gene – CAUSES – C0162638|Apoptosis] 
Abstract 
“Overall, our results indicated that AKBA enhances apoptosis induced by cytokines 
and chemotherapeutic agents, inhibits invasion, and suppresses osteoclastogenesis 
through inhibition of NF-kappaB-regulated gene expression.” 
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[C0003392|Antineoplastic Agents – CAUSES – C0162638|Apoptosis] 
[C0079189|cytokine – CAUSES – C0162638|Apoptosis] 
[PMID16717254] 
Abstract 
“This raises the possibility that anti-apoptotic agents might be neuroprotective in PD.” 
[C0040616|Anti-Anxiety Agents – TREATS – C0030567|Parkinson Disease] 
Abstract 
“Propargylamines have been demonstrated to be potent anti-apoptotic agents in both in 
vitro and in vivo studies, presumably by maintaining glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) as a dimer and thereby preventing its nuclear translocation 
where it blocks upregulation of anti-apoptotic proteins.” 
[C0040616|Anti-Anxiety Agents – STIMULATES – C1565114|Apoptosis Inhibiting 
Proteins] 
[PMID17052658] 
Title 
“Lack of replication of thirteen single-nucleotide polymorphisms implicated in 
Parkinson’s disease: a large-scale international study.” 
[C0752046|Single Nucleotide Polymorphism – ASSOCIATED_WITH – 
C0030567|Parkinson Disease] 
Abstract 
“A genome-wide association study identified 13 single-nucleotide polymorphisms 
(SNPs) significantly associated with Parkinson’s disease.” 
[C0752046|Single Nucleotide Polymorphism – ASSOCIATED_WITH – 
C0030567|Parkinson Disease] 
[PMID17156147] 
Title 
“Fibrogenesis in Crohn’s disease.” 
[C0596570|fibrogenesis – ASSOCIATED_WITH – C0010346|Crohn’s disease] 
Abstract 
“While the pathogenesis of inflammation in CD has been extensively investigated, 
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knowledge of stricture pathogenesis remains limited.” 
[C0021368|Inflammation – COEXISTS_WITH – C0010346|Crohn’s disease] 
[PMID17185560] 
Abstract 
“We report that a synonymous SNP in the Multidrug Resistance 1 (MDR1) gene, part 
of a haplotype previously linked to altered function of the MDR1 gene product P-
glycoprotein (P-gp), nonetheless results in P-gp with altered drug and inhibitor 
interactions.” 
[C0752046|Single Nucleotide Polymorphism - COEXISTS_WITH - 
C0376622|ABCB1 gene] 
[PMID17339843] 
Title 
“Inflammation as a causative factor in the aetiology of Parkinson’s disease.” 
[C0021368|Inflammation – CAUSES – C0030567|Parkinson Disease] 
Abstract 
“Parkinson’s disease (PD) is a progressive neurodegenerative disorder affecting mainly 
the elderly, although a small proportion of PD patients develop the illness at a much 
younger age.” 
[C0030567|Parkinson Disease – ISA – C0524851|Neurodegenerative Disorders] 
Abstract 
“These factors are examined in this review along with a consideration of the possible 
use of anti-inflammatory drugs in PD.” 
[C0003209|Anti-Inflammatory Agents – TREATS – C0030567|Parkinson Disease] 
[PMID17470824] 
Abstract 
“Adalimumab, a fully human tumor necrosis factor (TNF) antagonist, is an effective 
treatment for patients with Crohn disease who are naïve to the chimeric TNF 
antagonist, infliximab.” 
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[C0666743|infliximab – TREATS(INFER) – C0010346|Crohn’s disease] 
[C1122087|adalimumab  - INHIBITS – C1448177|TNF protein, human] 
Abstract 
“No anti-TNF agent has been evaluated prospectively in patients with Crohn disease 
who had responded to another anti-TNF agent and then lost that response or were 
intolerant of the agent.” 
[C0040616|Anti-Anxiety Agents – TREATS(INFER) – C0010346|Crohn’s disease] 
Abstract 
“To determine whether adalimumab induces remissions more frequently than placebo 
in adult patients with Crohn disease who have symptoms despite infliximab therapy or 
who cannot take infliximab because of adverse events.” 
[C1122087|adalimumab – TREATS(INFER) – C0010346|Crohn’s disease] 
Abstract 
“Adalimumab induces remissions more frequently than placebo in adult patients with 
Crohn disease who cannot tolerate infliximab or have symptoms despite receiving 
infliximab therapy.” 
[C1122087|adalimumab – TREATS(INFER) – C0010346|Crohn’s disease] 
[PMID17908040] 
Abstract 
“TNF-alpha is secreted by the brain resident marcophage (the microglial cell) in 
response to various stimuli. It has been demonstrated to play a major role in central 
nervous system (CNS) neuroinflammation-mediated cell death in AD, PD and 
amyotrophic lateral sclerosis (ALS) as well as several other CNS complications.” 
[C0002395|Alzheimer's Disease – AFFECTS - C0007587|Cell Death] 
[C0002736|Amyotrophic Lateral Sclerosis – AFFECTS - C0007587|Cell Death] 
[C0030567|Parkinson Disease -  AFFECTS - C0007587|Cell Death] 
[PMID17984451] 
Title 
“Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease.” 
[C0003211|Anti-Inflammatory Agents, Non-Steroidal – PREVENTS – 
C0030567|Parkinson Disease] 
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Abstract 
“Markers of neuroinflammation, including activated microglia and increased levels of 
circulating proinflammatory cytokines, have been observed in the brains and CSF of 
patients with Parkinson disease (PD).” 
[C0079189|cytokine – ASSOCIATED_WITH(INFER) – C0030567|Parkinson Disease] 
Abstract 
“Our study contributes to the growing body of literature suggesting a protective role for 
nonsteroidal anti-inflammatory drugs (NSAIDs) in Parkinson disease (PD).” 
[C0003211|Anti-Inflammatory Agents, Non-Steroidal – TREATS – 
C0030567|Parkinson Disease] 
Abstract 
“Yet the link between anti-inflammatory agents and PD in humans remains uncertain, 
despite indications that neuroinflammation may contribute to cell death in the PD brain 
and experimental evidence of anti-inflammatory agents such as nonsteroidal anti-
inflammatory drugs (NSAIDs) exerting neuroprotective effects in animal models.” 
[C0003209|Anti-Inflammatory Agents – AFFECTS – C0007587|Cell Death] 
[PMID19221310] 
Abstract 
“Imaging of nondopaminergic targets such as inflammation or alpha-synuclein 
deposition may provide further insight into the etiology of PD.” 
[C0021368|Inflammation – CAUSES – C0030567|Parkinson Disease] 
[PMID8015728] 
Abstract 
“Since TNF-alpha is an important signal transducer of the immune system with 
cytotoxic and stimulator properties, these results suggest that an immune response may 
occur in the nigrostriatal dopaminergic regions in Parkinson’s disease and that TNF-
alpha may be related, at least in part, to the neuronal degeneration.” 
[C0301872|Immune response – ASSOCIATED_WITH – C0030567|Parkinson 
Disease] 
[C1456820|Tumor Necrosis Factor-alpha – DISRUPTS – C0027746|Nerve 
Degeneration] 
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[PMID8196673] 
Abstract 
“An understanding of the molecular basis of the complex I defect in PD and its 
relationship to other biochemical changes will provide important insight into the 
potential chain of events that lead to dopaminergic cell death in PD.” 
[C0030567|Parkinson Disease – AFFECTS - C0007587|Cell Death] 
[PMID9422513] 
Abstract 
“Various molecules such as cytokines and anticancer drugs, as well as factor 
deprivation, rapidly induce apoptosis (programmed cell death), which is 
morphologically characterized by cell shrinkage and the blebbing of plasma 
membranes and by nuclear condensation.” 
[C0079189|cytokine – CAUSES - C0162638|Apoptosis] 
[PMID9550432] 
Title 
“A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's 
disease.” 
[C0079189|cytokine – CAUSES - C0010346|Crohn's disease] 
[C1456820|Tumor Necrosis Factor-alpha – CAUSES - C0010346|Crohn's disease] 
Abstract 
“To assess the role of TNF-alpha in mucosal cytokine regulation, the effects of TNF-
alpha on lamina propria mononuclear cell (LPMC) Th1 production were determined.” 
[C1456820|Tumor Necrosis Factor-alpha - INTERACTS_WITH - C0079189|cytokine] 
[PMID9820396] 
Abstract 
“This study aimed to shed more light on the interrelation between DHEAS and cortisol 
(and humoral markers of inflammation) in chronic inflammatory bowel disease.” 
[C0020268|Hydrocortisone - ASSOCIATED_WITH - C0021390|Inflammatory Bowel 
Diseases] 
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[C0057277|Dehydroepiandrosterone Sulfate - ASSOCIATED_WITH - 
C0021390|Inflammatory Bowel Diseases] 
Abstract 
“DHEAS was lower in patients with CD (p &lt; 0.005) and UC (p &lt; 0.005) than in 
controls, which was, in part, dependent on previous corticosteroid treatment (p &lt; 
0.01).” 
[C0057277|Dehydroepiandrosterone Sulfate - TREATS(INFER) - 
C0009324|Ulcerative Colitis] 
[C0057277|Dehydroepiandrosterone Sulfate - TREATS(INFER) - C0010346|Crohn's 
disease] 
Abstract 
“DHEAS as a marker of inflammation was low in CD and UC.” 
[C0009324|Ulcerative Colitis – ISA - C0021368|Inflammation] 
[C0010346|Crohn's disease – ISA - C0021368|Inflammation] 
[C0057277|Dehydroepiandrosterone Sulfate – PREDISPOSES - 
C0021368|Inflammation] 
[C0057277|Dehydroepiandrosterone Sulfate - PREDISPOSES(SPEC) - 
C0009324|Ulcerative Colitis] 
[C0057277|Dehydroepiandrosterone Sulfate -  PREDISPOSES(SPEC) - 
C0010346|Crohn's disease] 
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Table E-3. Precision and recall using citations for Parkinson – Crohn study 
Result New Intermediate Terms Relevancy (Topic) Precision Recall 
d0 Inflammation Neuroimmunology 1 0.333 
d1 Anti-Apoptotic Agents Cell Death 1 0.667 
d2 Single Nucleotide 
Polymorphism 
Genetics 1 1 
d3 Chronic Inflammation Neuroimmunology 1 1 
d4 Immune Response Neuroimmunology 1 1 
d5 Cytokine Neuroimmunology 1 1 
d6 Anti-Inflammatory Agents Neuroimmunology 1 1 
d7 ABCB1 Gene Genetics 1 1 
 
 
Table E-4. Precision and recall not using citations for Parkinson – Crohn study 
Result New Intermediate Terms Relevancy (Topic) Precision Recall 
d0 Inflammation Neuroimmunology 1 0.333 
d1 Anti-Apoptotic Agents Cell Death 1 0.667 
d2 Single Nucleotide 
Polymorphism 
Genetics 1 1 
d3 Chronic Inflammation Neuroimmunology 1 1 
d4 Immune Response Neuroimmunology 1 1 
d5 Cytokine Neuroimmunology 1 1 
d6 Anti-Inflammatory Agents Neuroimmunology 1 1 
d7 ABCB1 Gene Genetics 1 1 
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 Appendix F
MeSH Details 
 
Table F-1. MeSH Categories 
A – Anatomy 
B – Organisms 
C – Diseases 
D – Chemicals and Drugs 
E – Analytical, Diagnostic and Therapeutic Techniques, and Equipment 
F – Psychiatry and Psychology 
G – Phenomena and Processes 
H – Disciplines and Occupations 
I – Anthropology, Education, Sociology, and Social Phenomena 
J – Technology, Industry, and Agriculture 
K – Humanities 
L – Information Science 
M – Named Groupos 
N – Health Care 
V – Publication Characteristics 
Z – Geographicals 
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